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ABSTRACT  
 
Mechanisms of Aryl Hydrocarbon Receptor  
 and Estrogen Receptor Action 
in Breast Cancer Cells. (December 2004) 
Jeong Eun Lee, B.S., Seoul Women’s University; 
M.S., Seoul Women’s University 
Chair of Advisory Committee: Dr. Stephen Safe
 
 
 
In MCF7 and T47D cells cotreated with 1 nM 2,3,7,8-tetrachlorodibenzo-p-dioxin 
(TCDD) plus 0.1-10 mM 3’,4’-dimethoxy flavone (DMF), there was a concentration-
dependent decrease in the TCDD-induced ethoxyresorufin O-deethylase (EROD) 
activity. Gel mobility shift assays showed that 3’,4’-DMF inhibited TCDD-induced aryl 
hydrocarbon receptor (AhR) transformation in rat liver cytosol and blocked TCDD-
induced formation of the nuclear AhR complex in MCF7 and T47D cells. The 
antiestrogenic activity of TCDD in estrogen-induced transactivation assays in MCF7 
cells was reversed by 3’,4’-DMF, confirming the AhR antagonist activity of this 
compound in breast cancer cells. 
Cotreatment of T47D and MCF7 cells with TCDD and 10 mM resveratrol 
inhibited induction of CYP1A1 mRNA and EROD activity. Resveratrol did not inhibit 
TCDD-induced AhR transformation and reporter gene activity. Actinomycin D chase 
experiments in T47D cells showed that the mechanism of inhibition of CYP1A1 mRNA 
and EROD activity is due to an increased rate of CYP1A1 mRNA degradation, 
  
iv 
suggesting that resveratrol inhibits CYP1A1 via an AhR-independent post-
transcriptional pathway. 
Vitamin D receptor-interacting protein 150 (DRIP150) coactivated estrogen 
receptor a (ERa)-mediated transactivation and the response was AF2-dependent in 
ZR75 breast cancer cells. C-and N-terminal NR-boxes (amino acids 1186-1182 and 73-
69, respectively) were not necessary for coactivation of ERa. Analysis of DRIP150 
deletion mutants identified a 23 amino acid sequence (811-789) required for 
coactivation. The 23 amino acid contained two regions at amino acids 789-794 and 
795-804  which resembled a-helical motifs identified in Lanuguinosa lipase/histamine N-
methyl transferase and hepatocyte nuclear factor 1, respectively. A squelching assay 
using specific point mutations within each a-helix showed that  the NIFSEVRVYN (795-
804) region was the critical sequence required for the coactivator activity of DRIP150. 
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CHAPTER I 
 
INTRODUCTION 
Identification of AhR 
 Individuals are constantly exposed to a variety of low molecular weight 
compounds including secondary plant metabolites, mycotoxins, venoms, 
pharmaceuticals, and the by-products of industrialization. For several decades 
scientists have been aware that adaptive mechanisms exist to minimize toxicity from 
these ubiquitous dietary and environmental compounds. A metabolic response to 
polycyclic aromatic compounds (PAHs) combustion by-products was first described in 
the late 1950s. In these early rodent experiments, the administration of 
benz[a]anthracene, benzo[a]pyrene or 3-methylcholanthrene (MC) led to the induction 
of a number of liver microsomal enzyme activities collectively referred to as 
arylhydrocarbon hydroxylase (AHH) (1). This induced metabolism met the criterion of an 
adaptive response in that the upregulated enzymes were able to oxidize the same PAH-
inducing agents upon short-term re-exposure. Similar adaptive responses were also 
observed for other classes of structurally unrelated xenobiotics such as phenobarbital, 
other barbiturates, drugs and various pesticides. Initial exposures to these compounds 
led to increased expression of microsomal and soluble enzymes with metabolic activity 
toward the inducing agent resulting in a decreased pharmacological response unless a 
metabolite was the active agent (2). 
 
This dissertation follows the style of the Journal of Biological Chemistry. 
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Classical murine genetics provided initial insights into the regulation of AHH  
activity. First, it was observed that the inducibility of AHH activity varied significantly  
among inbred mouse strains, with C57 strains being highly responsive to PAHs, 
whereas the DBA and AKR strains were described as nonresponsive (3). Crosses and 
back-crosses of these strains indicated that multiple alleles at a single locus controlled 
inducibility of AHH. This locus initially became known as Ah, for arylhydrocarbon 
responsiveness (4,5). Although the terms responsive and nonresponsive are still widely 
used, their application should be limited to induction by PAHs, because halogenated 
aromatic hydrocarbons (HAHs) such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) 
soon were found to be orders of magnitude more potent than PAHs and were capable 
of eliciting AHH induction in nonresponsive strains (6). These results demonstrated that 
nonresponsive strains were actually less responsive, requiring 10-to100-fold higher 
doses of TCDD to attain the same level of enzyme induction observed in responsive 
strains. 
 Data from a number of laboratories led to the suggestion that a receptor existed 
for this large class of chemicals and that C57 mice harbored a receptor with a greater 
affinity for ligand than the corresponding receptor in DBA mice (7). Th  existence of this 
Ah receptor (AhR) was confirmed using radiolabeled TCDD congeners to demonstrate 
the existence of low-capacity, high-affinity binding sites in mouse hepatic cytosol (8). As 
predicted, the binding affinity for TCDD for receptors differed between mouse strains, 
with receptors from the responsive and nonresponsive strains displaying equilibrium 
dissociation constants of 6 and 37 pM, respectively (9). The segregation of these 
alleles, as well as structure-activity studies performed with TCDD and related 
compounds, confirmed the existence of the AhR and its role in regulating the induction  
 3
of AHH. The idea that the Ah locus encoded the AhR resulted in the recent renaming of 
this locus to Ahr by the Mouse Genome Nomenclature Committee (10).  
The AhR is highly polymorphic, particularly when compared with other nuclear  
receptors. This polymorphism extends beyond the classical responsive and 
nonresponsive phenotypes described above to include significant differences in 
receptor primary structure. For example, marked differences in AhR molecular weight 
have been revealed with the use of [125I]-photoaffinity ligands and antibodies (11,12). 
Three different ahr alleles, denoted with a “b” superscript from the prototype C57BL 
strain, have been identified that encode high-affinity receptors in responsive strains. 
The allele found in C57 strains, Ahrb-1, encodes a 95-KDa receptor with high affinity for 
TCDD, whereas a 104-KDa high-affinity allele, Ahrb-2, is found in most other commonly 
used laboratory strains such as C3H/He and BALB/c (13). Several wild-mouse strains, 
including Mus spretus, caroli,and molossinus, harbor a third high-affinity allele, Ahrb-3 , 
encoding a 105-KDa receptor protein (14). At present, only a single allele has been 
identified that encodes for the low-affinity receptor in nonresponsive strains (Ahrd) (15). 
This allele is denoted with a “d” superscript, from the prototype DBA strain, and 
encodes a receptor protein of 104 KDa (14). The structural and functional variability of 
the AhR is also evident across species. Photoaffinity labeling of hepatic cytosol 
indicates that the AhR can vary in molecular weight by almost 30 kilodaltons, e.g. C57 
mouse, 95; chicken,101; guinea pig, 103; rabbit, 104; rat,106; human,106; monkey,113; 
and hamster, 124 (12). Recent cloning studies have demonstrated that this difference in 
molecular weight is primarily due to differences in the position of the AhR’s translational 
termination codon, rather than differential splicing or posttranslational modifications (16-
19). 
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Structure/function of AhR and Arnt 
The basic-helix-loop-helix (bHLH) motif  has been described in a wide variety of  
transcription factors such as the mammalian proteins Myc, Max, MyoD, and E2A, and  
the Drosophila proteins Achaete-scute and Daughterless (20,21) that function as 
sequence-specific transcriptional regulators. This motif has been demonstrated to 
harbor subdomains that play roles in both DNA binding (basic region) and protein 
dimerization (HLH) (20,22,23). A feature of many bHLH proteins is the presence of a 
secondary dimerization surface adjacent to the HLH domain. One well characterized 
example of such a secondary dimerization domain is the lucine zipper, and bHLH 
proteins containing this motif are called bHLH-ZIP proteins (21). Myogenic 
determination protein MyoD and its relatives Myogenin, Myf-5 and MRF4 are among the 
most widely studied members of the bHLH proteins and illustrate many of the general 
features of these proteins (24,25). The myogenic bHLH proteins were identified based 
on their ability to activate muscle- pecific genes and induce muscle cell differentiation in 
nonmyogenic cells. These factors autoregulate their own expression and cross-regulate 
the expression of the other family members. Studies on the regulation of skeletal 
muscle development provide evidence for distinct roles for each of the myogenic factors 
in both determination and differentiation of muscle cell phenotype (26-28). All four 
myogenic factors form heterodimers with the E12 and E47proteins, which are 
alternately spliced products of the E2A gene, to generate functional DNA-binding 
complexes (20,24,29). Regulation of this system is maintained under diff ent 
physiologic conditions not only by the complement of dimeric partners that are 
expressed, but also by restricting the heterodimeric pairs that may form. Key regulators 
of partner availability are two dominant- egative inhibitory proteins, Id1 and Id2 (29,30).  
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These proteins have been shown to interact with E12 and E47, as well as with MyoD, 
forming nonfunctional complexes devoid of DNA-binding ability.  
Cloning of the AhR and Ah receptor nuclear translocator (Arnt) genes allowed 
amino acid sequence alignments, which revealed that these two proteins are similar in 
primary amino acid sequence to the Drosophila proteins Sim and Per (29-36). The 
homologous domain present in all four proteins has been termed the PAS domain, for 
Per-Arnt-Sim. In addition to the PAS motif, the AhR , Arnt, and Sim also have adjacent 
bHLH domains (Fig. 1). The AhR and Arnt are bHLH-PAS proteins. Sim is a bHLH-PAS 
protein involved in the specification of cell fate during midline cell differentiat on in 
Drosophila (37,38). Per, known to be involved in the maintenance of circadian rhythms, 
is the most unusual member of this family in that it does not contain a bHLH region and 
may function as  a dominant – egative inhibitor in a manner similar to the Id proteins of 
the MyoD system (30). Very recently, a number of new members of the bHLH-PAS 
superfamily have emerged from cloning studies. The hypoxia-inducible factor 1a (HIF-
1a), a regulator of cellular response to hypoxic stress, was purified and cloned from 
hepatoma cells and two additional bHLH-PAS members are the products of the similar 
and trachealess genes of Drosophila (39,40). Together these cloning and sequencing 
studies suggest that a superfamily of PAS proteins exists in a wide variety of cell types 
and organisms. 
 Fundamental questions remain concerning the endogenous function of the AhR 
and its role in the toxicity of TCDD. The use of gene targeting technology to inactivate 
murine genes in vivo (knockout mice) has been a powerful technique to elucidate 
protein function, confirming  predicted actions in some cases while uncovering 
unexpected roles in others. The Ahr  gene is an ideal candidate for targeted  
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FIG. 1. Schematic representation of the bHLH-PAS family proteins. The 
stippled areas represent the bHLH region and the black areas the PAS domain. For 
the AhR, the region marked Dimerization indicates bHLH and PAS sequences 
required for AhR-Arnt dimerization and therefore also for DNA binding. The region 
marked Ligand indicates the ligand-binding domain as mapped by photoaffinity 
labeling of deletion constructs, and the region marked TAD indicates the 
transactivation domain. For the other bHLH-PAS family members, percent amino 
acid identity to the AhR within the PAS region is indicated beneath each protein. 
Per does not contain a bHLH domain. 
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inactivation; Ahr null mice might demonstrate an unknown AhR function (endogenous 
pathway) and provide a valuable model system for investigation of TCDD-induced 
toxicity. Ahr null mice have been generated independently by two groups, yielding very 
different phenotypes (41,42). 
 Schmidt et al has used gene targeting to delete exon2, which encodes the bHLH 
DNA-binding and dimerization domain, generating an Ahr null mouse line (41). RT-PCR 
analysis detects the presence of a full-length alternatively spliced Ahr transcript, lacking 
exon2, produced from the targeted allele. This splicing event generates a frame- hift, 
and detailed Western blot, as well as functional assays, detect no AhR protein in this 
model system. The Ahrr2/r2 animals are viable and fertile; however, they exhibit a 
spectrum of hepatic defects suggesting that the AhR may play a previously 
unrecognized role in liver growth and development. Ahrr2/r2  mice appear normal at 
birth but display slowed growth for the first few weeks of life. At 1 week of age, these 
animals show a dramatic yet transient liver phenotype that includes decreased liver 
weight, fatty metamorphosis, and increased residual extramedullary hematopoiesis. 
Detailed analysis of the decrease in liver weight has shown that this aspect of the 
Ahrr2/r2   phenotype is present at all ages examined so far, from birth through 6 weeks. 
The fatty change of the liver, however, develops after birth and resolves entirely by 3 
weeks of age. The residual extramedullary hematopoiesis also resolves by this age. 
Older Ahrr2/r2  mice (beyond 3 weeks of age) begin to develop mild portal 
hypercellularity with thickening and fibrosis, and approximately 50 % of animals have 
enlarged spleens by 6 weeks. Although the underlying basis for this phenotype is 
unknown and will be the subject of much future study, it may represent a hepatic 
developmental delay. The phenotype may indicate a role for the AhR in liver growth and  
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maturation to a functionally metabolic organ. In addition to pr viding other functional 
roles for the AhR, these mice will serve as valuable tools to distinguish between 
receptor-mediated from nonreceptor-mediated effects of various AhR agonists.  
 Ahr  mice that display a quite different phenotype from Ah r2/r2   were first 
generated by Fermandez-Salguero at al (42). This group targeted their inactivating 
mutations to the first exon of the A r, deleting the initiation methionine and a portion of 
the basic region. In Ahrr1/r1 mice P4501A1 is not induced in response to TCDD. The 
mice display a 50% neonatal mortality rate, with inflammation of several major organ 
systems. Surviving Ahrr1/r1 mice have decreased liver weights and portal fibrosis 
similar to that seen in the Ahrr2/r2 mice; however, both phenotypes appear to be more 
severe in the Ahrr1/r1 mice. Additionally, the Ahrr1/r1 animals have a severely 
depressed immune system, with an 80% decrease in total splenic lymphoid cells at 2 
weeks of age that gradually resolves over time. This indicates a role for the AhR in 
neonatal lethality and immune function. However, there is no evidence of neonatal 
lethality or immune cell depletion in Ahrr2/r2 mice. The reasons underlying the 
phenotypic difference between the two Ahr null mouse lines remain unclear. 
AhR-mediated toxicities 
Genetic, biochemical, and molecular biology studies have revealed that the AhR 
mediates the toxic and biological effects of environmentally persistent TCDD and 
related compounds. The AhR was first described and studied based on its ability to bind 
and mediate the toxic and biological effects of PAHs, HAHs, and related compounds. 
The HAHs include a wide group of compounds such as polychlorinated dibenzo-p-
dioxin (PCDD), dibenzofurans (PCDFs), biphenyls (PCBs),  diphenyl ethers, 
naphthalenes and others (Fig. 2). There are 75 PCDD, 135 PCDF, 209 PCB congeners  
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FIG. 2. Structures of several classes of HAHs. 
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and hundreds of polychlorinated naphthalenes, azo- and azoxy-benzenes, terphenyls, 
quarterphenyls and biphenylenes. 2,3,7,8-TCDD or dioxin is the prototypical and most 
toxic member of this class of compounds. The term “dioxin” is used to indicate either 
TCDD specifically, or PCDD family in general. Biologically, TCDD is the most potent 
PCDD (43).  
The HAHs elicit a diverse spectrum of sex, strain, age, species, and tissue 
specific responses, which include body weight loss, thymic atrophy, immunotoxicity, 
hepatotoxicity and porphyria, chloracne and related dermal lesions, tissue specific 
hypo- and hyperplastic responses, carcinogenesis, teratogenicity, reproductive toxicity, 
and numerous biological responses such as the induction of phase I and phase II drug-
metabolizing enzymes(44). The role of the AhR in mediating the pleiotropic res onses 
elicited by HAHs can be inferred from two major lines of evidence. Firstly, for several of 
these responses, including dermal toxicity, immunotoxicity, porphyria, thymic atrophy, 
body weight loss, acute lethality (LD50 values), and teratogenicity, the potencies of 
several PCDD, PCDF, and PCB congeners are structure-dependent. Moreover, the 
structure-toxicity relationships for halogenated AhRs are similar to the structure-
induction AHH relationships and the most active congeners exhibit relatively high AhR 
binding affinities and are approximate isostereomers of 2,3,7,8,-TCDD. Secondly, 
pharmacogenetic studies with genetically inbred mice and their backcross provided the 
initial evidence which supported the role of the AhR in the induction of AHH by TCDD 
and 3-methylcholanthrene (MC). Subsequent research with both Ah responsive (Ahb 
allele ) and nonresponsive (Ahd allele) strains of mice demonstrated that several toxic 
effects elicited by TCDD, including hepatotoxicity, immunotoxicity, porphyria, body 
weight loss, and teratogenicity, segregate with the Ah locus. Allelic differences in  
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the murine Ah locus have been associated with carcinogenicity at distal and proximal 
sites, neonatal toxicity, immunotoxicity, susceptibility to atherosclerosis, bone marrow 
toxicity, and numerous other toxic effects. Some of these effects are related to 
differential induction of cytochrome P-4501A1 and the subsequent modulated 
metabolism of  toxins/carcinogens (45). 
A surprising number of deleterious biolog cal responses in human have been 
shown to result from TCDD exposure and these include epithelial hyperplasia, 
chloracne, induction of drug-metabolizing enzymes, altered estrogen receptor (ER) 
signaling, porphyria, deregulated lipid metabolism, decreased s rum thyroxine, wasting, 
metabolism of arachidonic acid to biologically active products, vitamin A depletion, 
cardiac dysfunction, utilization of brown adipose tissue, teratogenesis/embryotoxicity, 
inhibition of gluconeogenesis, immunosuppression, lipid peroxidation, epidermal growth 
factor receptor (EGFR) down-regulation, persistent thyroid hormone receptor activation, 
and tumor promotion(46).  
TCDD has a half-life of about 10-15 days in mice (47,48), 12-31 days in rats and 
5-10 years in humans. TCDD exhibits wide inter-and intra-species differences in LD50 
values (Table I) that range from 0.6 mg/kg in male guinea pigs (49) to 5500 mg/kg in 
hamsters(50). 
TCDD reduces fertility, litter size, uterine weights, alters ovarian function, 
increases incidence of spontaneous abortions and disrupts normal estrus cycling in 
several mammalian species. Studies have shown that TCDD delays vaginal opening 
and induces cleft phallus/clitoris in female rats. In several cases of clefting, the animals  
were also hypospadic. TCDD inhibits several estrogen-induced responses in the rodent   
uterus and modulates several endpoints regulated by estrogen such as uterine  
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TABLE I 
Acute lethality of TCDD to various species and strains 
Species/strain/sex Route LD50 
(mg/kg) 
Time of death 
(days post 
exposure) 
Follow-
up 
(days) 
Body weight 
loss 
Guinea pig oral 2 >5 30 50 
Mink oral 4.2 7-17 28 31 
Rhesus monkey oral ~70 14-34 42-47 13-38 
Rat/S-D/Male ip 60 NP 20 NP 
Rat/S-D/Female  25    
Mouse/C57BL/6 oral 182 24 30 25 
Mouse/DBA/2  2570 21  33 
Mouse/B6D2F1  296 25  34 
Rabbit oral 115 6-39 NP NP 
 ip 275 12-22 22 NP 
 dermal ~50 7-10 10-20 11 
Golden-syrian 
hamster  (male) 
oral 5051 9-43 55 NP 
NP-not provided; (51) 
 
 
 
 
peroxidase activity, EGFR levels, progesterone receptor (PR) levels and c-fos   
oncogene expression(52). Reproductive toxicity of TCDD in humans has been difficult 
to assess but is believed to cause an increase in spontaneous abortions and birth 
defects such as spina bifida and cleft palate (53). 
In several species such as rhesus monkeys, rats, mice, guinea pigs and 
chickens, treatment with TCDD causes various alterations in testicular morphology 
including loss of germ cells, appearance of degenerating spermatocytes and mature 
spermatozoa within the lumen of the seminiferous tubules and a reduction in the 
number of tubules containing mature spermatozoa. The ED50 for this response in rats is 
15 mg/kg and is accompanied by signs of overt toxicity, such as wasting syndrome, 
indicating that these are high-dose effects (54). 
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 Epidemiological studies show an association between dioxin exposure and 
decreased serum testosterone levels and increased serum follicle-stimulating hormone  
(FSH) and lutenizing hormones (LH) in male workers exposed to TCDD during the 
manufacturing of 2,4,5-trichlorophenol (55) 
 Developmental toxicity caused by TCDD-like congeners has been extensively 
documented in fish, birds and mammals and commonly includes decreased growth and 
prenatal mortality (56).In fertilized eggs from lake trout, the LD50 was 65 pg of TCDD 
(waterborne)/g egg. Injection of TCDD-like congeners in chicken eggs resulted in liver 
lesions, edema, thymic hypoplasia, beak deformations and cardiac malformation; 
however, none of these symptoms were observed in turkey eggs indicating that TCDD-
induced effects in bird embryos are highly species dependent (57). The embryo or fetus 
is more susceptible to TCDD than adults of the same species. The LD50 for TCDD in 
rainbow trout sac fry is 25 times lower than that in juvenile rainbow trout; 100-200 imes 
less in the chick embryo compared to adult chickens and 64-280 times lower in hamster 
fetus compared to adult hamsters (51). 
 In mammals, especially mice, TCDD exposure causes several structural 
malformations. These include cleft palate and hydronephrosis (58). Epidemiological 
studies have reported that the offspring of women exposed to HAH mixtures developed 
ectodermal dysplasia characterized by hyperpigmentation of the skin, mucous 
membranes, fingernails, toenails, presence of erupted teeth in neonates and 
hypersecretion of the meibomian gland. In addition, in utero exposure to these mixture 
also resulted in neurobehavioral abnormalities and delays in developmental milestones 
(59). 
TCDD disrupts the endocrine system by altering responses that are involved in  
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homeostatic control at the cellular, tissue, organ and organism levels. The anterior lobe 
ot the pituitary gland is a target for TCDD and exhibits both exaggerated and  
suppressed responses to its regulatory hormones following TCDD exposure. A 50 mg/kg
dose of TCDD decreased prolactin concentration within 4 h in male Sprague-Dawley (S-
D) rats (60). TCDD enhanced thyroid stimulating hormone directly or via the 
hypothalamic releasing hormone (51).  
 TCDD does not compete with glucocorti ids in binding to their intracellular 
receptors but it diminishes the binding capacity of hepatic glucocorticoid receptors, in a 
cell- and tissue-dependent manner, in the rat and mouse (61). Adrenalectomy 
increased mortality of male S-D rats exposed to TCDD (62). Studies have shown that 
adrenalectomy sensitizes rats to hepatic monooxygenase induction as well as 
glucocorticoid receptor downregulation by TCDD (51).  
 TCDD decreases serum insulin levels in rats (63) and studies with isolated 
pancreatic membranes from TCDD-treated guinea-pigs showed increased protein-
tyrosine kinase activities(64). A high nonlethal dose of TCDD (25 mg/kg) decreased 
plasma glucagon whereas a lethal dose (125 mg/kg) significantly increased glucagon 
levels in S-D rats (62). 
 TCDD reduces serum T4 concentrations rapidly in rats but has a variable 
response on T3 (65). TCDD is believed to exert its effects on serum thyroid hormones in 
rats by accelerated clearance of T4 (66) through selectively enhanced biliary excretion 
(67). Studies have suggested that hydroxylated metabolites of TCDD may compete with 
T4 for binding to transthyretin leading to TCDD-induced decline in serum T4 levels. 
TCDD also modulates concentrations of thyroid-hormone receptors. TCDD exposure 
resulted in an increase in mRNA for c-e b-A oncogene in livers of C57BL/6 mice but not  
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in DBA/2 mice implying elevated concentrations of nuclear T3 receptors by TCDD in the 
former strain (68).  
 TCDD dramatically decreases circulating melatonin levels but not pineal 
melatonin content (51). Studies suggest that decreased serum melatonin was possibly 
due to accelerated peripheral clearance following TCDD exposure (69). TCDD-induced 
changes in this important day/night signaling substance may contribute to biological 
effects such as shifts in corticosterone or feeding rhythms (70). 
 The toxic effects of HAHs are mediated through alterations in normal 
homeostatic processes that are regulated through interactions of growth factors, steroid 
hormones, and enzymes involved in the synthesis and degradation of these factors. 
TCDD can alter the levels of both growth factors and their receptors (56). 
 In vivo studies, in the hepatic plasma membranes of rats and guinea pigs, have 
shown that TCDD increases protein kinase activities such as protein kinase C (PKC) 
(71) and several tyrosine kinases (72). Induction of PKC by TCDD has been 
demonstrated in the rat testis(73), rat thymus(68), and in primary cultures of rat 
hepatocytes and thymocytes (74). TCDD also stimulates c-ras protooncogene product 
in hepatic plasma membranes. Studies have also reported that TCDD activates 
phospholipase C (75). 
 HAHs induce phase I and phase II drug-metabolizing enzymes. These include a 
broad spectrum of P450-dependent monooxygenase enzyme activities including 
several PAH hydroxylases, steroid hydroxylases, O-dealkylases, several haloaromatic 
hydroxylases, N-dealkylases, and barbituate hydroxylases. Phase II enzymes include 
epoxide hydrolase, glucuronosyl transferase, glutathione-S-transferase and reductase  
(52). TCDD can induce the level and activity of a number of enzymes involved in  
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metabolism, particularly of endogenous substrates.  
TCDD is classified as a probable human carcinogen by the EPA and as a
possible human carcinogen by IARC (76). TCDD is a trans- pecies (rat, mouse and 
hamster), trans-strain (Sprague-Dawley and Osborne-Mendel rats; B6C3F1, Swiss-
Webster and B6C mice), trans-sex, multisite complete carcinogen. TCDD is a potent 
carcinogen in laboratory animals with tumors observed at doses as low as 0.001 mg/kg 
body weight per day (77,78). In rats, TCDD induced neoplasms in the lung, oral, and 
nasal activities, thyroid and adrenal glands and liver (79). In mice, TCDD-induced 
neoplasms were seen in the liver, subcutaneous tissue, thyroid gland, lung, and 
lymphopoietic tissue (80). In hamsters, TCDD produced squamous cell carcinoma of 
the facial skin (81). Epidemiological data from occupationally exposed workers show 
that TCDD exposure is associated with several cancers in humans: respiratory, lung, 
thyroid gland, connective and soft tissue sarcoma, hematopoietic system, liver and all 
cancers (82-86). 
  Carcinogenic effects of TCDD are produced via a receptor-mediated, 
nongenotoxic, epigenetic mechanism. In two-stage liver and skin models, TCDD 
exhibits considerable promotional activity (87). TCDD is a promoter of liver tumors 
following initiation with a single 10 mg/kg dose of diethylnitrosamine (DEN), with an 
increase in the number of foci and the production of well-differentiated hepatocellular 
carcinomas. The PCB congeners that most actively promote hepatic tumors (3,3’,4,4’-
tetraCB and 2,3,4,4’,5-penta CB) are also inducers of hepatic CYP1A1-dependent 
monooxygenases. In addition to promotional activity, particularly in the liver, PCBs can 
alter the metabolism of other carcinogens also, thereby increasing cancer incidence. 
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Mechanisms of AhR action 
The AhR is primarily a cytosolic protein complexed with two 90-kDa heat shock 
proteins (Hsp90) and lower molecular weight chaperons and this complex does not bind 
DNA (88,89). In a manner similar to steroid hormone receptors, Hsp90-AhR interactions 
are destabilized by ligand binding, a process referred to as transformation (90). The  
ligand-activated AhR heterodimerizes with the bHLH protein Arnt forming a dimeric 
complex that binds to xenobiotic regulatory elements (XREs) in target gene promoters 
such as CYP1A1. Induction of CYP1A1 involves the classical activation cascade of the 
AhR, e. g. binding of the ligand to the AhR, heterodimerization with Arnt protein, 
formation of a complex with XRE and subsequent gene activation (Fig. 3). 
Some xenobiotics activate CYP1A1 gene expression in spite of their inability to 
compete with TCDD for AhR binding and ligand-independent induction includes stress 
conditions such as hyperoxia and hydrodynamic shearing  a d enhanced AhR 
transcription during the differentiation of  monocytes and keratinocytes (91,92). 
 CYP1A1 inducers that do not bind the AhR have been categorized into 
structurally-related chemical families. For example benzimidine family members which 
enhance CYP1A1 include omeprazole (OME), which inhibits H+/K+-ATPase, and is 
currently used in the treatment of gastric ulcers. The fungicide thiabendazole (TBZ) 
.also induces CYP1A1. The second structural  groups are the carotenoids (precursors 
of retinoids) canthaxanthin and ß-apo-8’-carotenal. Finally two other structurally 
unrelated compounds also induce CYP1A1; carbaryl an important insecticide which 
belongs to the carbamate family  and primaquine a drug which is of extreme importance 
in malaria chemotherapy. These results suggest that other signaling pathways may be 
involved in activation of CYP1A1. Retinoids are capable of inducing CYP1A1 through  
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FIG. 3. General CYP1A1 induction model also known as the AhR signaling    
transduction pathway. 
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retinoic acid responsive element (RARE). Carotenoids, which are precursors of retinoids, 
and thereby structurally related may activate CYP1A1 through the retinoic acid receptor 
 (RAR) signaling pathway.  Crosstalk between the AhR and RAR signaling pathways 
may be related to modulation of RAR-dependent pathways. Tyrosine kinase activation 
may also play a role in ligand-i ependent activation of CYP1A1 however the 
mechanism of this response is unknown. For omeprazole, carbaryl and primaquine, 
CYP1A1 induction by these chemicals is inhibited by a PKC inhibitor, staurosporine, 
suggesting that these chemicals could activate PKC. AhR and Arnt are both 
phosphoproteins and phosphorylation of the AhR seems to occur predominantly on its 
carboxyterminal end. Furthermore, AhR and Arnt are both phosphorylated on threonine 
residues, suggesting that a serine/threonine kinase may be directly or indirectly involved 
in regulation of AhR/Arnt functions. Overall, little is known about PKC-dependent  
regulation of AhR or Arnt activities. However, recent studies showed that PKC-
dependent phosphorylation of  both AhR and Arnt is required for the classical AhR 
signaling pathway in some tissues/cells suggesting that other types of CYP1A1 
inducers that modulate phosphorylation may facilitate assembly of a fully functional 
transcription complex (93). 
Several studies have reported interactions of AhR and ER signaling pathways in 
a number of tissues/cells and this includes the following pathways: 1) the AhR may 
suppress ER-induced gene expression by interactions of the AhR with critical regions of 
17b-estradiol (E2)-responsive gene promoters, 2) the AhR induces downregulation of 
ER levels, 3) the AhR increases the metabolism of E2, and 4) activation of AhR may 
release Hsps that inhibit ER signaling while squelching ER-dependent coactivators. 
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  The presence of inhibitory DREs (iDREs) which interact with the AhR may 
disrupt or prevent ER-mediated transcription and these have been identified in 
cathepsin D, pS2, Hsp27, and c-fos gene promoters (94-97). Induction of the cathepsin 
D gene by E2 requires the binding of both ER and Sp1 to promoter elements, and 
activated AhR binds to a DRE located between the ERE and Sp1 motif, preventing 
ER/Sp1-DNA binding (Fig. 4). Identification of a functional iDRE in the cathepsin D gene 
promoter suggested that this same motif may play an important role in inhibitory AhR-
ER crosstalk and functional iDREs have now been characterized in other E2-responsive 
genes. Zacharewski and coworkers first showed that TCDD inhibited E2-induced pS2 
gene expression in breast cancer cells and promoter analysis identified a functional 
iDRE (GCGTG at –521 to –517 ) over 100 bases upstream from an imperfect 
palindromic ERE (-405 to –393) that binds ERa and is required for E2-responsiveness 
(96). The mechanism of inhibitory AhR-ER crosstalk associated with the pS2 gene 
promoter is due to competitive AhR/ rnt-AP1 binding to overlapping response elements 
and subsequent modulation of AP1-ER interactions (Fig. 4). Similar interference with 
DNA-bound transcription factors has been observed in regulation of other gene 
promoters (98). In the Hsp27 promoter, the functional iDRE is located near the 
transcription start site and may act by interfering with the general transcription 
machinery (Fig.4). Inhibitory AHR-ER crosstalk for the c-fos gene is associated with 
quenching or masking of DNA binding by competing transcription factors since the 
results from gel mobility shift  and DNA footprinting assays indicate that the AhR/Arnt 
and ER/Sp1 compete for binding at the overlapping GC-rich/iDRE motif (Fig.4). In 
addition to cathepsin D, pS2, Hsp27 and c-fos gene promoters, E2F1, adenosine 
deaminase, insulin-like growth factor binding protein 4 and retinoid acid receptor a1  
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FIG. 4. Summary of inhibitory AhR-ER crosstalk dependent on direct interactions 
of the AhR with functional iDREs in the cathepsin D, pS2, Hsp27, and c-fos gene 
promoters. (94-97) 
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genes are also induced by E2 in breast cancer cells through ER/Sp1 interaction with 
GC rich promoters (99-105) ; TCDD also inhibits hormone activation of these genes, 
however, the mechanisms of these interactions are unknown. TCDD decreases ER 
levels in the uterus and breast cancer cells, possibly by enhancing the rate of receptor 
turnover or by inhibiting replenishment of ER. TCDD activates proteosome-dependent 
degradation of ERa (106). Other drugs that down-regulate ER include phorbol esters, 
retinoids, cytotoxic drugs such as adriamycin, nonesterified fatty acids such as 
arachidonic acid, and differentiation-inducing agents such as forskolin. 
TCDD induces phase I and phase II enzymes that metabolize E2. Induction of 
CYP1A1 catalyzes E2 2-, 15a- and 16a-hydroxylation, and CYP1A2 and 1B1 induce 
hydroxylation of E2 at the C-2 and C-4 positions (107-110). By lowering E2 levels in 
hormone responsive cells, E2-induced responses may also be decreased. 
 Studies have demonstrated that regulation of ER action and the activities of 
other members of the nuclear receptor superfamily (111) are dependent on interactions 
with other nuclear proteins including both activator and corepressor proteins that are 
important tissue/cell-specific mediators of nuclear receptor function (112-116). AhR 
interacts with the coactivators RIP140 (117), ERAP-140 and corepressor SMRT (118). 
It has been suggested that another mechanism associated with AhR-mediated 
antiestrogenic responses may be related to competition between the AhR and ER 
signaling pathways for common coactivators or corepressors. Although there is no 
direct data illustrating AhR-mediated squelching of E2-induced responses,  
 activation of other steroid hormone receptors does decreases ER-d pendent activation 
of some genes (116). 
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Diverse AhR agonists 
 AhR ligands have been separated into two major categories, those that are 
synthetic in nature (i.e., formed as a result of anthropogenic or nonbiological activity)  
and those occur naturally (i.e., formed in biological systems as a result of natural 
processes). The majority of the high affinity AhR ligands that have been identified and 
characterized to date are members of the first category and include planar, hydrophobic 
HAHs (such as the polyhalogenated dibenzo-p-dioxins, dibenzofurans, and biphenyls) 
and PAHs (such as 3-MC, Benzo(a) pyrene, benz[a]anthracenes, and benzoflavones), 
and related compounds (119-122). The metabolically more stable HAHs represent the 
most potent class of AhR ligands, with binding affinities in the pM to nM range, whereas 
the metabolically more liable PAHs bind with lower affinity (nM to m  range ). Strucure- 
activity relationships using a large number of HAHs and PAHs suggests that the AhR 
ligand binding pocket can bind planar ligands and that high affinity ligand binding 
appears to be dependent upon key electronic and thermodynamic characteristics of the 
ligands (122-127). There are many excellent reviews on the physiochemical 
characteristics and biological/toxicology potency of these “synthetic” HAH/PAH AhR 
ligands (122,127). An interesting recent development has been the identification of a 
relatively large number of AhR ligands whose structure and physiochemical 
characteristics are dramatically different from the “classical” HAH and PAH ligands 
(128). Classical AhR ligands and CYP1A1 inducers include TCDD, 3,3’,4,4’,5-
pentacholorobiphenyl, 2,3,7,8-tetrachlorodibenzofuran, 3-MC, benzo[a]pyrene, b-
naphthoflavone. Nonclassical synthetic AhR ligands and/or CYP1A1 inducers include 
YH439, thiabendazole, omeprazole, SKF71739, (1S. 2R)-(-)cis-1-amino-2-indanol, 5-
methyl-2-phenylindole, 2(methylmercapto)aniline, 1-methyl-1-phenylhydrazine, 1,5-
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diaminonaphthalene, guanabenz, SRN-P2:109.NH2, 2-(4-amino-3-
methylphenyl)benzothiazole (129). High-throughput screening analysis of a 
combinatorial chemical library using an AhR-responsive reporter gene system (130). 
has identified numerous novel AhR agonists, including several compounds whose 
structures contain only a single unsaturated ring (131). Although the majority of the 
currently identified nonclassical AhR ligands/agonists are relatively weak inducers of 
CYP1A1 and /or low affinity AhR ligands (when compared with TCDD), the identification 
of this striking structural diversity of AhR ligands is important because it indicates that 
the spectrum of synthetic AhR ligands is likely to be much broader than originally 
anticipated. Thus, attempts to identify endogenous and natural ligands should not be 
restricted by previous views of the structural requirements for AhR ligands. 
 The greatest source of exposure of animals and humans to AhR ligands 
(synthetic and natural) comes from the diet. Numerous studies have described and 
characterized a variety of naturlly occurring dietary chemicals that can directly activate 
and/or inhibit AhR signaling pathways. The earliest reports of natural AhR inducers 
came from observations that extracts of vegetables or vegetable-d rived materials 
could induce CYP1A1 activity (132,133). Subsequently, the ability of several dietary 
plant compounds, such as indole 3-carbinol (I3C) (121,132), 7,8-dihydrorutacarpine 
(134), dibenzoylmethanes(135), curcumin (136), and carotinoids [e.g., canthaxanthin, 
astaxanthin, and the apo-carotinoid, b-apo-8’carotenal (137,138)], to competitively bind  
the AhR  and/or induce AhR-dependent gene expression was reported. Conversion of 
dietary indoles (including I3C) in the mammalian digestive tract to significantly more 
potent AhR ligands/agonists was also demonstrated. In fact, indolo-(3,2,-b)-carbazole 
(ICZ), an acidic condensation product formed from I3C (itself a weak AhR ligand), has 
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perhaps the highest affinity of any “natural” AhR ligand identified to date (~0.2-3.6 nM), 
and it is a potent inducer of AhR-dependent gene expression in cells in 
culture(121,132). 3,3’-Diindolylmethane (DIM), another acidic condensation product of 
13C, is also an established AhR agonist (139). The formation of relatively potent AhR 
ligands from precursors that have little or no AhR agonist activity is significant, 
especially considering that most dietary ligands are themselves relatively weak AhR 
ligands/agonists. Flavonoids, including flavones, flavanols, flavanones, and isoflavones, 
represent the largest group of naturally occurring dietary AhR ligands. Although the 
majority of these natural plant products are AhR antagonists (140-144), numerous 
agonists, such as quercetin (145), diosmin (146), tangeritin (147), and tamarixetin (140), 
have also been identified. In addition to interacting with the AhR, many of these 
flavonoids are also substrates for CYP1A1 (148). These chemicals are widely 
distributed in dietary vegetables, fruits, and teas (149-151), and flavonoid levels in 
human blood have been reported to be in the low mM range (152-154), concentrations 
sufficient to inhibit/activate the AhR. Thus, it is not surprising that crude extracts of a 
large number of different vegetables, teas, fruits, and natural herbal products have AhR 
agonist and/or antagonist activity (155,156). Thus, plant-derived materials appear to 
commonly contain AhR ligands or products that can readily be converted into AhR 
ligands, and as such, they are perhaps the largest class of natural AhR ligands to which 
humans and animals are exposed. 
 The existence of endogenous physiological AhR ligands has been suggested by 
numerous studies in which the AhR signaling pathway is active in the absence of 
exogenous ligands. The identification of of nuclear AhR complexes in unexposed cells 
in culture and tissue slices (157-159), combined with the demonstration that disruption 
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of AhR expression using antisense resulted in decreased development of mouse 
blastocysts (160) and alterations in normal ce l cycle progression (161,162), supports 
the existence of endogenous AhR ligands. The ability of hydrodynamic shear stress 
conditions (163) as well as methylcellulose suspension (92,164) to induce CYP1A1 in 
cells in culture and of hyperoxia to induce CYP1A1 in rat lungs and liver in vivo (91,165) 
are consistent with the formation of endogenous AhR ligands in these conditions. The 
best evidence for a role of the AhR in normal development and 
physiological/biochemical processes derives from the occurrence of numerous 
physiological changes and developmental abnormalties in AhR knockout animals 
(41,166,167). These changes are presumed to result from loss of AhR activation by an 
endogenous ligand, although the identity of the responsible chemical(s) remains to be 
determined. Recently, however, a variety of endogenous chemicals have been 
identified that can bind to the AhR and/or active AhR-dependent gene expression. 
Although the majority of these chemicals are relatively weak when compared to TCDD, 
these studies confirm that such ligands do exist. Not surprisingly, these endogenous 
activators represent several structurally distinct classes of chemicals. These chemicals 
include indoles, tetrapyroles and arachidonic acid metabolites. Although the role of 
these chemicals in AhR signaling in vivo remains to be confirmed, their ability to 
activate the AhR in vitro and in cells in culture suggests that they may also play a role in 
regulating AhR function in vivo. 
AhR antagonists and mechanisms of action 
 One approach to questions involving the function of the AhR and the role of 
ligands in regulating this function is to determine how changes in ligand structure alter 
activity of the protein. A large number of studies have focused on the structure-activity 
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relationships for agonist activity of potential ligands (8,120,168,169). However, fewer 
studies have considered the structural basis for potential antagonist proprerties. A 
number of compounds that bind to the AhR and have weak agonist activity have been 
shown to antagonize some biochemical and biological responses induced by TCDD. 
These compounds include several  PCB congeners (170), 1-amino-2,7,8-
trichlorodibenzo-p-dioxin (171), 6-methyl-1,3,8-trichlorodibenzofuran (172), alpha-
naphthoflavone (ANF), and other flavone derivatives (173), 1,7- and 4,7-phenanthroline 
(174), as well as certain benzocoumarins (175) and ellipticines (176-179). Other than 
conforming to the structural requirements necessary for AhR binding as originally 
predicted by Poland and Knutson (119), revised by Gillner etal. (121), and recently 
refined by Waller and McKinney (123), there are no obvious structural similarities 
among these compounds that would suggest requirements for antagonist activity. This 
may be related, in part, to different endpoints examined as well as the potential of these 
compounds to elicit antagonist activity by different mechanisms. Nevertheless, a 
determination of any consistent structural features necessary for antagonist activity 
would be valuable in the identification and/or synthesis of potent antagonists that could 
be used as probes to define the ligand structural features required for AhR agonists. 
This approach would also delineate structure-dep ndent relationships among AhR 
actions, including TCDD-induced altered gene expression and other biological and/or 
toxicological responses. In an attempt to define such features, a number of ellipticine 
derivatives and structurally-related compounds were examined. This class of 
compounds was selected based on the ability of certain of them to bind to the AhR 
(176), inhibit its transformation to a DNA-binding state (177), and inhibit benzo[a]pyrene 
hydroxylase activity (176,179), a TCDD-inducible response. Certain ellipticine and 
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flavone derivatives represent two of the most potent groups of AhR antagonists 
identified to date.  
The structural requirement for substituted ellipticines and flavonoids that exihibit  
antagonist activity have been investigated using an assay which determines their 
inhibition of TCDD-induced binding of the AhR to a DRE in a gel mobility shift assay. 
The results showed that the compounds should fit the hypothetical van der Waals 
receptor cavity (123) and not contain bulky substituent groups. Secondly, the 
compounds should be planar and polycyclic aromatic/heteroaromatic. As previously 
suggested (123), these two properties appear to be required for the best binding activity 
of agonists or antagonists. Finally, an antagonist should possess an electron-rich 
heteroatom e. g. ring nitrogen, near or along an otherwise relatively unsubstituted X-
axis terminus of the van der Waals cavity (180). 
Potent AhR antagonists are planar, with a lateral electron ri h center. To further 
define structural requirements and mechanisms for antagonism, flavone derivatives 
were synthesized and the most potent flavones contained a 3’-methoxy group and a 4’-
substituent having one or more terminal atoms of high electron density (-N3, -NO2, or –
NCS). Furthermore, these compounds exhibited low agonist activity as indicated by 
their inability to induce AhR-D E binding or luciferase activity. Compounds containing 
bulkier 3’ or 4’-substituents, or a 3’-OH group were less potent ant gonists, and some 
were partial agonists. In rat liver cytosol, 3’-methoxy-4’azido- and 3’-methoxy-4’-
nitroflavones bound competitively to the AhR, indicating that they bind to the TCDD-
binding site. When hepatoma cells were exposed to these flavones, AhR complexes 
were primarily immunoprecipitable from the cytosol and contained the 90 kDa Hsp. In 
contrast, AhR in TCDD-treated cells was primarily immunoprecipitable from nuclear 
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extracts and was associated with Arnt but not the 90 kDa Hsp. Immunocytofluorescence 
analysis in intact cells further indicated that the potent AhR antagonists inhibited nuclear 
uptake of AhR and blocked TCDD-dependent down-regulation of AhR. These data 
indicate that the most potent antagonists bind the AhR with high affinity but canot 
initiate receptor transformation and nuclear localization (181). 
Bioflavonoids and related synthetic analogs exhibit a broad spectrum of 
biological activity. Naturally occurring plant flavonoids such as naringenin (flavanone), 
apigenin (flavone), and genistein (isoflavone) which are substituted with hydroxyl 
groups at the 4’ and 3,5,or 7 positions are weak estrogens which bind the estrogen 
receptor and elicit estrogen-induced responses (182-184). Other studies have reported 
that naturally occurring polyhydroxylated flavonoids, chalcones, and structurally related 
synthetic analogs exhibit antimutagenic and anticarcinogenic activities (185-192) and 
inhibit activities of a number of enzymes including protein kinases (193-196), porcin-5-
lipoxygenase (197), ornithine decarboxylase (192), glutathione, reductase (198), P450 
isozymes (199), and HIV proteinase (200). Bioflavonoids can also enhance some P450-
dependent activities, inhibit or enhance carcinogen-induced tumors or DNA binding 
(185,191,201-205) and inhibit human platelet aggregation (199). The flavonoid-
mediated effects are dependent on numerous factors including the structure of the 
compound, the target organ or cell, and the response.  
The synthetic flavone, 5,6-benzoflavone (b-naphthoflavone), inhibited 
carconigen-induced tumor formation in the mouse skin model and this activity was 
related, in part, to inhibition of P450-dependent metabolic activation of carcinogens 
(185,190-192). Interestingly, b-naphthoflavone binds to the AhR and is often used as a 
prototypical inducer of AhR-mediated CYP1A1 and CYP1A2 gene expression 
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(199,206,207). 7,8-Benzoflavone (a-naphthoflavone, aNF) binds with moderate affinity 
to the AhR and has been extesively characterized as a partial AhR antagonist (208-
212). It was shown that in various cancer cell lines, at concentrations < 10-6 M, aNF 
inhibited TCDD-induced CYP1A1 gene expression and this was paralleled by 
decreased formation of the nuclear AhR complex (208). In contrast, aNF was an AhR 
agonist at a concentrations of 10-5 M (213).  
Our laboratory has been investigating the modulatory effects of various, 3’,4’-
substituted flavones on AhR-mediated signal transduction pathways and among the 3’-
methoxy-4’-nitro, 4’-amino-3’-methoxy-, 4’-methoxy-3’-nitro-, and 3’-amino-4’-
methoxyflavones, 3’-methoxy-4’-nitro- and 4’-amino-3’-methoxyflavone have been 
extensively characterized as AhR antagonists. These compounds act by inhibiting 
formation of the nuclear AhR complex (173,180,181,214) (Fig. 5) and similar results 
have been observed for 2’-amino-3’-methoxy-flavone (215,216). However, many of 
these substituted flavones are also protein tyrosine kinase inhibitors and cytotoxic at 
doses > 10 mM (193,215,216). Henry and coworkers (181) investigated a series of 3’-
methoxy-4’-substituted flavones and showed that the most active AhR antagonists 
contained 4’substituents with high electron density (nitro, azido, and thiocyanate). It was 
hypothesized that this structural feature facilitated critical hydrogen bonding with the 
AhR. In contrast, 3’-methoxy-4’-aminoflavone was less active as an AhR antagonist 
(181) than previously observed in our laboratory in breast cancer cell lines (173), and 
this may be due, in part, to cell context. We also observed that although 4’-
methoxyflavone did not inhibit induction of CYP1A1 by TCDD, this compound blocked 
TCDD-induced transformation of the rat cytosolic AhR (214), and we therefore 
hypothesized that 3,’4’-dimethoxyflavone (DMF) (Fig. 5), which contains two vicinal 
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methoxy groups, may be an effective AhR antagonist in breast cancer cell lines despite 
the lack of a 4’-substituent with high electron density.  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG. 5. Structures of 3’-methoxy-4’-nitroflavone (1), 4’-amino-3’-methoxyflavone 
(2), and 3’,4’-dimethoxyflavone (3). 
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One of the research objectives of this study was to characterize 3’,4’-DMF as an AhR 
antagonist or agonist.  
Selective AhR modulators (SAhRMs) 
 Prolonged exposure to mitogenic stimulation by estrogen has been considered 
an important etiologic factor for development of breast and endometrial cancer (217). 
Tamoxifen has been used extensively for treating ER-positive tumors, however, 
tamoxifen acts as an ER-agonist in the uterus and increases the risk for endometrial 
cancer (218). Hence there is a need for development of new classes of antiestrogens 
that can be used alone or in combination with tamoxifen. Res arch in our laboratory has 
demonstrated that TCDD inhibits E2-induced responses in the rodent uterus and 
mammary tumors (growth inhibition) and in breast and endometrial cancer cell lines 
through complex inhibitory AhR-ER crosstalk. Inhibitory AhR-ER crosstalk is the basis 
for development of non-toxic AhR agonists or SAhRMs for modulating action of 
hormones in a tissue-specific manner. 6-alkyl-1,3,8-trichlorodibenzofuran and 
substituted DIM represent two structural classes of SAhRMs. These compounds are 
relatively non-toxic and inhibit ER-positive and ER-negative mammary tumor growth, 
and synergize with tamoxifen to inhibit breast cancer growth and block tamoxifen-
induced estrogenic activity in the uterus (219). Studies also indicate hat SAhRMs inhibit 
prostate cancer cell growth, and there is evidence for inhibitory AhR-androgen receptor 
crosstalk. SAhRMs represent a novel class of drugs for treatment of hormon-depentent 
cancers, and combined therapies of SAhRMs plus tamoxifen and other selective ER 
modulators (SERMs) provides a new approach for treating women with breast cancer 
(220). 
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 Several studies have shown that alternate-substituted (1,3,6,8- or 2,4,6,8-) 6-
alkyl-substituted PCDFs are relatively non-t xic AhR agonists that exhibit potent 
antiestrogenic activity. Dickerson and coworkers (221) compared the structure-
dependent antiestrogenic activity , in the female rat uterus, of a series of 6-alkyl-1,3,8-
substituted alkyl PCDFs substituted on two of the four lateral positions (2,3,7,8) to alkyl 
PCDD/PCDFs that contained three or four lateral substituents. The antiestrogenic 
potencies of most compounds were similar but the alkyl PCDFs substituted on three or 
four lateral substituents were more potent inducers of CYP1A1 than the 1,3,6,8-
substituted PCDFs and were potentially more toxic than the corresponding alternate-
substituted PCDF. The protoype for the alkyl PCDF, 6-methyl-1,3,8-
trichlorodibenzofuran (6-MCDF) (Fig. 6), exhibits low toxicity(52,222,223) but elicits the 
same broad spectrum of antiestrogenic responses reported for TCDD (52,221). Initial 
studies in the female rat uterus showed that MCDF was approximately 300-700 times 
less potent as an antiestrogen and 10,000-100,000 times less toxic than TCDD for the 
traditional AhR mediated toxic responses (224). MCDF bound competitively with 
moderate affinity to the rodent cytosolic AhR (EC50=10-100 nM) but was a weak agonist 
for several AhR-mediated biochemical and toxic responses including induction of 
lethality, porphyria, teratogenicity, immunotixicity and CYP1A1 and CYP1A2 (225). 
Moreover, MCDF exhibited partial antagonist activities for several TCDD-induced 
responses (110). 6-MCDF and 8-methyl-1,3,6-triCDF (8-MCDF) significantly inhibited 
(>75%) tumor growth in the DMBA-mammary tumor model at a doses of 25, 10 or 5 
mg/kg per week and at these doses hepatic CYP1A1-dependent activity was not 
induced by the alkyl PCDFs. Studies have shown that 6-MCDF can significantly inhibit 
tumor growth at doses as low as 50 mg/kg/day. MCDF and several alkyl PCDFs also  
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FIG. 6. Structures of SAhRMs, 6-MCDF, I3C and DIM. 
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exhibited antiestrogenic activity in he rodent uterus and inhibited E2-induced uterine 
cytosolic and nuclear ER and PR levels (226). 
 Treatment of MCF7 cells with 6-MCDF resulted in downregulation of the ER and 
inhibition of E2-induced cell proliferation and cathepsin D secretion (227). In a structure-
activity relationship study, the antiestrogenic activities of a series of alternate-
substituted PCDFs was investigated in the cell proliferation assay and a reporter gene 
assay using E2-responsive Vit-CAT plasmid. Results showed that MCDF (10-5M) 
inhibited both E2-induced cell proliferation and CAT activity while the other congeners 
inhibited at least one response (222). These data indicate that 6-MCDF, which does not 
exhibit any affinity for theER, may be a prototype of a novel class of AhR-mediated 
antiestrogens that could be developed for treatment of breast cancer. 
 I3C (Fig.6 ) is an important phytochemical derived from glucobrassicin (3- 
indolylmethane glucosinolate)-a major component of cru iferous vegetables. I3C 
exhibits a broad spectrum of antiestrogenic activities in MCF7 cells and 
anticarcinogenic activities in several organs/tissues in laboratory animals including 
inhibition of diethylnitrosamine induced neoplastic lesions in SD rats , benzo[a]pyrene-
induced forestomach tumors in mice, aflatoxin-B1-induced hepatocarcinogenesis in 
rainbow trout (228). Several studies have demonstrated that I3C inhibits carcinogen-
induced and spontaneous endometrial and mammary tumors in rodents (229-231).  
Several studies have suggested that the anticarcinogenic effects of I3C may be 
partly dependent on its acid- atalyzed condensation products such as DIM (Fig. 6) as 
well as cyclic (Ctet) and linear (Ltet) tetramers of I3C. In addition, indolo-(3,2,-b)-
carbazole, (ICZ) has also been identified as a minor product (232,233).  
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Both I3C and DIM competitively bind the AhR with low relative binding affinities  
of 1.0, 7.8x10-5 and 2.6x10-7 for TCDD, DIM and I3C respectively (132). In addition, I3C 
and DIM inhibited TCDD-induced responses including EROD activity, CYP1A1 mRNA 
levels, formation of nuclear AhR complex and reporter gene activity using an Ah-
responsive plasmid construct in T47D human breast cancer cells indicating that both 
I3C and DIM are partial AhR antagonists (234).  
I3C and related indoles modulate P450-dependent metabolism of steroid 
hormones in a species-, sex- and age-dependent manner. High doses of I3C induced 
estradiol-2-hydroxylase activity primarily associated with CYP1A2 as well as 6b-
hydroxylation of androsterone (52). Studies have shown that ICZ is antiestrogenic in 
MCF7 cells. ICZ inhibited estrogen-induced cell proliferation, and [3H] thymidine uptake, 
nuclear PR levels and secretion of procathepsin D (235). 
DIM binds the AhR and elicits several AhR-mediated responses including 
inhibition of human breast cancer cell growth via AhR-mediated pathways 
(132,139,236). Studies show that DIM (5mg/kg/every day) is a potent inhibitor of DMBA-
induced mammary cancer in female SD rats and this was not accompanied by induction 
of hepatic CYP1A1-EROD activity (237). Induction of CYP1A1 gene expression (a 
marker of potential toxicity) and antiestrogenic activities by TCDD are usually observed 
at comparable concentrations in MCF7 cells. However, DIM exhibited antitumorigenic 
activity at doses which did not induce CYP1A1-dependent EROD activity or alter organ 
weights or histopathology (237). Furthermore, comparable in vitro antiestrogenic 
responses were observed for TCDD and DIM in MCF7 cells. DIM inhibited E2-in uced 
proliferation of MCF7 cells at concentrations as low as 0.1 mM. DIM also inhibited E2-
induced CAT activity in cells transfected with the Vit-CAT plasmid at concentrations of 
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0.1-10 mM whereas 50-100 mM DIM induced CYP1A1 gene expression. DIM induced 
the formation of AhR complex in gel mobility shift assays at a concentration (10mM ) 
which did not induce CYP1A1gene expression (237). 
The response profiles for 6-MCDF, I3C, and DIM, namely low AhR-mediated 
toxicity and CYP1A1/CYP1A2 induction and high antiestrogenic activity, suggest that 
these compounds are a novel class of SAhRMs that selectively inhibits E2-induced 
responses and may be useful AhR-based drugs for treatment of breast cancer. 
Resveratrol interactions with AhR 
 Resveratrol is a polyphenolic phytoalexin that is found in both free and 
conjugate forms inhigh concentrations in grapes, grape juice, and red wine and in other 
plant extracts (238,239). For example, average concentrations of trans-resveratrol (Fig. 
7) plus the glucoside conjugate are 3.88 mg/L in red grape juices, whereas lowe levels 
of the corresponding cis-isomers (0.85 mg/L) (Fig. 7) have been observed (239).  
Extracts containing resveratrol have been used in Chinese and Japanese medicine for 
treating inflammation and cardiovascular disease, and these applications are consistent 
with many of the biochemical properties observed for resveratrol (240-245). For 
example, resveratrol inhibits the oxidation of low-density lipoprotein, platelet 
aggregation, and eicosanoid synthesis implying protection against coronary heart 
disease, and protects isolated rat hearts from ischemia reperfusion injury. The 
antioxidant activity of resveratrol is believed to give potential cardio- nd 
neuroprotective effects (246). A role for resveratrol in cardiovascular disease has been 
proposed (247), but the estrogenic activity of this compound is inconsistent between 
studies (248-250). Resveratrol also inhibits tumorigenesis in mouse skin and  
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FIG. 7. Structure of resveratrol (3,4’,5 trihydroxystilbene). 
 
development of preneoplastic lesions in carcinogen-induced mouse mammary glands 
(251), and these chemopreventive responses may be related to other biochemical 
effects of resveratrol that include antioxidant responses and inhibition of 
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cyclooxygenase activity (252-254). Resveratrol has been examined in several model 
systems for its potential effect against cancer. Its anti-cancer effects include its role as a 
chemopreventive agent, its ability to inhibit cell proliferation, and its direct effect in 
cytotoxicity by induction of apoptosis. Moreover resveratrol exhibited therapeutic effects 
in pre-clinical studies (255). Depending on its concentration, resveratrol can either 
stimulate (as shown in ER-positive breast cancer and pituitary cells) (256) or inhibit cell 
proliferation (257-259). At the concentrations used in vitro, resveratrol is predominantly 
anti-proliferative as demonstrated in a variety of cancer cell lines (260). The 
mechanism(s) for this growth inhibitory activity of resveratrol could be due to inhibition 
of ribonucleotide reductase, a complex enzyme that catalyzes the reduction of 
ribonucleotides into he corresponding deoxyribonucleotides (261). Inhibitors of 
ribonucleotide reductases, such as gemcitabine (2’-diflluoro-2’-deoxycytidine), are used 
clinically for their inhibitory effects on DNA synthesis (262). A second possible 
mechanism for the observed anti-proliferative activity of resveratrol could be related to 
inhibition of DNA polymerase (263) or ornithine decarboxylase (264) activities. The 
antioxidant activity of resveratrol could be yet another mechanism for growth inhibition, 
as a slight pro- xidant intracellular milieu, an invariable finding in cancer cells (265), is a 
strong stimulus for proliferation. Resveratrol also inhibits cell proliferation by inducing 
cell cycle arrest in the G1/S phase (260). Resveratrol has been shown to exert 
sensitization effects on cancer cells that results in a synergistic cytotoxic activity when  
used in combination with cytotoxic drugs in drug-resistant tumor cells. Clearly, these 
studies with resveratrol provide support for the use of resveratrol in human cancer 
chemoprevention and in combination with chemotherapeutic drugs or cytotoxic factors 
for treatment of drug-refractory tumor cells (255). 
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 Resveratrol inhibits CYP1A1 expression/levels and CYP1A1-dependent activity 
in both in vivo and in vitro models (266-269), and it has been suggested that resveratrol 
may be an AhR antagonist. Interestingly, other hydroxylated phytochemicals (145,146) 
such as flavones and the flavonols quercetin and kaempferol, also interact with the 
AhR, but the former compound is an agonist, whereas kaempferol is an AhR antagonist 
and blocks induction of CYP1A1 in MCF7 human breast cancer cells (145). Previous 
studies on resveratrol as an AhR antagonist (146,266,267) showed that although 
inhibition of CYP1A1 was commonly observed, resveratrol’s mechanism of action and 
its interaction with the AhR were inconsistent. For example, Ciolino and coworkers 
(146) reported that resveratrol does not competitively bind the AhR but blocksTCDD-
induced formation of the nuclear AhR complex; in contrast, Casper and coworkers (267) 
showed that resveratrol bound the AhR but did not block formation of a nuclear AhR 
complex in T47D cells cotreated with TCDD. Therefore, our research objective is to 
reinvestigate resveratrol-AhR interaction as an AhR antagonist.  
 Our studies confirm that resveratrol inhibits CYP1A1-dependent EROD activity 
in both MCF7 and T47D breast cancer cells, induces transformation and nuclear uptake 
of the AhR complex, but does not inhibit induction of reporter gene activity in cells 
transfected with an Ah-responsive construct containing the –1142 to +2434 region of 
the CYP1A1 gene promoter. Actinomycin D chase experiments demonstrated that 
resveratrol decreased CYP1A1 mRNA stability by post-transcriptional processes, 
thereby decreasing cellular CYP1A1 via AhR-independent pathways.  
 The AhR antagonist activities of resveratrol is different from that described for 
the more classical antagonist, 3’,4’-DMF. The potential clinical applications for 
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resveratrol are substantial, however, results reported in thesis should be consiered i  
evaluating specific treatment protocols. 
Nuclear receptors and mechanisms of action 
 Radiolabeled steroid and thyroid hormones of high specific activity were first 
prepared in the late 1960’s, and were used as probes to identify the sites of hormone 
action (270). It has been known for nearly 30 years that these hormones act via 
intracellular receptor proteins whose principal target for action is in the nucleus. The 
receptor proteins were quickly surmised to be regulators of transcrip io  (271-274), and 
are now known to be part of the nuclear receptor superfamily. This large group of 
transcription factors includes proteins that mediate the action of the steroid hormones 
(such as estrogens, androgens, glucocorticoids, mineralocorticoids and the insect 
steroid hormone ecdysone), as well as the non-steroid hormones  (for example, thyroid 
hormone, vitamin D3 and the retinoids) and receptors that mediate the peroxisomal 
proliferation response to fatty acids and other factors (111,275-278). 
 Many other members of the superfamily have been identified by low stringency 
hybridization analysis; some of the genes thus identified encode proteins that are 
known to be expressed and have the conserved six-domain structure seen for the 
hormone receptors (279). It is possible that some of these so-called receptors may act 
as transcription factors alone, without ligands. To add to the complexity, most classes of 
receptors within this family contain more than one subtype (i.e., products of closely 
related genes); sometimes there are also different isoforms (i.e., products from alternate 
transcription start sites on the same gene) and products of mRNA splice variants. Both 
the concentration of these receptors and the relative ratio of subtypes and isoforms vary 
in different target tissues and at different stages of development. 
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 The signature of the nuclear receptor family is a six-domain structure, the most 
highly conserved portion of which is the small (~70-80 amino acids) domain, C, that is 
responsible for DNA binding. This domain has been known for some time to have a 
helix-loop-helix structure containing two zinc atoms, each chelated by four cystein thiols 
at the start of each helix. Three residues at the start of the first helix in this domain 
‘read’ a five to six base pair code in a DNA hormone-response element; the mechanism 
of this sequence-specific recognition is becoming increasingly clear through structural 
analysis of domain C-oligonucleotide complexes by X-ray crystallography (280). The 
large (~250 amino acid ) domain, E, which is moderately conserved across members of 
the family, is responsible for hormone binding and dimerization, and is critical for the 
regulation of transcription. The other amino terminal A/B domain, the hinge domain D, 
and a carboxy-terminal domain F are poorly conserved in length and sequence across 
the receptor family, and are involved in the modulation of receptor function (Fig. 8). 
Recent advances have clarified the various ways in which these nuclear 
receptors can become activated, as well as some of the molecular details of the 
modulation of the transcriptional activity of specific genes. The essential and intricate 
role of the ligand in controlling the regulation of gene transcription by these receptors 
has also been clarified (281). Although hormones and growth factors that interact with 
receptors at the cell membrane may ultimately affect gene transcription, they induce 
multiple-step signal transduction pathways that are extranuclear and direct ligand-
dependent activation of nuclear receptors.  
The classical picture of gene activation via nuclear receptors requires initial 
hormone binding to the receptor. The resulting receptor-ligand complex binds as a 
dimer to a hormone-r sponse element in the promoter region of a regulated gene to    
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FIG. 8. Structures of nuclear receptors. Common domain structure of representative  
members of the nuclear receptor superfamily, including the human estrogen receptor a 
(hERa ), human glucocorticoid receptor a (hGRa), human thyroid hormone receptor 
(hTRa1), human retinoic acid receptor a (hRARa), and two orphan receptors COUP-TF 
and HNF-4. The DNA-binding domain C and ligand-binding domain E are shown with 
their percent sequence identity (or similarity, in parentheses) compared to hERa. 
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activate gene transcription. However, this simple model has additional complexities. For 
example, when estrogen binds to the ER in breast cancer d uterine cells the result is 
the stimulation of transcription from some early response genes, such as c-myc, nd 
genes for growth factors (such as TGFa- or pS2) or growth factor receptors (such as 
EGF receptor) that are involved in the hormonal stimuation of cell proliferation (282). In 
contrast, the same ligand-binding event in pituitary and liver cells results in activation of 
other genes. In the pituitary, the expression of various secreted proteins such as 
prolactin is increased, whereas in liver levels of vitellogenin, among others, is 
increased.  
 Another source of variability is the cellular distribution of the receptor in the 
absence of ligand. Receptors for certain non-steroidal ligands (e.g.,thyroid hormone and 
the retinoids) are already bound to their response elements in the absence of ligand 
(Fig. 9) (283). Ligand binding may strengthen DNA binding, and may alter the 
conformation of the receptor to enhance transcription. In the absence of ligand, DNA-
bound receptors repress gene transcriptional activity (284,285). In contrast, some 
steroid hormone receptors (e. g., the glucocorticoid receptor) are largely cytoplasmic in 
the absence of ligand. In the cytoplasm these receptors are complexed with h at-shock 
proteins, chaperonins, and other proteins such as immunophilins (286). Ligand binding 
induces release of these proteins and the receptor translocates into the nucleus, 
dimerizes, and interacts with appropriate hormone respons  elements (Fig. 9). In such 
a sheme, the unliganded receptor is not a transcriptional repressor, since it is held in 
the cytoplasm. And the cytoplasmic localization of unliganded receptors varies with 
different receptors and cell context.  
 Another level of variability in receptor action is the content of ligand-activated 
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FIG. 9. The subcellular location of unliganded nuclear receptors affects their 
modulation of gene transcription. (a) Unliganded receptors for nonsteroid ligands 
such as the thyroid hormone and retinoic acid receptors are typically bound as dimers 
to their hormone response elements (HREs), in the absence of ligand, and act as 
transcriptional repressors (b) The unliganded receptors for some steroid hormones, 
such as glucocorticoids, are largely held as monomers in the cytoplasm and are 
complexed with heat-shock proteins (90, 23), chaperonins (70) and immunophilins (40, 
52, 54); in this state, they have no effect on transcription. Ligand binding releases the 
receptor from the cytoplasmic aggregate, and the activated receptors bind as dimers to 
the HREs and activate transcription. 
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receptor dimmers. Non-steroidal hormone receptors such as the hyroid hormone, 
vitamin D and retinoic acid receptors can either form homodimers or heterodimerize 
with the retinoid X receptor (RXR) (279,283). The receptor for the insect steroid 
hormone ecdysone is active only as a heterodimer with the protein ultraspiracle, a 
homolog of the RXR. The preference of the thyroid, vitamin D and retinoic acid 
receptors for pairing with themselves or with another partner depends on several 
factors, including the relative cellular concentrations of the monomeric components (not 
forgetting the different subtypes and isoforms) and of their cognate liga ds. Ligand 
binding can, in some situations, modulate the formation of specific complexes (287).  
Dimerization of steroid hormone receptors primarily involves homodimerization. 
However, heterodimerization is possible between receptor sub ypes (which may have 
some differences in ligand-binding specificity) and between receptor isoforms (which 
often have distinctly different transcriptional activities). Examples of subtypes and 
isoforms that heterodimerize are the glucocorticoid recepto  a and b, and progesterone 
receptor A and B forms, respectively. Receptor dimerization and recpetor stability are 
important factors for development of pharmaceuticals such as hormone receptor  
antagonists (e.g., antiestrogens and antiprogestins, for exampl ) (288-291).  
 Interaction of nuclear receptors with the DNA response elements can also be 
variable. Response elements are portrayed as consensus sequences of inverted or 
direct repeats of a defined five- to six-nucleotide sequences, with various spacers 
between the repeats. However, such response elements found in responsive genes 
often contain functional nonconsensus sequences; half- ites and multiple repeats of 
response elements. These elements are often found in complex, upstream-enhancer 
regions, clustered together or even overlapping with response elements for other known 
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transcription factors, which may synergize or compete for binding with nuclear 
receptors. Sequences that flank the core response elements can also affect the DNA 
binding of these receptors (292). And the structure of the DNA response element, since 
it affects the recognition between the receptor and the DNA, may also affect the 
interaction between the receptor and the ligand. Given all these sources of variability, it 
is not surprising that the response to a specific hormone depends on both the cell in 
which it is acting and the gene whose activity it modulates (282). 
 A curious but major difference from the classical scheme for nuclea re eptor 
action is ligand-induced gene transactivation in the absence of direct DNA-binding by 
the receptor. For these genes the hormone-rec ptor complex functions by interacting 
with other DNA-bound transcription factors (293-295) such as fos/jun (AP1) and thus 
acts as a ligand- ependent co-regulator, rather than a ligand-dependent transcription 
factor.  
 Another major deviation from the classical scheme for activation of genes by 
nuclear receptors is ligand-independent transactivation. In some cells/tissues there is  
significant crosstalk between different signal transduction pathways that activate 
transcription. For example growth factors that operate through receptor tyrosine kinases 
or via cAMP or other second messengers can directly a ivate nuclear receptors in the 
absence of ligand (282). Moreover, in some cases, these alternative pathways may 
synergize with the normal ligand-mediated pathway (296). The molecular mechanisms 
for these interactions are not well understood, but it is possible that phosphorylation of 
specific sites on the nuclear receptors may enhance the transcriptional activity of the 
unliganded receptor (282,297). Several groups (297-299) have shown that ER can be 
phosphorylated on Ser-118 by mitogen-activated protein kinase, which is activated 
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through a cascade initiated by binding of EGF to its receptor. Mutation of this serine to 
an alanine abolishes EGF-mediated activation (298). Substitution of a glutamic acid, 
which can mimic a phosphorylated amino acid, permits EGF-mediated activation but 
does not produce a constitutively activated receptor (298). These data suggest that 
phosphorylation of Ser-118 is necessary, but insufficient, to induce EGF-mediated 
transcriptional activation and phosphorylation of another sites in ER or alteration of 
other factors are required.  
 Once a nuclear receptor is bound to DNA, the subsequent increase in the rate of 
gene transcription has its own sources of regulatory complexity. First, it is important to 
recognize that the rate at which a gene is transcribed depends both on the local 
chromatin architecture, and on the rate at which an active RNA polymerase preinitiation 
complex can be assembled. Nuclear receptors appear to affect both of these 
processes, both directly and indirectly via ‘transcription intermediary factors’ 
(TIFs)(277,300,301), although their effect on chromatin architecture is poorly 
understood. Ther is evidence that DNA-bound nuclear receptors interact directly with 
some of the proteins comprising the basal transcription machinery, such as TFIIB or 
TATA-binding protein associated factors (TAFs) (302-304). If they suppress or stimulate 
a rate-limiting step in the assembly of an active RNA polymerase II preinitiation 
complex, this would result in repression or activation of transcription. In many cases the 
relevant interactions between nuclear receptors and basal transcription factors appear  
to be indirect, and are mediated by various coregulatory proteins.  
Estrogen receptor 
 It was first shown that the effects of the hormone E2 required initial binding to a 
nuclear receptor ER (305) followed by binding to  a unique DNA sequence named ERE 
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(estrogen response element). The molecular mechanisms of estrogen action required 
the molecular cloning of the ER cDNA and the development of molecular biological 
techniques for analysis of transcription. A number of nuclear receptors ar  known to 
have subtypes encoded by similar but distinct genes and isoforms that are produced, in  
part, by alternative splicing. And these include TRa, b; ARa, b, g; RXR a, b, g; PPARa, 
b, g etc. may be raised. Interestingly, classical steroid hormone receptors (ER, GR, PR, 
and AR) were long thought not to have subtypes. 
 However, in 1996, Kuiper et al. (306) found in a rat prostate cDNA library a new 
type of ER designated as ERb, and the former (classical) receptor was designated as 
ERa. Subsequently, the human and mouse ERbs have also been cloned (307,308) and 
these cDNAs encoded ERb proteins lacked 53 amino acids at their N-terminus. The first 
complete human ERb cDNA was cloned by Ogawa et al. (309) and found to contain 530 
amino acids (Mr  59.2 kDa) and Figure 10 shows the structural comparison of the ERa 
and ERb. ERb has an amino acid identity of 96% to ERa in the DNA-binding domain 
(C), which strongly suggests that ERb would also recognize and bind ERE, and this has 
been confirmed by DNA binding experiments. The ligand binding domain (E) has much 
less homology between ERb and ERa (53%). However, Kd values for binding of E2 to 
ERb and ERa are similar  (e.g., 0.6 nM vs 0.2 nM) as determined in different 
laboratories (306,310). The N-terminal A/B and C-terminal E/F domains are known to 
have transactivation function 1 (AF1) and transactivation function 2 (AF2), respectively. 
The fact that these domains are much less conserved suggests that coregulatory 
proteins interacting with ERb and ERa are probably different.  
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FIG.10. Structural comparison of ERa and ERb. The A to F regions represent 
classical nomenclature for the structurally similar amino acid sequences of nuclear 
receptors. The degree (%) similarities of ERa and ERb in the A/B, C, D and E/F 
domains are indicated. 
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Crucial issues for ERa and ERb are their functional differences and roles in 
different organs at various stages of development. Tissue distribution of ERa and ERb 
is highly variable. ERa is highly expressed in major female organs such as ovary, 
uterus, vagina, mammary gland and certain areas of CNS especially in hypothalamus. 
ERb is not always significantly expressed in those cells except for ovary but higher 
levels of ERb are found in male organs and different areas of CNS including some part 
of hypothalamus and cerebral cortex. More specifically, in the rat, ERb mRNA was 
found to be expressed abundantly in prostate and ovaries and less abundantly in 
uterus, lung, testis, brain and artery (311). In the prostate there are higher levels of ERb 
in epithelial cells compared to stromal cells whereas ERa i expressed in both cell types 
(306). Human ERb m RNA is more abundantly expressed in testis rather than in 
prostate (307,310) suggesting that there are also species differences in the distribution 
of ERb. 
Specific antibodies for the study of ERa and ERb expression at the protein level 
have been utilized (312). In ovary, ERb protein is expressed more strongly in granulosa 
cells than in theca cells (312). In contrast, ERa is expressed in both cell types and also 
in interstitial cells (311). There are also ontogenetic changes in expression of ER 
subtypes; in the pituitary ERb is abundantly expressed from 12 days of gestation, while 
ERa appears only after 17 days. In the adult, ERa is widely distributed in anterior lobe 
of the pituitary gland, whereas ERb is restricted to certain regions of the anterior lobe 
(312).  
The ultimate role of these receptors has been investigated in the corresponding 
ER knockout animals. The first ERa knockout (ERKO) mice were produced by Lubahn 
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et al (313) in 1993. Deletion of ERa was not lethal but both male and female ERKO 
mice are infertile The basic female reproductive organs such as uterus, ovary and 
mammary gland were almost normally formed during the pre- and n onatal stages, 
suggesting compensation by other signaling pathways including ERb. However, 
development of these organs in ERKO mice after puberty was severely impaired 
indicating the requirement of these tissues for ERa and E2 (313). These organs 
remained immature. Female ERKO mice did not exhibit lordosis when mounted by a 
male, they became aggressive and frequently showed  infanticide (314). It was also 
observed that male ERKO mice showed abnormalities in spermatogenesis (315) a  well 
as sexual behavior and/or function, indicating that ERa plays a significant role even in 
male mice (315,316). When the first male human patient expressing an ERa ull 
mutation was found, the major symptoms were the extraordinary long longitudinal 
bones with epiphyseal unclosure and a lowered bone mass (317). However, this was 
not observed in male ERKO mice (311). Although they had similarity lowered bone 
mineral density, they had rather shorter longitudinal bones and this was also prevalent  
in female mice. This discrepancy may be due to the differences in bone physiology 
between humans and mice or to the genetic background of the patient. Incidentally, no 
female patients with either ERa or ERb deficiency has get been reported. Some 
aberrant bone metabolism may be expected considering that osteoporosis frequently 
occurs in postmenopausal women. There is evidence that a transgenic rat expressing a 
dominant negative ERa can maintain bone density but has a much lower capacity to 
recover from bone loss when ovariectomized rats are treated with E2. In fact, several 
alternatively spliced isoforms of ERb have been reported including ERb2 (318) and 
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ERbcx (310), the latter appearing to acts a dominant negative regulator of ERa but not 
ERb.  
It should be noted that the secondary effects of other factors especially in the 
hypothalamic-pituitary axis must be considered in analysis of knockout phenotypes. For 
example, phenotypic changes observed in ERa knockout mice indicate that in adults 
some of the effects are due to  the high circulating levels of lutenizing hormone (LH) 
which can result in failure of the normal maturational events in the ovary (311). 
More recently, ERb knockout (bERKO) mice and their phenotype has been  
analyzed (319). Homozygous mice were found to be fertile and did not exhibit abnormal 
sexual behavior in males or females. Female mice, however, exhibited a reduced 
ovarian function and fewr pups per pregnancy than normal females. Young male mice 
showed no apparent abnormalities, however, older mice exhibited hyperplasia of the 
prostate and bladder. Female ERb knockout mice tend to have longer and denser 
bones (320). Estrogen administration inhibits the response to vascular injury in 
ovariectomized female ERa and ERb knockout mice as observed in wild –type mice, 
suggesting that at least one of the ERs or an unidentified ER mediates the vascular 
protective effects of estrogen (321,322). The reproductive tract in bERKO mice are 
much less affected than in ERKO mice, however, this does not exclude a role for ERb in 
some aspects of reproduction. It is interesting to note that the phenotype of aromatase 
knockout mice closely resembles that of ERKO (but not bERKO) mice (323). The 
double-knockout of both ERa and ERb has also been reported; these animals are 
infertile and exhibit normal reproductive tract development until pre- a d neonatal 
stages (324). ERa -/- ERb-/- females exhibit abnormal follicle differentiation and then 
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follicles resemble seminiferous tubules of the testis. In addition, Sertoli-like cells appear 
and Mullerian inhibiting substance, sulfated glycoprotein-2 and Sox9 are also 
expressed. This apparent transdifferentiation indicates that a postnatal sex reversal 
occurs in the ovaries when both ERa and ERb are lost (324). 
Molecular mechanisms of action of ER 
 E2 acts by binding to ERa/ER. In addition to the well-known genomic effects 
exerted by E2 which are mediated by the classical nuclear receptors ERa and ERb 
(Fig.11), E2 also induces rapid responses (1-10 min) in different cellular models (325-
328). Indeed, both E2 and its cell-impermeant conjugate E2-BSA induce activation of 
intracellular second messengers such as calcium, nitric oxide formation, activation of 
kinases such as tyrosine kinases, protein kinase A and protein kinase C, extracellular 
signal-regulated kinase (ERK) and protein kinase B (PKB) both in neuronal, vascular 
and bone systems (326) (Fig. 11). Such rapid nongenomic effects are initiated at the 
plasma membrane level but the nature and characteristics of the mediating receptor is 
still a matter of debate (329). Studies on both nuclear and membrane receptor in CHO 
cells transfected with ER(330) and immunohistochemical analysis of pituitary cells (331) 
support the idea that E2-induced rapid effects are mediated by a small fraction of the 
nuclear a or b receptors targeted to the cell surface. However, classic ER does not 
posses either idrophobic domains or potential sites of myristoylation or palmitoylation 
that will anchor the receptor to the plasma membrane. However it is possible that the  
nuclear ER is associated with the  cell surface by interacting with plasma membrane-
associated caveolae and other membrane associated proteins. In fact, a subpopulation 
of ERa has been localized to plasma membrane caveole in endothelial cells where it 
mediates short term effects of E2 through activation of associated endothelial nitric  
 55
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG.11. Hypoyhetical model of estrogen action through different intracellular 
signaling pathways. A: genomic pathway through classical cytosolic/nuclear receptors 
acting as nuclear transcriptional factors; B: nongenomic pathway mediating rapid effects 
through unusual membrane receptor (B2) or classical cytosolic/nuclear receptor 
spanning through plasma membrane (B1) or acting through multi-proteic complex 
assosciated to the inner part of plasma membrane (B3). E2: estrogens; iER: classical 
cytosolic/nuclear ER; mER: membrane ER; Gp: G protein; iNOS: inducible nitric oxide 
synthase; NO: nitric oxide; TK: tyrosine kinases; AC: adenylate cyclase; SH2: Src 
homology domain; PLC: phospholipase C; PKA: protein kinase A; ERK1/2: ERKs1/2; 
DAG: diacyl glycerol; IP3: inositol 3-phosphate; PKC:protein kinase C; cAMP: cyclic 
adenosin monophosphate; PIP2: phosphatidyl inositol biphosphate. 
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oxide synthase (332).  
A different mechanism of nongenomic effects mediated by ER has been 
hypothesized for E2-induced proliferation in LNCap prostate and MCF7 breast cancer 
cells. Indeed, estradiol and androgen have been reported to simulate proliferation in 
prostate and mammary cancer cells through direct activation of Src at the plasma 
membrane (333,334). In this model, the androgen receptor (AR) and ERa/b bind to 
inactive Src forming a ternary complex associated with the inner side of the plasma 
membrane. This complex subsequently activates Src kinase through Ras/ERK effectors 
resulting in increased cell proliferation (333,334). This type of nongenomic model for 
ERa has been confirmed in MCF7 cells hypersensitive to E2 due to prolonged growth in 
E2-deficient media. In this model ER is sequestered at the plasma membrane and E2 
stimulates ERK through formation of ER complexed with Src/Grb2/SOS. Functional 
experiments in specific cell types that do not express either ERa or ERb (335-337) also 
exhibit nongenomic effects of E2 also in the absence of classic ER, suggesting that 
these rapid effects may be mediated by peculiar isoforms of ER, different from the a 
and b, that are expressed on plasma membranes (326,338-340) (Fig. 11). Indeed, a 
novel G-protein coupled membrane ER has been characterized in murine macrophage 
cell lines (335). Calcium influx stimulated by both E2 and E2-BSA is inhibited by 
pertussis toxin but not by classic ER blockers such as tamoxifen and raloxifen. 
Interestingly, the activated receptor is sequestered upon agonist stimulation in an 
energy and temperature-d pendent manner but independently of clathrin and caveolin 
pathways. A recent study indicates that the rapid effects exerted by estradiol in 
spermatozoa and testis are mediated by a membrane receptor of about 29 kDa 
molecular weight that is encoded by a distinct gene consisting of exons 4-8 of the ERa 
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gene associated with a novel exon called S which is not present in either ERa or ERb 
(341). A novel estrogen membrane receptor which mediates estrogen-like effects and 
has a similar molecular weight has also been identified in uterus, liver and human 
spermatozoa (339,341-343). Similarity between membrane ER and g-a renergic 
receptor has been also hypothesized (338). A putative ER which negatively regulates T-
type calcium-current in mammalian spermatogenic cells has been reported (344), while 
in Atlantic croaker both estradiol and xenoestrogens reduce production of androgens by 
Leydig cells in vitro, by binding to estrogen membrane receptors in the testis (327).  
 A novel functional ER involved in modulation of the rapid effects of  
progesterone has been identified in human sperm plasma (325,342,343). Indeed, 
progesterone at physiological concentrations similar to those found in tubal fluid and 
cumulus oophorous rapidly stimulates signal transduction pathways in human 
spermatozoa: and these include an increased intracellular calcium levels, acrosome 
reaction, activation of protein kinase C, ERK and phospholipase A2 (345,346). Western 
and immunofluorescence techniques have confirmed the presence of specific binding 
sites for 17bE2 on sperm surface (342,343,345). This 29 KDa membrane receptor 
shares hormone binding domain homology with nuclear ERa, mediates the rapid and 
sustained calcium influx stimulated by 17 E2 and interferes with the progesterone-
induced calcium response and acrosome reaction (343). Interestingly, the well-known 
environmental xenostrogens such as bisphenol A (BPA) and octylphenol polyethoxylate 
do not activate this membrane receptor response in human spermatozoa in vitro (325). 
 Although ERs in the membrane and nuclear ER act by very different 
mechanisms (signaling vs. transcriptional transactivation ), their biological roles may 
overlap or be complementary. E2 activates gene transcription using ER from both 
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receptor pools. One may envision that kinase signaling can rapidly activate 
transcription, which can then be sustained by subsequent action by nuclear ER which  
is facilitated by phosphorylation of ER coactivator proteins. Signaling from the 
membrane may also amplify the actions of the nuclear receptor and play a role in the 
posttranslational modification of proteins that are induced through transactivation. For  
example of the anti-apoptotic protein, Bcl-2 is activated by E2, in part through an Sp-1
site contained within the Bcl-2 promoter (100). Moreover, it has recently been shown 
that the survival function of Bcl-2 an be downregulated by phosphorylation within the 
“loop domain” of the protein (347). E2 can prevent inactivating phosphorylation of this 
protein by c-Jun NH2-terminal kinase (JNK), thereby enhancing breast cancer cell 
survival (348). Thus the activity and concentrations of this protein are modified by 
discrete cellular pools of ERs allowing both rapid and prolonged regulation of this cell 
survival protein. HSP27 and other family members associate with ERs, especially in 
breast cancer (349). The HSP27 gene is an acknowleged target for nuclear ER 
transcriptional upregulation (350). Recently, it has been shown that the modulation of 
HSP27 phosphorylation occurs in response to E2 acting at membrane ER and that this 
is important hormone-d pendent pathway in endothelial cells (351). Thus, membrane 
and nuclear pools of ERs have different but complementary actions to regulate the short 
and longer term cell biological consequences of HSP27 function.  
Coactivators 
 Steroid hormone receptors are members of a superfamily of ligand-dependent 
transcription factors. As such they have a DNA binding domain that recognizes specific 
target gene sequences along with separate transcriptional activation domains. What 
sets steroid hormone receptors (and other nuclear hormone receptors) apart from other 
 59
families of sequence specific transcriptional activators is the presence of a ligand 
binding domain (LBD) that acts as a molecular switch in which the hormone induces a 
conformational change in the receptor to turn on t anscriptional activity. Ligand bound  
steroid hormone receptors recruit coactivator protein complexes that play an essential 
role in receptor-mediated transcriptional activation. Coactivators function as adaptors in 
a signaling pathway that transmits transc iptional responses from the DNA bound 
receptor to the basal transcriptional machinery (352). Coactivators are generally defined 
as proteins that can interact with DNA-bound nuclear receptors and enhance their 
transcriptional activation function (353). Hormone receptor agonists induce a 
conformational change in the AF2 domain that creates a new protein interaction site on 
the surface of the LBD that is recognized by LXXLL motifs in the p160 family, steroid 
receptor coactivator (SRC) family of coactivators. In contrast, ER antagonists such as 
the antiestrogen tamoxifen induce an alternate conformation in AF-2 that occludes the 
coactivator binding site and recruits corepressors that can actively silence steroid 
responsive genes. Thus, the cellular availability of coactivators and corepressors is an 
important determinant in the biological response to both steroid hormone receptor 
agonists and antagonists (352). 
The SRC family of coactivators 
Although many nuclear receptor coacitvators have been identified, the SRC 
family has been the focus of intense study. The first nuclear receptor coacitvator, SRC-
1 was cloned by using the PR-LBD as bait in a yeast-two-hybrid screen of a human B-
cell cDNA library (354). SRC-1 interacts in a ligand-dependent manner with ER and 
other NRs and enhances AF-2 dependent transcriptional activation. Recent data also 
detail the enhancement of ER (355) and AR (356-358) AF-1 activities by SRC-1. In 
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addition, SRC-1 interacts with the general transcription factors TBP and TFIIB, although 
the functional consequences of these interactions are unknown (359,360). Furthermore, 
SRC-1 is able to enhance transcriptional activation mediated by NF-kB, SMAD3, and 
AP-1 (361-363), supporting a role for nuclear receptor coactivators in multiple 
intracellular signaling pathways. Subsequent studies have identified two functionally 
distinct SRC-1 isoforms, SRC-1a and SRC-1e, which contain unique C-termini, 
suggesting that alternative splicing may also regulate SRC-1 function (364). 
The identification of transcription intermediary factor 2 (TIF2) and GR-interacting 
protein1 (GRIP1) established the SRC family of coactivators (365,366). TIF2 was 
isolated in a Far-western screen as an ER-and RAR-interacting factor, while GRIP1 was 
isolated using the GR-LBD as bait in a yeast-two-hybrid screen. TIF2 and GRIP1 share 
94% amino acid identity, and represent the human and murine orthologs, respectively. 
TIF2 and GRIP1 associate in vivo with hormone-bound RAR, ER and PR and 
coactivate ligand- ependent transactivation. Like SRC-1, GRIP1 also enhances 
receptor AF-1 activity in addition to that of the AF-2 domain (356). Intriguingly, the 
inv(8)(p11q13) chromosomal translocation results in a fusion between TIF2 and MOZ 
gene, which contributes to the pathogenesis of acute myeloid leukemia (AML), 
suggesting a role for transcriptional regulation by nuclear receptor coactivators in these 
leukemias (367). 
The third member of the SRC family was reported simultaneously by several 
groups as an RAR-interacting protein (RAC3), a CBP-interacting protein (p/CIP), a 
hRARb-stimulatory protein (ACTR), a gene amplified in breast cancer (AIB-1), and a 
TR-interacting protein (TRAM-1) (368-372). p/CIP represents the mouse homolog, while 
RAC3/ACTR/AIB-1/TRAM are human isoforms. In addition to coactivating many nuclear 
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receptors, pCIP enhances the activity of interferon-a a d cAMP regulatory element 
binding protein (CREB), suggesting that this coactivator may be involved in multiple 
signaling pathways (370). Furthermore, RAC3/TRAM-1 expression can be upregulated 
by hormone treatment, which represents another possible mechanism by which 
coactivators potentiate hormone action (373,374). 
One of the most important remaining questions to be answered concerning the 
function of SRC coactivators in vivo focuses on whether or not these three cofactors 
serve redundant functions. Although all three SRC family members possess similar 
properties in terms of interactions with nuclear receptors and enhancement of 
transcriptional activation, several reports suggest that their activities are not completely 
overlapping and outline differences between SRC-1 and TIF2/GRIP1 versus 
RAC3/ACTR/pCIP/AIB-1 functions. For example, microinjection of expression plasmids 
for SRC-1 or NCoA-2, but not pCIP, were able to rescue RAR-dependent activation in 
SRC-1 immunodepleted cells (370). Also, the relative contribution of each coactivator 
may depend on cell or tissue type and/or coactivator levels in these cells. 
RAC3/ACTR/AIB-1 is expressed at high levels in placenta, heart, and HeLa cells 
relative to TIF2 and SRC-1; thus it may serve a more prominent role in regulating 
nuclear receptor function in these cells (374). In addition, AIB-1 was cloned as a gene 
that is amplified in ER-positive BT474, MCF7 and ZR75 breast cancer cell lines (372) 
and AIB-1 mRNA and protein levels are higher in these cells. SRC-1 and TIF2/GRIP1 
are expressed at relatively low levels in these cell lines, suggesting that AIB-1 is 
specifically involved in the pathogenesis of these tumors. Furthermore, the viability of 
an SRC-1 knockout mouse may, in part, be due to the observed compensatory 
overexpression of GRIP1/TIF2 in certain tissues (375). RAC3/pCIP levels are 
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unchanged in these tissues compared to the wild-type mouse, again supporting a 
different functional role for this coacitvator versus SRC-1 and TIF2/GRIP1. Finally, a 
recent study demonstrates that SRC-1 does not colocalize with ERa in rat mammary 
epithelial cells, but rather is expressed in a distict subset of cells, suggesting that 
TIF2/GRIP1 or RAC3/ACTR/AIB-1 may be more important for ERa function in these 
cells (376).  
The model of SRC function for regulating nuclear receptor activity is illustrated in 
Figure 12. Hormone binding triggers nuclear translocation of Type I steroid receptors 
(ER, PR, AR, GR and MR) and the release of the corepressor complex from Type II 
non-steroid receptors (RAR, TR and VDR) and subsequent recruitment of an SRC 
coactivator to the target gne promoter. SRC interacts with the AF-2 domain of each 
monomer of the dimer via multiple, a-helical nuclear receptor boxes (NR boxes) located 
in the receptor-interacting domain. SRC is likely complexed with the steroid receptor 
RNA coactivator (SRA), which enhances AF-1 activity. After initial SRC docking to the 
receptor, additional coactivators are recruited to the complex. These include CBP/p300, 
a cofactor of cAMP response element-binding protein (CREB), which uses the NR 
boxes of the SRC transcriptional activation domain for interaction with coacitvator, and 
the CBP/p300-associated factor P/CAF. Additionally, direct interactions between 
CBP/p300 and nuclear receptors and between P/CAF and SRC have also been 
reported, which may enhance complex formation. Furthermore, SRC recruits 
coactivator-associated arginine methyltransferase 1 (CARM1) to the target gene via a 
different domain than that required for CBP/p300 binding. Once this complex is 
assembled, the histone acetyltransferase (HAT) activities of CBP/p300, P/CAF, and 
possibly SRC itself, together with the histone methylase activity of CARM1, serve to 
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FIG.12.  Model of SRC coactivator function. Upon binding hormone the nuclear 
receptor recruits an SRC coactivator through ligand-dependent AF2 interaction, which 
subsequently results in the recruitment of additional coactivators to the complex. SRC  
interacts with the receptor and CBP/p300 via LXXLL nuclear receptor boxes. The 
histone acetylation and methylation activities of various constituents of the coactivator 
complex facilitate relaxation of the chromatin architecture at the target gene promoter, 
thereby enhancing transcriptional activation. It should be noted that this is only a 
general model for a coactivator complex. It is likely that additional cofactors are involved 
and that different receptors may recruit different components of the complex, thus 
achieving a level of specificity among receptors and coactivators. NR=nuclear receptor, 
SRC=steroid receptor coactivator, SRA=steroid receptor RNA coacitvator, 
CARM=coactivator associated arginine methyltransferase, CBP=CREB-binding protein, 
PCAF=p300/CBP-associated factor. 
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remodel the chromatin architecture, thus facilitating the access of additional 
transcription factors, coactivators such as the vitamin receptor interacting protein 
(DRIP)/ thyroid receptor associated protein (TRAP) complex, and/or the basal 
transcription machinery to the target gene promoter to activate transcription (353). 
Caveats to this model likely exist. The coactivator complex may contain different 
components depending on the specific nuclear receptor, cell type, or target gene. 
Different coactivator complexes may determine the specificity among different receptors 
and is consistent with the potential redundancy among the members of the SRC family.  
With the intense focus on hormone action and plethora of receptor cofactors that have 
been cloned, it is likely that additional members of the coactivator complex have yet to 
be identified. In addition, non-histone substrates for the enzymatically active cofactors 
may be involved; as described above, CBP/p300 can acetylate non-histone proteins 
such as ACTR, p53 and TFIIE/TFIIF. Finally, it is possible that receptors recruit single, 
pre-formed coactivator complexes to the target gene upon hormone binding. Although 
the precise details of transcriptional activation by nuclear receptors are unclear, the 
SRC family of coacitvators is critical to receptor function and will continue to warrant 
investigation on their role in intercellular signaling pathways (353). 
The LXXLL motif 
 The SRC family of coactivators shares a common domain structure, with the 
most highly conserved region being the N-t rminal bHLH-PAS domain (Fig. 13). The 
bHLH region functions as a DNA-binding or dimerization surface in many transcription 
factors, including the MyoD family of proteins (20,22). The PAS motif is also found in 
several transcriptional regulators, including Per, AhR, and Sim. Similar to the bHLH 
domain, the PAS domain also plays  a role in protein- protein interactions and  
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FIG.13.  SRC family domain structure.  Schematic representation of the structural 
domains of SRC coactivators. The N-terminus contains the highly conserved bHLH and 
PAS A/B domains. The centrally located receptor-in e acting domain (RID) and 
activation domain (AD) each contains three LXXLL motifs, while SRC-1 contains an 
additional, non-conserved motif at the C-terminus. The C-terminus contains a 
glutamine-rich domain. The specific domains for interaction with P/CAF, CBP/p300, and 
CARM1, as well as the histone acetyltransferase (HAT) domain, are indicated. 
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dimerization. However, the function of the bHLH-PAS domains of SRC coacitvators 
remains unknown, although it is likely to mediate intra- or intermolecular interactions. 
This bHLH-PAS domain is followed by a centrally located receptor interacting domain 
(RID) and C-terminal transcriptional activation domain (AD). C-terminal AD and RID has 
HAT activity. 
 The RID of SRC coactivators mediates ligand-dependent, direct interactions with 
nuclear receptors (114,374,377). Intriguingly, detailed analysis of the sequence of the 
RID identified a conserved LXXLL motif (NR box), where L is leucine and X is any 
amino acid (378). Three such motifs are found in the RID of SRC coactivators, with an 
additional, non-conserved NR box also present at the C-terminus of the SRC-1 isoform 
SRC-1a. Site-directed mutagenesis and peptide competition experiments have provided 
strong evidence for the requirement of these motifs for mediating interactions between 
coactivators and liganded nuclear receptors (370,378,379). Further support for the role 
of these motifs in mediating agonist-dependent interactions with nuclear receptors is 
found in a study in which phage-displayed peptide libraries were screened for peptides 
that interact specifically with agonist or antagonist bound ER (380). Many peptides 
isolated with estradiol-bound ERa contained the LXXLL motif, while those isolated with 
tamoxifen-bound receptor did not. These findings suggest that the activation of ERa by 
tamoxifen that is observed in some tissues might occur via a different mechanism than 
estradiol-induced activation, such as through the recruitment of non-LXXLL containing 
coactivators to tamoxifen-specific surfaces of the ER. Crystallographic and protein 
structure prediction analyses have indicated that these motifs form amphipathic a-
helices with the l ucine residues comprising a hydrophobic surface on one face ot the 
helix. The helix is able to interact with the AF-2 domain of the liganded receptor via a 
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hydrophobic groove made up of residues from receptor helices 3,4,5 and 12 that is the 
result of the conformational change induced by hormone binding (370,381-384). 
 The most interesting aspect of NR box function is the revelation that a receptor-
specific code exists, where different nuclear receptors prefer different NR boxes of the 
RID for interaction with coactivators (379,382,385,386). For example, a 13-aa peptide 
encompassing GRIP1 motif ii efficiently blocked interaction between GRIP1 and the 
TRb-LBD in vitro, while a peptide comprising motif iii was a more potent competitor for 
GR binding (382). Similarly, yeast-two-hybrid assays demonstrate that mutation of TIF2 
motif ii is most deleterious to interactions with PPARa, while a motif i mutation has the 
greatest effect on the TIF2-RXRb interaction (386). In all cases, however, mutation of a 
single motif does not completely abolish coactivator interactions with nuclear receptors, 
suggesting that multiple NR boxes contribute to the overall, high- ffinity binding to the 
receptor. It is likely that the precise arrangement of multiple motifs and structural 
nuances of each receptor determines the relative contributions of each NR box to the 
interaction.  
This receptor-specific code has also been analyzed in vivo in terms of 
transcriptional coactivation of nuclear receptors by SRC-1 via site-directed mutagenesis 
and antibody microinjection assays (385). The requirement of specific NR boxes for 
transactivation of reporter genes by different receptors was determined by injecting anti-
SRC-1 antibodies into cells along with rescuing plasmids for wild-type or NR box 
mutants of SRC-1. Anti-SRC-1 IgG completely abolishes transcriptional activation by 
ER, PR, RAR, TR and PPARg, while coinjection of wild-type SRC-1 rescues receptor 
function. Mutation of NR box ii prevented rescue of ER function in SRC-1 
immunodepleted cells, while NR boxes ii and iii were required for rescue of RAR and 
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TR activity and boxes I and ii for PR activity. Furthermore, in the case of PPARg, 
different ligands elicited different NR box requirements for SRC-1 coactivation. 
Troglitazone-bound PPARg preferred NR box ii over box i, while the opposite was 
observed in indomethacin-treated cells. Together, these data support receptor-specific 
LXXLL motif requirements for coactivation function and receptor interactions that 
account for the presence of multiple NR boxes within SRC coactivators and imply that 
these motifs do not serve merely redundant functions. 
Other determinants that contribute to the specificity of NR box selectivity by 
different nuclear receptors include residues flanking each NR box. For instance, a 
chimeric peptide containing the GRIP1NR box iii motif in the context of the flanking 
sequences of NR box ii competed for TR-LBD binding with a similar potency as the 
peptide comprising NR box ii (382). Also, using phage-displayed libraries enriched for 
LXXLL-containing peptides, it was demonstrated that several subclasses of these 
peptides exist which contain different flanking residues and which vary in their ability to 
interact with different ER mutants and other receptors (387). Furthermore, it has been 
shown that the flanking N-terminal amino acids are not essential, while the eight 
residues C-terminal to the NR box are required for SRC-1 mediated coacitvation of 
RAR, TR, and ER (385). These studies also revealed additional preferences of ER and 
RAR for different NR box ii C-terminal amino acids. Intact residues +12 and +13 (where 
L of LXXLL is +1) are required for SRC-1 rescue of ER activity, while residues at +6, +7, 
+11 and +13 are necessary for rescue of RAR function. Finally, since most nuclear 
receptors require two intact NR boxes for coactivator interactions, the spacing between 
the motifs can also serve as a determinant for recognition. Deletion of 30 of the 50 
amino acids between NR boxes ii and iii abolished the ability of SRC-1 to rescue IgG-
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mediated inhibition of RAR activity (385). In contrast, proper spacing between NR boxes 
i and ii was required for coactivation of PPARg, consistent with the requirement for intact 
motifs i and ii for maximal PPARg transactivation. 
In addition to SRC-1, a coactivator called proline glutamic acid and leucine-rich 
protein 1 (PELP1) is also a LXXLL dependent coactivator. For PELP1, a 540 aa region 
containing seven LXXLL motifs is important for the binding to ERa. Furthermore, 
transfection of PELP1 (541-1282), which has a deletion of the seven LXXLL motifs, 
failed to activate the transcription by E2 in RE reporter assays, suggesting that LXXLL 
motifs are required for ER binding, and subsequent transactivation coactivated by 
PELP1 (388). 
Coactivators that do not possess LXXLL motifs include CBP/p300-interacting 
transactivators with glutamic acid [E]/aspartic acid [D]-rich –C-terminal domain 1 
(CITED1). The N-terminal region of the conserved CR2 domain which shares a strictly 
conserved C-terminal transcriptional activating domain among the CITED family and 
binds to the CBP/p300 transcriptional integrators is required for functional interactions 
with ERs (389). 
LXXLL independent coactivators containing NR boxes have also been reported 
(390). For example, a coactivator called cell division cycle 25B (Cdc25B) contains a 
putative NR box (378) in the N-terminal region. The N-terminal fragment (aa 1 to 66) 
that contains a putative NR box failed to bind ER and Cdc25B with the NR box mutation 
still enhances ER and GR transactivation similar to that bserved for wild-type Cdc25B 
(390).  
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DRIP150 
Using an affinity column immobilized with the  LBD of the vitamin D receptor 
(VDR), a complex of at least 13 VDR interacting proteins (DRIPs) ranging in size from 
30 to 250 kDa were isolated from Namalwa B-cell nuclear extracts   (391,392). These 
proteins selectively bind as a complex to VDR in a 1,25(OH)2D3-dependent manner. 
DRIP150 is one of the DRIP complex which exhibits AF2-dependent interactions with 
the VDR and AR (393) and interactions with the AF1 domain of the GR (394). DRIP150 
is also a component of several multiprotein complexes. (i) DRIP150 is part of the DRIP-
thyroid hormone receptor associated protein (TRAP) complex, which binds in a ligand-
dependent manner to the AF2 regions of the VDR and TR in vitro, and is required for 
transcriptional activation by VDR and TR in vitro and in vivo (391,395). DRIP150 does 
not contact AF2 of VDR directly, but rather is brought to the AF2 region of VDR by 
another member of the complex, DRIP205 which is regarded as a main anchor DRIP 
(TRAP220/PPAR-binding protein (PBP)) which tethers the complex to the NR (392). (ii) 
DRIP150 is also a component of the NAT complex involved in transcriptional 
repression, and has been termed hRGR1 due to its homology to yeast RGR1, a 
component of the RNA polymerase holoenzyme mediator complex (396). (iii) The DRIP 
complex is essentially identical to the activator recuited ofactor (ARC) complex, which 
binds to and is required for transactivation by other transcription factors, such as 
SREBP-1a, NF-cB p65 and VP16 (397). (iv) DRIP150 is also a part of the SRB/MED-
containing cofactor (SMCC) transcriptional regulatory complex (398). DRIP150 is also a 
member of the smaller cofactor required for SP1 activation (CRSP) complex 
(CRSP150), which is required for SP1 activation in a purified transactivation system 
(399,400).  
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The differences between DRIPs and p160 (SRC) and p300 coactivators are as 
follows: first, this DRIP complex plays a more global role in transcriptional activation 
rather than being specific for nuclear receptors. For example, ARC was identified as a 
coactivator for VP16 and p65 (401), while SMCC enhances p53 activity (398). 
Secondly, the DRIP complex does not have intrinsic HAT activity. 
The mechanism by which the DRIP and SRC complexes contribute to nuclear 
receptor function is unclear. One possibility involves a two-step model (Fig. 14) in which 
the SRC complex with HAT activity is first recruited to the nuclear receptor to open up 
the chromatin network via histone acetylation (402). This would allow access for the 
large DRIP complex, which would subsequently remodel chromatin, facilitating the 
organization of the pre-initiation complex or binding of other transcription factors. 
However, it is also possible that the DRIPs may recruit RNA polymerase to the target 
gene promoter, for several subunits are homologous to proteins found in Mediator, a 
transcriptional regulatory complex that associates with RNA pol II (403). In support of 
this, RNA pol II can be isolated with the SMCC complex at low ionic stre gth (398). 
However, this model requires hormone-bound receptor binding to the DRIP complex 
which then binds the pol II holoenzyme to activate transcription (404). It is also possible 
that SRC and DRIP functions are not integrated, but exhibit cell-type, promoter, or 
transcription factor specificity. Specificity may also be the result of the alteration of one 
or more of the subunits of the complex, depending on the target gene. Overall, it is clear 
that the DRIP complex is likely involved in the regulation of a broad range of signaling 
pathways.  
The biological roles of DRIPs have been investigated in transgenic mouse 
models. Using the distrupted and mutated PBP (DRIP205) gene, it was reported that  
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FIG.14.  Model for coactivator assembly. A two-step hypothesis for recruitment of  
coactivators involves SRC-1 binding to nuclear receptors and recruits CBP. CBP and 
associated proteins induce HAT-dependent chromatin remodeling. DRIP complexes 
then bind receptors and subsequently recruit the RNA polymerase II complex. 
HRE=hormone responsive element. 
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DRIPs are essential for embryogenesis and eye-ant nnal disc development. PBP(+/-) 
mice are healthy, fertile, and do not differ significantly from PBP(+/+) control littermates. 
PBP null mutation (PBP(-/-)) in mice is embryolethal at embryonic day 11.5, suggesting 
that PBP is an essential gene for mouse embryogenesis (405). Drosophila homologues 
of the transcriptional coactivation complex subunits TRAP240 and TRAP230 are 
required for identical processes in eye-antennal disc development, suggesting that 
TRAP240 and TRAP230 act in concert to mediate an unknown developmental signal or 
a combination of signals (406). 
 One of the research objectives of this research is focused on the mechanism of 
DRIP150 coactivation of ERa and ERa/Sp1 in breast cancer cell lines. The studies 
have investigated the domain of DRIP150 required for functional activity and the results 
demonstrate the DRIP150 enhances ERa and ERa/sp1-dependent transactivation and 
coactivation of DRIP150 was LXXLL-independent. Analysis of DRIP150 has identified a 
unique aa sequence DIPAHLNIFSEVRVYNYRKLILC at aa region 789-811 that is 
required for coactivation activity.  
The model of DRIP150 coactivation for ERa-mediated transactivation is shown 
in Fig. 15. 
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FIG.15.  Model of DRIP150 coactivation for ERa-mediated transactivation. 
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CHAPTER II 
 
MATERIALS AND METHODS 
3’,4-DMF 
Cells, chemicals, biochemicals and plasmids 
 TCDD was prepared by Dr. S. Safe in this laboratory (> 98% pure by 
chromatographic analysis).  3',4'-DMF was purchased from Lancaster Synthesis Inc. 
(Windham, NH) (97%) carefully stored in the dark to avoid photodecomposition.  MCF-7 
and T-47D human breast cancer cells were obtained from the American Type Culture 
Collection (ATCC, Manassas, VA). Ethoxyresorufin, 17b-estradiol (E2), Dulbecco’s 
modified Eagle’s medium nutrient mixture F-12 Ham (DME F-12) without phenol red, a-
minimum essential media (aMEM), phosphate-buffered saline (PBS), acetyl-CoA, and 
100X antibiotic/antimycotic solution were purchased from Sigma Chemical Co. (St. 
Louis, MO).  Minimum Essential Medium (MEM) was purchased from Life Technologies 
(Grand Island, NY).  [a-32P]ATP (3000 Ci/mmol) and [14C]chloramphenicol (53 
mCi/mmol) were purchased from NEN Research Products (Boston, MA).  Poly[d(I-C)] 
and T4-polynucleotide kinase were purchased from Boehringer Mannheim 
(Indianapolis, IN).   The wild-type double-stranded DRE oligonucleotide 5'-GATCTC 
CGGTCCTTCTCACGCAACGCCTGGGG -3' and mutant DRE 5'-GATCTCCGGTCC 
TTCTACATCAACGCCTGGGG-3' were synthesized by Gene Technologies Laboratory 
(College Station, TX).  All other chemicals and biochemicals used in these studies were 
the highest quality available from commercial sources.  
Cell growth  
 MCF-7 cells were grown as monolayer cultures in MEM supplemented with 10% 
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fetal bovine serum plus sodium bicarbonate (2.2 g/L), gentamycin (2.5 mg/L), 
penicillin/streptomycin (10,000 units/L and 10 mg/L), amphotericin B (1.25 mg/L) and 10 
mg insulin. T47D cells were grown in aMEM supplemented with 2.2g/l sodium 
bicarbonate, 5% fetal bovine serum (FBS) and 10 ml antibiotic-antimycotic solution 
(Sigma).  Cells were maintained in 150-cm2 culture flasks in an air:carbon dioxide (95:5) 
atmosphere at 37°C.  The plasmid pRNH11c contains the regulatory human CYP1A1 
region from the Taq I site at -1142 to the BclI site at +2434 fused to the bacterial 
chloramphenicol acetyltransferase (CAT) reporter gene (kindly provided by Dr. R. 
Hines, University of Wisconsin at Milwaukee, Milwaukee, WI).  The creatine kinase B 
construct (pCKB) contains the -2900 to +5 promoter insert linked to a CAT reporter 
gene and was provided by Dr. P. Benfield (Dupont-Merck Pharmaceutical Co., 
Wilmington, DE).  The human ER (hER) expression plasmid was kindly provided by Dr. 
Ming-Jer Tsai (Baylor College of Medicine, Houston, TX).
Ethoxyresorufin O-deethylase (EROD) activity 
EROD activity was determined essentially as describd (407). Trypsinized cells 
were plated into 48-well tissue culture plates (2´10
5
 cells/ml), allowed to attain 60% 
confluency, and treated with 1 nM TCDD, 0.1 - 10 mM 3',4'-DMF or their combination for 
24 hr.  After 24 hr, cells were washed  by PBS; 185 ml of PBS was added to each well, 
and cells were incubated in a 37°C water bath for 2 min.  The reaction was started by 
adding 50 ml ethoxyresorufin (1 mg ethoxyresorufin/40 ml methanol) in a 37°C w ter 
bath for 13 min.  After incubation for 13 min, the reaction was stopped by adding 100 ml 
of fluorescamine.  The 48-well tissue culture plate was scanned for fluorescence 
measurements using the cytofluorTM 2350 fluorescence measurement system and 
results for each treatment group were determined as means ± SE for at least three 
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separate experiments. 
Transient transfection assay  
 Cells were seeded at ~60-7 % confluency in 100 mm tissue culture dishes in 
DME-F12 without phenol red medium supplemented with 5% FBS treated with dextran-
coated charcoal (DCC), 1.2 g/l sodium bicarbonate and 10 ml/l antibiotic solution.  After 
24 hr, cells were transiently cotransfected with 10 mg pCKB and 5 mg hER or 10 mg 
pRNH11c using the calcium phosphate method.  After 6 hr, cells were shocked with 
25% DMSO in PBS.  Cells were treated with chemicals dissolved in DMSO (0.1%)  for 
48 hr, and DMSO served as a control.  After 48 hr, cells were washed twice with PBS 
and scraped from the plates.  Cell lysates were prepared in 0.1 ml 0.25 M Tric-HCl, pH 
7.8 by three freeze-thaw-sonication cycles.  Protein concentrations were determined 
using bovine serum albumin (BSA) as a standard, and aliquots of cell lysate were 
incubated with 1 ml [14C]chloramphenicol (52 mCi/mol) and 42 ml of 4 mM acetyl-CoA at 
37°C.  Ethyl acetate was then added; the extract was dried, redissolved in 20 ml ethyl 
acetate and metabolites separated by thin-layer chromatography (TLC) in 95:5 
chloroform:methanol.  Following TLC, acetylated products were visualized and 
quantitated using Packard Instant Imager (M idian, CT).  CAT activity was calculated 
as the percentage of that observed in cells treated with DMSO alone (arbitrarily set at 
100%).  
Cell proliferation assay 
Cells were seeded at 7.5 X 104 cells/well in 6-well plates in media containing 2 
ml DME/F12 without phenol red, supplemented with 5% FBS treated with dextran-
coated charcoal (FBS-DCC).  After 24 hr, the media were changed (5% FBS-DCC) and 
cells were treated with E2, TCDD, 3',4'-DMF or their combinations for 11 days.  The 
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media was changed and cells were treated with the same chemicals every 48 hr.  Cells 
were then trypsinized,  harvested and counted using Coulter Z1 cell counter (Beckman 
Coulter, Brea, CA). 
Preparation of cytosolic and nuclear extracts 
Cytosol from male Sprague-Dawley rat liver was essentially prepared as 
described (Liu et al., 1993).  Cells grown in 100 mm Petri dishes and treated with 
DMSO and the test compounds  (3',4'-DMF or TCDD) dissolved in DMSO were 
harvested and washed twice in 5 ml HE buffer (25 mM HEPES, 1.5 mM EDTA; pH 7.6).  
Then 0.5 ml of HEGD (25 mM HEPES, 1.5 mM EDTA 10% glycerol, 1.0 mM 
dithiothreitol; pH 7.6) buffer was added to each plate and cells were scraped and 
incubated on ice, and then processed with a Dounce homogenizer. Homogenates were 
centrifuged at 12,000 x g for 5 min.  Supernatants were discarded, and the pelleted 
fractions were resuspended in 0.1 ml of HEGD buffer containing 0.5 M potassium 
chloride (pH 7.6), allowed to stand for 30 min to 1 hr at 4°C, nd nuclear extracts were 
prepared by centrifuging at 12,000 x g for 10 min at 4°C.  The supernatants 
representing nuclear extracts were collected and stored in -80°C until used.  The protein 
concentrations were determined using BSA as a standard.  Nuclei prepared by this 
method were found to be inact and were greater than 90% free of extranuclear cellular 
contamination, as determined by microscopic examination and trypan-blue staining. 
Gel electrophoretic mobility shift assay 
Nine pmol of synthetic human DRE oligonucleotide was labeled at the 5' end 
using T4-polynucleotide kinase and [a-32P] ATP.  Nuclear extracts from MCF-7 (5 mg) or 
T47D (2 mg) cells treated with DMSO (control), 5 nM TCDD, 5 mM 3',4'-DMF alone or in 
combination were incubated in HEGD buffer with poly[d(I-C)] for 15 min at 20°C.  The 
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mixture was incubated for an additional 15 min (20° C) after the addition of [32P]-labeled 
DNA.  Reaction mixtures were loaded into a 5% polyacrylamide gel 
(acrylamide:bisacrylamide, 30:0.8) and electrophoresed at 110 V in 0.9 M Tris borate 
and 2 mM EDTA, pH 8.0, and analyzed as described below for the transformed 
cytosolic AhR-DRE complex.  Rat liver cytosol was incubated with different 
concentrations of 3',4'-DMF alone or in combination with TCDD at 20°C for 2 h.  Cytosol 
(80 mg) in HEGDK buffer [HEDG + 0.4 M potassium chloride) with 1 mg of poly[d(I-C)] 
was further incubated for 15 min at 20°C.  A 100-fold excess of unlabeled wild type and 
mutant DRE oligonucleotides was added for the competition experiments and incubated 
at 20°C for 5 min. Following addition of [32P]-labeled DNA, the mixture was incubated 
for an additional 15 min at 20°C. Protein-DNA complexes were resolved on a 5-6% 
polyacrylamide gel (acrylamide:bisacrylamide ration, 30:0.8) and run in 1X TBE buffer 
(0.9 M Tris, 0.09 boric acid, 2 mM EDTA, pH 3.8) at 110 V.  Bound complexes were 
visualized by autoradiography and quantitated by densitometry using the Molecular 
Dynamics Zero-D software package (Sunnyvale, CA) and Sharp JX-330 scanner 
(Sharp, Mahwah, NJ), and subjected to autoradiography using a Kodak X-Omat film 
(Eastman Kodak, Rochester, NY) for appropriate times at -80°C.
Statistical analysis 
Statistical differences between different treatment groups were determined using 
Student's t test or ANOVA (Scheffe's) and the levels of significance were noted (p < 
0.05).  The results were expressed as mean ± SE for at least 3 replicate determinations 
for each experiment. 
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Resveratrol 
Cells, chemicals and biochemicals 
TCDD was prepared in this laboratory (> 98% pure by chromatographic 
analysis) and resveratrol (99%) was commercially available from Sigma Chemical Co. 
(St.Louis MO).  Trimethoxyresveratrol was quantitatively prepared from resveratrol by 
methylation of resveratrol using diazomethane in ether/methanol and by monitoring the 
reaction progress by thin-layer or gas-liquid chromatography.  The resulting product 
was >99% pure by gas chromatographic analysis.  3'-Methoxy-4'-nitroflavone was 
prepared as described (Lu et al., 1995). Actinomycin D and dehydroisoandrosterone 
(DHEA), ethoxyresorufin, Dulbecco’s modified Eagle’s medium nutrient mixture F-12 
Ham (DME F-12) without phenol red, a-minimum essential media (aMEM), phosphate-
buffered saline (PBS), acetyl-CoA and 100X antibiotic/antimycotic solution were 
purchased from Sigma Chemical Co.  MCF-7 and T47D human breast cancer cells 
were obtained from the American Type Culture Collection (ATCC, Manassas VA). 
Minimum Essential Medium (MEM) was purchased from Life Technologies (Grand 
Island, NY). [g-32P]ATP (3000 Ci/mmol) and [14C]chloramphenicol (53 mCi/mmol) were 
purchased from NEN Research Products (Boston, MA). Poly[d(I-C)] and T4-
polynucleotide kinase were purchased from Boehringer Mannheim (Indianapolis, IN).  
The dioxin response element (DRE), and mutant DRE were synthesized by the Gene 
Technologies Laboratory at Texas A&M University. The murine CYP1A1 cDNA probe 
was obtained from ATCC and the plasmid pGMB1.1 was a gift from Dr. Don Cleveland 
(Johns Hopkins University) and carries the mouse b-tubulin cDNA into the EcoR I site of 
pGMB1.1.  Digestion of the plasmid yielded a 1.3-kb fragment that was used to detect 
b-tubulin mRNA. RNA extraction solution (RNA STAT-60TM) was purchased from Tel-
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Test (Friendswood, TX).  All other chemicals and biochemicals used in these studies 
were the highest quality available from commercial sources. The plasmid pRNH11c 
contains the regulatory human CYP1A1 region from the Taq I site at -1142 to the BclI 
site at +2434 fused to the bacterial CAT reporter gene (kindly provided by Dr. R. Hines, 
University of Wisconsin at Milwaukee WI).
Cell growth  
 MCF-7 cells were grown as monolayer cultures in MEM supplemented with 10% 
fetal bovine serum (FBS, Intergen, Purchase, NY) plus NaHCO3 (2.2 g/L), gentamycin 
(2.5 mg/L), penicillin/streptomycin (10,000 units/L and 10 mg/L), amphotericin B (1.25 
mg/L) and 10 ug insulin. T47D cells were grown in aMEM supplemented with 2.2g/l 
sodium bicarbonate, 5% FBS and 10 ml antibiotic-an mycotic solution (Sigma).  Cells 
were maintained in 150-cm2 culture flasks in an air:carbon dioxide (95:5) atmosphere at 
37°C.  Media was changed twice per week and when cells became confleunt, cells were 
trypsinized, passed and reseeded for use in specific studies.  
EROD activity 
EROD activity was determined as described (407). Trypsinized cells were plated 
into 48-well tissue culture plates (2 x 105 cells/ml), allowed to attain 60% confluency, 
and treated with 1 nM TCDD, 0.1-10 mM resveratrol for 18-24 hr. For kinetic studies, 
cells were pretreated with 1 nM TCDD for 18 hr, media was removed and cells were 
then treated with DMSO, 10 mM resveratrol and 0.5 mM MG132, a proteosome inhibitor 
for 1, 3, and 12 hr. Cells were washed with PBS and 185 ml of PBS was added to each 
well and incubated in a 37°C water bath for 2 min. The reaction was started by adding 
50 ml ethoxyresorufin (1.25 mg) in a 37°C water bath for 13 min.  After incubation for 13 
min, the reaction was stopped by adding 100 ml of fluorescamine (60 mg). 
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Fluorescamine was added to standard wells and the 48-w ll tissue culture plate was 
scanned for fluorescence measurement in Cytofluorä 2350 fluorescence measurement 
system as described (Willett et al., 1997).  Each treatment was carried out in triplicate 
and results are presented as means ± SE. 
Microsomal preparation  
Cells grown in 150 mm plates were treated with 1 nM TCDD for 24 hr; cells were 
then trypsinized, resuspended in 10 ml HEGD buffer (25 mM HEPES, 1.5 mM EDTA, 
10% glycerol, 1.0 mM dithiothreitol; pH 7.6) and centrifuged. The supernatant was 
discarded and 0.5 ml hypotonic HED buffer (25 mM HEPES, 1.5 mM EDTA, 1.0 mM 
dithiothreitol; pH 7.6) was added to the pellet; the pellet was resuspended and placed 
on ice for 10-15 min. Samples were centrifuged for 10 min and homogenized using a 
Teflon pestle/drill apparatus. HEGD buffer (1 ml) was added to the homogenates and 
centrifuged at 3,000 rpm for 10 min. The resulting supernatant was further centrifuged 
for 45 min at 4°C, and the microsomal pellet was resuspended in 100 ml Tris-sucrose 
buffer (38 mM Tris-HCl, 0.2 M sucrose; pH 8.0) and stored at -80°C until used. The 
protein concentration of the microsomal pellet was quantitated by the method of 
Bradford (1976).  Microsomes were diluted with a cofactor solution containing BSA, 
NADPH, NADH, and MgSO4 in 0.1 M HEPES  to 20 mg protein/5 ml, and 5 ml aliquots 
were added to 96-well Falcon plates at 0°C, treated with DMSO and different 
concentrations of inhibitors.  Fifty ml of 25 mM ethoxyresorufin was added to each well 
and incubated at 37°C for 10 min, and the reaction was stopped by addition of 100 ml of 
MeOH. EROD activity was determined in CytofluorTM 2350 fluorescence measurement 
system. The Control experiment was carried out using trimethoxyresveratrol and 
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diindolylmethane (DIM). Each experiment was determined in triplicate and results are 
expressed as means ± SE. 
Transient transfection assay  
The plasmid pRNH11c contains the -1142 to +2434 regulatory region from the 
human CYP1A1 gene fused to the bacterial chloramphenicol acetyltransferase (CAT) 
reporter gene. Cells were seeded in 100 mm Petri dishes and grown until 70% 
confluent. Ten mg of the test plasmid, 2 mg of the b-galactosidase plasmid and 2.5 M 
calcium chloride were used for transfection. After transfection for 6 hr, cells were 
shocked using 25% glycerol in PBS and treated with the test chemicals (resveratrol, 
TCDD or their combination) for 30-48 hr.  Cells were washed with PBS and scraped 
from the plates. Cell lysates were prepa d in 1X lysis buffer (Promega) by freeze-thaw 
cycles with liquid nitrogen. Protein concentrations were determined using BSA as a 
standard.  Each cell lysate (20 mg) was incubated with 0.2 mCi d-threo-[dichloroacetyl-
1-14C]chloramphenicol and 4 mM acetyl-CoA as substrates at 37°C for 2-5 hr. Following 
thin-layer chromatography, acetylated metabolites were visualized and quantitated 
using a Packard Instant Imager (Meridian, CT). CAT activity was calculated as the 
percentage of that observed in cells treated with DMSO alone and normalized relative 
to b-galactosidase activity.  
Preparation of cytosolic and nuclear extracts 
Hepatic cytosol from untreated female Sprague-Dawley rats was essentially  
prepared as described (Lu et al., 1995).  Cells grown in 100 mm petri dishes and 
treated with DMSO and the test compounds (resveratrol or TCDD) for 30 min to 1 hr 
were harvested and washed twice in 5 ml HE buffer (25 mM HEPES, 1.5 mM EDTA; pH 
7.6). 0.5 ml of HEGD (25 mM HEPES, 1.5 mM EDTA 10% glycerol, 1.0 mM 
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dithiothreitol; pH 7.6); buffer was added to each plate and cells were scraped, incubated 
on ice and processed using a Dounce homogenizer. Homogenates were centrifuged at 
12,000 g for 5 min; the supernatant was discarded and the pelleted fraction was 
resuspended in 0.1 ml of HEGD buffer containing 0.5 M potassium chloride (pH 7.6). 
After incubation for 30-6  min at 20°C, the nuclear extracts were obtained by 
centrifugation at 12,000 g for 10 min at 4°C. The supernatants representing nuclear 
extracts were collected and stored in -80°C until used. Nuclei prepared using this 
procedure was >90% free of extranuclear material as determined by trypan blue 
staining. 
Gel electrophoretic mobility shift assay 
Nine pmol of synthetic human DRE oligonucleotide was labeled t the 5' end 
using T4-polynucleotide kinase and [A-32P]ATP and incubated with 5 ml 10X 
phosphorylation buffer, 3 ml polynucleotide kinase (10 m/ml), 33 ml H2O and 5 ml [32P]- 
labeled ATP mixture at 37°C for 30 min. The mixture was purified through TE-10
column (Clontech) and [32P]DRE (120,000 cpm) was used for each sample. Nuclear 
extracts (2-5 mg) from cells treated with DMSO, 5 nM TCDD, 5 mM resveratrol or TCDD 
plus resveratrol were incubated in HEGD buffer with 1 mg salmon sperm DNA at 20°C 
for 10 min to bind non-specific DNA-binding proteins. Excess (100-fold) unlabeled wild 
type DRE or mutant DRE was added to some samples and incubated at 20°C for 5 min. 
Experiments with rat liver cytosol (80 mg/incubation) used different concentrations of 
various compounds which were then incubated at 20°C for 2 hr. The mixtures were 
further treated with 1 mg of poly[d(I-C)] for 15 min at 20°C, and competition experiments 
used 100-fold excess of unlabeled wild type and mutant DRE and incubated at 20°C for
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5 min.  [32P]-labeled DNA was then added to cytosolic or nuclear extracts and incubated 
for an additional 15 min at 20°C. Reaction mixtures were loaded onto 5% 
polyacrylamide gel and electrophoresed at 120V in 0.9 M Tris-borate and 2 mM EDTA, 
pH 8.0. for 2.5 hr. Gels were dried and protein-DNA complexes were visualized by 
autoradiography using a Packard Instant Imager. The gel was also exposed to a 
phosphoscreen for 12 hr and visualized by autoradiography using a Storm 
PhosphoImager (Molecular Dynamics, Sunnyvale, CA). 
RNA preparation and northern blot analysis  
Cells were plated into 100 mm petri dishes with media containing 5% charcoal-
stripped FBS and, when cells reached 60% confluency, they were treated with 1 nM 
TCDD, 5 mM resveratrol, or their combinations in serum free media for 6 hr. For the 
kinetic study, cells were pretreated with 1 nM TCDD in serum free media for 12 hr, 
media was changed and DMSO, DHEA (1 mM) and resveratrol (5 mM) with 5 mg/ml 
actinomycin D was added to each plate for 2, 6, and 10 hr.  After treatment, RNA was 
extracted from the plates using RNA STAT-60TM purchased from Tel-Test 
(Friendswood, TX).  RNA extracts from different treatment groups were dissolved in 
nuclease free water, heated at 55-60°C for 15-30 min, vortexed, and quantitated at 
260/280 nm. RNA (30 mg) was mixed with 2x sample buffer (20% formaldehyde, 1.65% 
1M Na2HPO4, pH 6.8, 63.5% formamide and 15% 6X loading buffer), electrophoresed 
on a denaturing 1.2% agarose gel at 60 V for 2.5 hr, and transferred to a hybond nylon 
membrane in 1X SPC buffer (20 mM Na2HPO4, 2 mM CDTA, pH 6.8) for 36-48 hr. The 
membrane was then exposed to UV light for 5 min to cross-link RNA to the membrane 
and baked at 80°C for 2 hr. The membrane was then prehybridized in a solution 
containing 5X SSPE (0.75 M NaCl, 50 mM NaH2PO4, 5 mM EDTA), 10% dextran 
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sulfate, 0.1% polyvinyl pyrolidine, 0.1 % ficoll, 0.1% bovine serum albumin and 1% SDS 
for 18-24 hr at 62°C. The CYP1A1 or b-tubulin cDNA probes were [32P]-labeled using a 
Boehringer-Mannheim random primer kit. [32P]-labeled cDNA (5 x 106 cpm) probes were 
heated at 100°C for 5 min and cooled on ice for 5 min prior to use and the membrane 
was hybridized for approximately 24 hr in the prehybridization solution. After 
hybridization, the membrane was washed at 20°C for 15 min (2X) in a solution 
containing 1X SSPE and 2% SDS, sealed in a plastic bag.  Bands were scanned using 
a Packard Instant Imager, and the membrane was exposed to phosphoscreen for 1-2 
days. CYP1A1 signals were visualized by autoradiography and qutitated using a 
Storm PhosphoImager.  The membrane was then stripped by the washing solution at 
62°C for 10 hr, prehybridized for at least 2 hr and rehybridized with 5 x 106 cpm [32P]-
labeled b-tubulin cDNA probe (in 10 ml) for 24 hr.  Washing, visualizat on and 
quantitation methods were carried out as described above, and CYP1A1 mRNA was 
standardized relative to b-tubulin mRNA. 
Statistical analysis 
Statistical differences between different treatment groups were determined using 
Student's t test or ANOVA (Scheffe's) and levels of significance were noted (p < 0.05). 
Results were expressed as means ± SE for at least three replicate determinations for 
each treatment group. 
DRIP150 
Cell lines, chemicals  and biochemicals 
 The ZR-75 human breast cancer cell line was obtained from the American Type 
Culture Collection (ATCC, Manassas, VA) and cells were cultured in RPMI-1640 
(Sigma, St. Louis, MO) supplemented with 10 % fetal bovine serum (FBS) (Summit 
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Biotechnology, Fort Collins, CO). Medium was further supplemented with sodium 
bicarbonate, glucose, Hepes, sodium pyruvate  and antibiotic/antimycotic solution 
(Sigma). Cells were maintained at 37°C with a humidified CO2:air (5:95) mixture. 
Phenol-free Dulbecco’s modified Eagle’s medium/F-12 media, phosphate-buffered 
saline, and E2 were also obtained from Sigma. [g-32P] ATP (3000Ci/mmol) was 
purchased form PerkinElmer Sciences (Boston, MA) and poly [d(I-C)] from Roche 
Molecular Biochemicals (Indianapolis, IN). Restriction enzymes, 5x luciferase lysis 
buffer, luciferin and TNT7 in vitro translation kit were purchased from Promega 
(Madison, WI). Reagents for b-galactosidase analysis were obtained from Tropix 
(Bedford, MA) and anti-Xpress antibody from InVitrogen (Carlsbad, CA). ER antibodies 
for gel mobility shift and coimmunoprecipitation assays and ProteinG-plus Agarose 
were purchased from Santacruz Biotechnology (Santacruz, CA). Recombinant human 
ERa protein was obtained from PanVera (Madison, WI) and all other chemicals and 
biochemicals were obtained form commercial sources at the highest quality available. 
Oligonucleotides and plasmids 
 The consensus estrogen-response element (ERE) probe used in gel mobility 
shift assays was synthesized by the Gene Technologies Laboratory (College Station, 
TX) and the sequence was 5’-GTC CAA AGT CAG GTC ACA GTG ACC TGA TCA 
AAG TT-3’. ERa expression plasmid was kindly provided by Dr. Ming-Jer Tsai (Baylor 
College of Medicine, Houston, TX). Expression plasmids for ERa mutants with deletion 
of amino acid 1- 78 (HE19) and TAF1 containing D538N, E542Q, and D545N 
mutations were kindly provided by Dr. Pierre Chambon (Institut de Genetique et de 
Biologie Moleculaire et Cellulaire, Illkirch, France) and Dr. Donald McDonnell (Duke 
University, Durham, NC), respectively. cDNA encoding DRIP150 was kindly provided by 
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Dr. Leonard P. Freedman (Merck Research Laboratories, West Point, PA). The 
expression plasmid for the GRIP-1 NR-box polypeptide GAL4 fusion protein was also 
provided by Dr. Donald McDonnell (Duke University). The expression plasmid for the 
AF1 polypeptide was generated in this laboratory by cloning amino acids 1-180 of ERa 
into NheI/EcoRV site of pcDNA3.0.  pcDNA3.1 –His-LacZ was purchased from 
InVitrogen (Carlsbad, CA). The pERE3  reporter containing three consensus ERE sites 
linked to a luciferase gene was created by cloning an oligonucleotide with three ERE 
elements into BamHI- indIII cut pXP-2 plasmid (408). ERa-GAL4 fusion protein was 
constructed as follows. First, the GAL4DBD fusion expression vector pM 
(CLONTECH,PaloAlto, CA) was digested with BamHI and HindIII, and the oligo 
sequence GATCCGTGTCTGCAGACGTCGACA was inserted into this digested vector. 
This oligo was added to create more space between restriction enzymes BamHI and 
SalI in the polylinker of vector pM, providing a more efficient digestion of these two 
enzymes when cut simultaneously. This new vector, pM (+10) was then used for 
construction of the pM-ER plasmid. Primers used for preparing GAL4DBD fusion protein 
with ER were upper primer CTG TGG ATC CGT ATG ACC ATG ACC CTC CAC ACC 
AAA and lower primer, TCA TGG TCG ACT CAG ACT GTG GCA GGG AAA CC. After 
PCR amplification, the ERcDNA fragment was digested with BamHI and SalI and 
cloned into pM(+10) digested with BamHI/SalI to give pM-ER. The 17m5-GAL4-Luc 
plasmid containing five copies of the yeast GAL4 recognition motif linked to a luciferase 
reporter gene was provided by Dr.Patrick Balaguer (INSERM 458, Montpellier, France) 
and Dr.Tim Zacharewski (Michigan state University, East Lansing, MI). 
Cloning of DRIP150 mutants 
The Ù1145-1454 m1(mutant1) of DRIP150 was generated by the KpnI/XhoI  
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digestion of plasmid pcDNA3.0-DRIP150. After cutting with KpnI/XhoI, the fragments 
were run on 1% agarose gel, and 3.5kb fraction was eluted and ligated with KpnI/XhoI 
cut pcDNA3.0 vector. Except for m1, all other clones expressing DRIP150 mutants were 
generated by PCR amplification and primers used for preparing DRIP150 mutants and 
GAL4DBD fusion proteins are summarized in Table II and Table III. Xpress tagged m2 
and m11 DRIP150 mutants were generated by putting the appropriate fragments into 
Xpress tagged HisA-pcDNA3.1 vector. PM23aa and related point mutants were 
generated by inserting DRIP150 23 aa (#789-811 region) and the 23 aa region with the 
mutated DRIP150 aa #792 (Ala->Pro), #801(Arg->Pro) or double mutant into the pM 
vector. The 23aa regions were also inserted into the vector pET-28b(+) which is His-
tagged in order to express large amounts of this peptide for characterization by X-ray 
crystallization. 
After PCR amplification, cDNA fragments of m2 and m3 were digested with 
KpnI/EcoRI and cloned into pcDNA3.0 digested with KpnI/EcoRI. cDNA fragments of 
m4, m5, m6, m7, m8, m9, m10, m11, m12 were digested with KpnI/XbaI and cloned into 
pcDNA3.0 digested with KpnI/XbaI. The cDNA fragment of Xpress-tagged m2 was 
digested with ECoRI/XbaI and cloned into HisA-pcDNA3.1 digested with ECoRI/XbaI. 
The cDNA fragment of Xpress-tagged m11 was digested with BamHI/XbaI and cloned 
into HisA-pcDNA3.1 digested with BamHI/XbaI. The cDNA fragments of pM23aa, 
pM23A792P, pM23R801P, and pM23A792P/R801P were also digested with 
BamHI/XbaI and cloned into pM digested with BamhI/Xba. The cDNA fragment of pET-
28b(+)-23aa was digested with BamHI/XhoI and cloned into pET-28b(+) digested with 
BamHI/XhoI. 
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TABLE II 
Primers used for preparing DRIP150 mutants 
Constructs Primers used Vectors 
cloned 
In 
Ù789-1454 
m2 
Upper primer, GGC TAA CTA GAG AAC CCA CT 
Lower primer, AAA GAA TTC CTA TGG TAG AGA 
ACG TGC AAA TTC 
pcDNA 
3.0 
Ù325-1454 
m3 
Upper primer, same as m2 
Lower primer, AAA GAA TTC CTA CAC AAG GTC TCC 
CCA CCG TTC 
pcDNA 
3.0 
Ù977-1454 
m4 
Upper primer, AGA GCT CTC TGG CTA ACT AGA 
GAA CCC ACT 
Lower primer, AAA TCT AGA CTA CCT TCT TCG AGC 
ATC CTG ATT G 
pcDNA 
3.0 
Ù886-1454 
m5 
Upper primer, same as m4 
Lower primer, AAA TCT AGA CTA GAG TTT GTT GAT 
GGC ATT TA 
pcDNA 
3.0 
Ù870-1454 
m6 
Upper primer, same as m4 
Lower primer, AAA TCT AGA CTA TAA TAA CTG AAC 
CAC ATT 
pcDNA 
3.0 
Ù865-1454 
m7 
Upper primer, same as m4 
Lower primer, AAA TCT AGA CTA ATT TGG TGT TTT 
GTT GAA CAT 
pcDNA 
3.0 
Ù1-754 & 
Ù886-1454 
m8 
Upper primer, AAA GGT ACC GCC GCC ATG GAG 
CCT GTT GGT GGT AGA AAG GTG GTT GAA 
Lower primer, same as m5 
pcDNA 
3.0 
Ù850-1454 
m9 
Upper primer, same as m4 
Lower primer, AAA TCT AGA CTA ATT GTG ACA GTT 
ACT GCA ACC 
pcDNA 
3.0 
Ù827-1454 
m10 
Upper primer, same as m4 
Lower primer, AAA TCT AGA CTA CGA ATT CCA TTG 
GAT ACT AAT 
pcDNA 
3.0 
Ù812-1454 
m11 
Upper primer, same as m4 
Lower primer, AAA TCT AGA CTA ACA CAA GAT AAG 
TTT TCG GTA 
pcDNA 
3.0 
Ù1-77 & 
Ù865-1454 
m12 
Upper primer, AAA GGT ACC GCC GCC ATG GAT 
GTG GAA AGG AAA ATA GAA ATA GTG CAG 
Lower primer, same as m7 
pcDNA 
3.0 
Ù789-1454 
Xpress-
tagged m2 
Upper primer, AAA GAA TTC TGA CCG CCG CCA 
TGG CCC CAG TGC AGC TGG AGA ACC ACC 
Lower primer, AAA TCT AGA CCT ATG GTA GAG 
AAC GTG CAA ATT C 
HisA-
pcDNA 
3.1 
Ù812-1454 
Xpress-
tagged m11 
Upper primer, AAA GGA TCC AGA CCG CCG CCA 
TGG CCC CAG TGC AGC TGG AGA ACC ACC 
Lower primer, AAA TCT AGA CCT AAC ACA AGA TAA 
GTT TTC GGT A 
HisA-
pcDNA 
3.1 
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TABLE III 
Primers used for preparing GAL4DBD fusion proteins 
Constructs Primers used Vectors 
cloned 
in 
pM23 aa Upper primer, AAA GGA TCC GTA CCG CCG 
CCA TGG ACA TAC CTG CTC ATC TAA ATA 
Lower primer, AAA TCT AGA ACT AAC ACA AGA 
TAA GTT TTC GGT AAT 
pM 
pM23A792P  
 
Upper primer, AAA GGA TCC GTA CCG CCG 
CCA TGG ACA TAC CTC CTC ATC TA 
Lower primer, same as PM-23 aa 
pM 
pM23R801P  
 
Upper primer, same as PM-23 aa 
Lower primer, AAA TCT AGA ACT AAC ACA AGA 
TAA GTT TTC GGT AAT TAT AAA CAG GAA CTT 
CTG AGA 
pM 
pM23A792P/R801P 
 
Upper primer, same as A792P m PM-23 aa 
Lower primer, same as R801P m PM-23 aa 
pM 
PET-28b(+)-23aa Upper primer, AAA GGA TCC GAC CGC CGC 
CAT GGA CAT ACC TGC TCA TCT AAA TA 
Lower primer, AAA CTC GAG ACA CAA GAT AAG 
TTT TCG GTA AT 
pET-
28b(+) 
 
 
 
Transient transfection assays 
 ZR75 breast cancer cells were grown and maintained in RPMI1640 
supplemented with 10% FBS. Cells were seeded onto 12-well plates in phenol-free 
Dulbecco’s modified Eagle’s medium/F-12 supplemented with 2.5 % charcoal-stripped 
FBS. After 18 hr, cells were transfected by the calcium phosphate method with 1 mg of 
pERE3 reporter plasmid, 0.25 mg of a CMV b-gal expression plasmid, the appropiate 
ERa expression plasmid, and the appropriate DRIP150 expression plasmid. After 6-8 
hr, cells were shocked with 25% glycerol in phosphate-buffered saline (PBS) for 75 sec, 
rinsed once with PBS, and treated with either DMSO or 10 nM E2 in Dulbecco’s 
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modified Eagle medium/F-12 plus 2.5 % charcoal-stripped fetal bovine serum for 36 hr. 
Cells were harvested by scraping the plates in 100 ml of 1x lysis buffer (Promega). 
Thirty five ml of the cell lysate was used for performing luciferase assays on a Lumicount 
Luminometer (Packard Instrument Co.). Thirty five ml of the cell lysate was used for 
determining b-galactosidase (b-gal) activity on a luminometer. Nomalized luciferase 
values were calculated by dividing the luciferase by the -gal activities for a given 
sample. Results are expressed as means + S.E. for at least 3 separate experiments for 
each treatment group and compared with the DMSO control group (arbitrarily set at 1) 
for each set of experiments. 
Gel elctrophoretic mobility shift assays 
 Five picomoles of synthesized ERE was labled at the 5’ end using T4-
polynucleotide kinase and [g-32P] ATP. Plasmids containing the DRIP150, m1, m2 and 
m3 cDNAs were used to in vitro transcribe and translate the corresponding protein in a 
rabbit reticulocyte lysate system (Promega). Three ml of recombinant human ERa (500 
fmol) was mixed with 3ml of BSA (500 ng/ml), 2 ml of poly(dI-dC) (1 mg/ml), 5 ml of 5x 
binding buffer (20 mM Hepes-5% glycerol, 100 mM KCl, 5 mM MgCl2, 0.5 mM DTT, 1 
mM EDTA) and 1 ml of E2 (3.5x10-7M) to give final concentration 2.5x 10-8 M E2 and 
incubated on ice for 15 min. In vitro translated DRIP150, m1, m2 or m3 were then 
added to the above mixture and incubated on ice for 5 min. To balance the volume, in 
vitro translated PcDNA3.0 was also added. For supershift experiments, 2ml of normal IgG 
or ER antibody was added to the  mixture after 5 min and then incubated on ice for an 
additional 5-10 min and 5 ml of [32P]-labeled ERE probe (120,000 cpm) was added to 
the reaction mixture, giving a final volume of 25 ml.The mixture was  incubated at 20°C 
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for 15 min. Samples were then loaded onto 5% polyacrylamide gel and run at 110V in 
0.09 M Tris, 0.09 M borate, 2 mM EDTA (pH 8.3) for 2.5 hr. The gel was dried, exposed 
to a phosphoscreen for 12 hr and protein-DNA binding was visualized by 
autoradiography using a Storm PhosphoImager (Molecular Dynamics, Sunnyvale, CA). 
Coimmunoprecipitation assays 
Two hundred ml of reticulocyte lysate was mixed with 40 ml of Protein G plus 
Agarose and 17 ml of ER antibody and shaken for 1 hr at 4°C to preclear ER expressed 
in the reticulocyte. After 1 hr, the mixture was centrifuged at 1,500xg for 5 min, and the 
supernatant was used to in vitro translate DRIP150, ER and PcDNA3.0. DRIP150, ERa 
and PcDNA3.0 were in vitro translated using [
35S]-methionine in a rabbit reticulocyte 
lysate system (Promega, Madison, WI) and 10 ml of the in vitro translated [35S]-DRIP150 
was mixed with 2 ml of in vitro translated [35S]-ER and incubated with 13.2x10-7M E2 to 
give a final concentration of 100 nM E2 on ice for 15 min. Ten ml of ERa antibody was 
then mixed with Protein G plus Agarose (1:2 ratio) and added to the above mixture and 
incubated for 3 hr at 4°C with shaking every 30 min. For samples not containing [35S]-
DRIP150, only [35S]-ER (2 ml) was mixed with ER antibody-Protein g plus Agarose 
mixture and incubated for 3hr at 4°C as described above. PBS (1 ml) was then added to 
each sample, and shaken for 30 sec then centrifuged at 1,500xg for 5 min. After 
centrifugation, the supernatant was discarded carefully and the pelleted fraction (100 ml) 
was mixed with 20 ml of 1x sample buffer (50 mM Tric-HCl pH 6.8, 2% SDS, 0.1 % 
bromophenol blue, 10 % glycerol and 100 mM DTT) containing b-mercaptoethanol.  
The sample was then boiled for 5 min, loaded onto SDS-polyacrylamide gel and run at 
150 V for 4 hr. The gel was dried, exposed to a phosphoscreen for 3 days and proteins 
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were visualized by autoradiography using a Storm PhosphoImager (Molecular 
Dynamics, Sunnyvale, CA). 
Western immunoblot assays 
 COS-7 cells were seeded in 6 well plates at a concentration of 200,000 
cells/well in phenol-free Dulbecco’s modified Eagle’s medium/F-12 with 2.5 % charcoal-
stripped FBS. After 24 hr, the media was removed and serum and antibiotic-free 
phenol-free Dulbecco’s modified Eagle’s medium/F-12 was added to the wells. X-press 
tagged DRIP150 m2 and DRIP150 m11 were then transfected using the lipofectamine 
transfection method (InVitrogen, Carlsbad, CA). After 6 hr, the media was removed and 
phenol-free Dulbecco’s modified Eagle’s medium/F-12 with 2.5% charcoal-stripped FBS 
was added and cells were incubated for 36 hr.  Cells were then harvested in lysis buffer 
(50 mM Hepes, pH 7.5, 150 mM NaCl, 10%(V/V) glycerol, 1% TritonX-100, 1.5 mM 
MgCl2, 1 mM EGTA, 10 mg/ml aprotinin, 50 mM phenylmethylsulfonyl fluoride, 50 mM 
sodium orthovanadate), placed on a rocker at 4°C to extract soluble protein, and 
centrifuged at 14,000 xg for 10 min at 4°C. Protein was quantitated and an equal 
amount of proteins (150 mg) diluted with loading buffer was boiled and loaded on 10% 
SDS-polyacrylamide gel. Samples were electrophoresed at 150-180 V for 3-4 hr. For 
samples containing in vitro translated Xpress-tagged m2 and m11, Xpress tagged 
DRIP150 m2 and DRIP150 m11 were in vitro translated in a rabbit reticulocyte lysate 
system (Promega), diluted with loading buffer, boiled, loaded on 10% SDS-
polyacrylamide gel, and electrophoresed at 150-180 V for 3-4 hr. The separated 
proteins were transferred (in a buffer containing 48 mM Tris-HCl, 29 mM glycine, and 
0.025 % SDS) to PVDF membrane (Bio-Rad, Hercules, CA). Specific proteins were 
detected by incubation with mouse monoclonal anti-Xpress antibody (1:5000 dilution) 
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for 4 hr, rinsed with distilled water (3x) followed by blotting with horseradish peroxidase-
conjugated anti-mouse secondary antibody (1:5000 dilution) for 1.5 hr. The membrane 
was then washed with PBS-Tween20 (0.05%) and blots were exposed to 
chemiluminescent substrate (ECL) (NEN Life Science Products, Boston, MA) and 
placed on Kodak X-Omat AR autoradiography film. The detected bands were scanned 
using a Sharp JX-330 scanner (Sharp Electronics Corp., Mahwah, NJ). 
Statistical analysis 
Statistical differences between different treatment groups were determined using 
Student's t test or ANOVA (Fisher’s Protected LSD) and the levels of significance were 
noted (p < 0.05).  The results were expressed as mean ± SE for at least 3 replicate 
determinations for each experiment. 
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CHAPTER III 
 
RESULTS* 
Effect of 3’,4’-DMF on EROD and CAT acivity 
3',4'-DMF (0.1 - 1.0 mM) alone did not significantly induce EROD activity in MCF-
7 or T47D breast cancer cells, whereas the AhR agonist TCDD was a potent inducer in 
both cell lines (Fig. 16). In cells cotreated with 1 nM TCDD and 0.1 - 10 mM 3'4'-DMF, 
there was significant inhibition of induced EROD activity by 3',4'-DMF at the 1.0 and 10 
mM doses, and almost complete inhibition was observed at the highest conc n ration of 
3',4'-DMF. To ensure that this inhibitory response was not just due to direct interactions 
of 3',4'-DMF with CYP1A1 protein, the effects of 3',4'-DMF on TCDD-induced CAT 
activity in MCF-7 or T47D cells transfected with Ah-responsive pRNH1c were also 
investigated. The results (Fig. 17) show that 3',4'-DMF alone did not exhibit AhR 1 
agonist activity, but 3',4'-DMF significantly inhibited TCDD-induced CAT activity in MCF-
7 and T47D cells cotreated with 3',4'-DMF + TCDD. Previous studies with AhR agonists 
that inhibit induction of CYP1A1 by TCDD have shown that some of these compounds 
such as alkyl substituted PCDFs and I3C/DIM exhibit AhR agonist activity in breast 
cancer cell lines and inhibit E2-induced growth and transactivation (234,237,409).  
                                                  
*Part of the data reported in this chapter is reprinted with permission from 3’,4’-
Dimethoxyflavone as an Aryl Hydrocarbon Receptor Antagonist in Human Breast 
Cancer Cells by Jeong Eun Lee and Stephen Safe, 2000. Toxicological Sciences, 58, 
235-242. Copyright 2000 by the Society of Toxicology and Involvement  of a Post- 
Transcriptional Mechanism in the Inhibition of CYP1A1 Expression by Resveratrol in 
Breast Cancer Cells by Jeong Eun Lee and Stephen Safe, 2001. Biochemical 
Pharmacology, 62, 1113-1124. Copyright 2001 by Elsevier Science Inc. 
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FIG. 16. Induction of EROD activity by TCDD and inhibition by 3',4'-DMF. MCF-7 
(A) or T47D (B) cells were treated with 1 nM TCDD, 0.1 - 1  mM 3',4'-DMF alone, or 1 
nM TCDD plus 3',4'-DMF (0.1 - 10 mM), and EROD activity was determined. TCDD 
alone significantly (p < 0.05) induced EROD, and 1.0 and 10 mM 3',4'-DMF significantly 
(p < 0.05) inhibited this induced response in both cell lines. The results illustrated in 
Figures 16 through 19 are means ± SE for three replicate experiments for each 
treatment group. 
 
 98
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG. 17. Induction of CAT activity by TCDD and inhibition by 3',4'-DMF. MCF-7 (A) 
or T47D (B) cells were transiently transfected with pRNH11c, treated with TCDD, 3',4' 
DMF or their combination, and CAT activity was determined. TCDD alone significantly 
(p < 0.05) induced CAT activity, and cotreatment with 10 mM 3',4'-DMF significantly (p < 
0.05) inhibited induction of CAT activity by TCDD in both cell lines. 
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Effect of 3’,4’-DMF on cell proliferation assay 
Therefore, we initially investigated the growth inhibitory effects of 3',4'-DMF
alone or in combination with E2 in MCF-7 and T47D breast cancer cells. 3',4'-DMF 
alone significantly induced T47D cell proliferation (0.1 and 1.0 mM) and appeared to 
exhibit weak estrogen or growth-stimulatory activity in both cell lines; however, this 
response was not observed at the highest concentration (10 mM) (Fig. 18). In cells 
treated with 3',4'-DMF plus E2, proliferation was not enhanced by 3',4'-DMF, and 10 mM 
3',4'-DMF inhibited E2-induced proliferation of both MCF-7 and T47D cells. Previous 
studies have also reported growth inhibitory effects of 3'-methoxy-substituted flavones 
(215), and this may be related to their inhibition of constitutive and hormone-i duced 
kinase activities (193). 3',4'-DMF did not reverse the inhibition of E2-induced 
proliferation by TCDD (data not shown) and this is probably related to the dose-
dependent stimulatory and inhibitory effects of this compound.  
Effect of 3’,4’-DMF on E2-inducible CAT assay 
Therefore, we also investigated the AhR antagonist activity of 3',4'-DMF in MCF-
7 cells transfected with the E2-responsive pCKB construct and treated with E2, TCDD 
or their combination. The results (Fig. 19) show that E2 induced CAT activity in MCF-7 
cells transfected with pCKB, whereas 10 mM 3',4'-DMF or 10 nM TCDD alone were 
inactive. TCDD, but not 3',4'-DMF, significantly inhibited E2-induced activity, and 3',4'- 
DMF reversed the inhibition f E2-induced activity by TCDD which is consistent with an 
AhR antagonist effect by 3',4'-DMF. E2-induced activation of pCKB is not inhibited by 
AhR agonists in T47D cells (410), and therefore, the AhR antagonist activity of 3',4'-
DMF was not determined for this response in T47D cells.
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FIG. 18. Effects of 3',4'-DMF on growth of breast cancer cells. MCF-7 (A) or T47D 
(B) cells were treated with different concentrations of 3',4'-DMF alone or in combination 
with 1 nM E2. Significant (p < 0.05)a induction of T47D cell growth was observed only at 
concentrations of 0.1 and 1.0 mM 3',4'-DMF and significant (p < 0.05)b inhibition of E2-
induced growth of both cell lines was observed only at the highest concentration (10 
mM) of 3',4'-DMF. 
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FIG. 19. Interactive effects of 3',4'-DMF and TCDD on the induction of pCKB by E2.  
MCF-7 cells were transfected with pCKB, treated with E2, TCDD, 3',4'- MF  or their 
combinations, and CAT activity was determined. E2 significantly induced CAT activity 
(p < 0.05); this response was inhibited by TCDD and the inhibitory response was 
reversed after cotreatment with 3',4'-DMF. 
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Effect of 3’,4’-DMF on AhR transformation 
Thus, 3',4'-DMF blocks TCDD-induced CYP1A1 and inhibitory AhR-ER 
interactions in breast cancer cells, and the results in Figure 20 illustrate the effects of 
TCDD, 3',4'-DMF and their combination on the formation of a nuclear AhR complex in 
MCF-7 and T47D cells. Nuclear extracts from MCF-7 or T47D cells treated with DMSO 
gave weak to non-detectable binding to [32P]DRE in a gel mobility shift assay.  In 
contrast, an intense band was observed in extracts from cells treated with TCDD and 
this band was competitively decreased after competition with a 100-fold excess 
unlabeled wild-type DRE but was unaffected by competition with a mutant DRE 
oligonucleotide. In contrast, incubation of [32P]DRE with nuclear extracts from MCF-7 or 
T47D cells treated with 5 nM 3',4'-DMF alone or in combination with TCDD gave 
minimal to non-detectable retarded bands demonstrating that 3',4'-DMF blocked TCDD-
induced formation of the nuclear AhR complex in breast cancer cell lines. Previous 
studies show that TCDD induced transformation and DRE binding of rat hepatic 
cytosolic AhR as illustrated in Figure 21. In contrast, 0.5 - 0 mM 3',4'-DMF did not 
transform the rat cytosolic AhR; however, in cytosols cotreated with TCDD plus 3',4'-
DMF, there was significant inhibition of TCDD-induced transformation. These results 
suggest the 3',4'-DMF competitvely binds the cytosolic AhR complex and blocks 
formation of the transformed nuclear AhR complex, and these results are consistent 
with previous reports on other 3'-methoxy-substituted flavones (173,180,181,215). 
Effects of resveratrol on CYP1A1 gene expression and EROD activity 
Results summarized in Figure 22 show that 1 nM TCDD alone induced CYP1A1 
mRNA levels (3.5-fold) and CYP1A1-dependent EROD activity in T47D and MCF-7 
breast cancer cells, whereas concentrations as high as 10 nM resveratrol were inactive  
 103
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG. 20. Effects of 3',4'-DMF on formation of the nuclear AhR complex. MCF-7 (A) 
or T47D (B) breast cancer cells were treated with DMSO, TCDD, 3',4'- MF or TCDD 
plus3',4'-DMF, and nuclear extracts were isolated and analyzed by gel mobility shift 
assays. TCDD induced a specifically-bound complex (see arrow) in both cell lines, 
whereas nuclear extracts from cells treated with 3',4'-DMF alone or in combination with 
TCDD gave a minimal to nondetectable bound complex. The mobility of the  
specifically-bound band was comparable to that observed using in vitrotranslated 
AhR/Arnt incubated with [32P]DRE (data not shown). 
A 
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Fig. 20. Continued. 
 
B 
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FIG. 21. Transformation of rat hepatic cytosolic AhR. Rat hepatic cytosol was 
Treated with 5 nM TCDD, 3',4'-DMF (0.05 - 50 mM) or their combination and analyzed 
by gel mobility shift assays. TCDD but not 3',4'-DMF transformed the AhR complex and
coincubation of TCDD with 3',4'-DMF resulted in inhibition of TCDD-induced 
transformation. 
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FIG. 22. Effects of resveratrol on CYP1A1 gene expression in breast cancer cells.  
(A) CYP1A1 mRNA levels. T47D cells were treated with solvent control (DMSO), 1 nM 
TCDD, 10 mM resveratrol and TCDD plus resveratrol (1 nM and 10 mM, respectively), 
and after 6 hr, mRNA was analyzed by Northern blot analysis as described in the 
Materials and Methods. Relative CYP1A1 mRNA levels were:  DMSO, 1.0 ± 0.08; 
TCDD, 3.53 ± 0.53; reservatrol, 1.1 ± 0.16, and TCDD plus reservatrol, 0.99 ± 0.1.  
Results are expressed as means ± SE for three separate experiments. TCDD 
significantly (p < 0.05) induced CYP1A1 gene expression, and this induced response 
was significantly (p < 0.05) inhibited my resveratrol. 
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FIG. 22. Continued. EROD activity in T47D (B) or MCF-7 (C) cells. Cells were treated 
with DMSO, 1 nM TCD, 0.1 to 10 mM resveratrol, and TCDD (1 nM) plus resveratrol 
(0.1-10 mM) for 24 hr, and EROD activity was determined as described in the 
Materials and Methods. TCDD significantly (* p < 0.05) induced EROD activity 
in both cell lines and the induced respone was significantly (** p < 0.05)inhibited by 1 
and 10 mM resveratrol in T47D and 10 mM resveratrol in MCF-7 cells. 
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as inducers of CYP1A1 mRNA or EROD activity. Induction of CYP1A1 mRNA levels in 
T47D cells by 1 nM TCDD was blocked after co-administration with 10 mM resveratrol.  
Moreover, in MCF-7 or T47D cells cotreated with 1 nM TCDD plus 0.1 to 10 nM 
resveratrol, there was a concentration-dependent decrease in EROD activity and these 
results were consistent with previous reports on interactions of these compounds with 
CYP1A1 in various cell lines (266,267,269). Incubation of resveratrol (0.1 - 50 mM) with 
TCDD-induced microsomes from MCF-7 and T47D cells only slightly decreased 
enzyme activity (£ 20%) at the 10 mM concentration and significantly decreased activity 
was observed at higher concentrations (Fig. 23). Incubation with DIM decreased 
enzyme activity as previously reported (234), and inhibition was also observed for 
trimethoxyresveratrol. Thus, the inhibitory effect of 10 mM resveratrol was not related to 
direct interactions of this compound with CYP1A1 protein reported that microsomal 
EROD activity and benzo[a]pyrene (BaP) hydroxylation was inhibited after incubation 
with 10 mM resveratrol (266,267), whereas in another study, the inhibitory effects were 
similar to those reported in Figure 23 (268). The reason for differences between studies 
is unclear since the positive inhibitory control (DIM) blocked EROD activity, and we also 
observed that the trimethoxy derivative of resveratrol inhibited this response. 
Interactions of resveratrol with the AhR 
 Competitive binding of resveratrol to the AhR was not observed using sucrose 
density gradients (269), whereas in another report, binding was observed in T47D cell 
whole cell assays (267). These differences were also reflected in results of gel mobility 
shift assays of nuclear extracts from cells treated with TCDD, resveratrol and their 
combination (266,267,269). Therefore, these latter studies were repeated in both MCF-
7 and T47D cells, and the results are summarized in Figure 24. 
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FIG. 23. Interactions of resveratrol with CYP1A1. Microsomes from T47D (A) and 
MCF7 (B) cells were incubated with resveratrol (0.1 - 50 mM), trimethoxyresverat ol (0.1 
– 10 mM) or DIM (0.1 - 10 mM) for 10 min, and EROD activity was determined as 
described in the Materials and Methods. Only minimal (< 22%) inhibition was observed 
for resveratrol (£ 10 mM), whereas both trimethoxyresveratrol and DIM inhibited EROD 
activity. Results are expressed as means ± SE for three separate determinations for  
each treatment group. 
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FIG. 24. Resveratrol-induced formation of the nuclear or transformed AhR 
complex. T47D (A) or MCF-7 (B) cells were treated with 5 nM TCDD, 5 mM resveratrol 
or their combination; nuclear extracts were obtained and analyzed by gel mobility shift 
assays as described in the Materials and Methods. A specifically-bound AhR-[32P]DRE 
complex was detected in all treatment groups.  
A 
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FIG. 24. Continued.
B 
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FIG. 24. Continued. (C) Transformation of the rat hepatic AhR. Rat hepatic cytosol was 
incubated with TCDD, resveratrol, the AhR antagonist 3'-methoxy-4'-nitroflavone or their 
combinations and the transformed complex was analyzed by gel mobility shift assay as 
described in the Materials and Methods. TCDD (lanes 9 - 11) and resveratrol (lanes 6 - 
8) induced formation of a specifically-bound AhR complex, whereas 3'-methoxy-4'-
nitroflavone blocked resveratrol-/ TCDD-induced complex formation but this compound 
alone did not induce transformation (lanes 3 - 5). This pattern of transformation was 
observed in duplicate experiments. 
C 
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Nuclear extracts from MCF-7 and T47D cells treated with 1 nM TCDD were incubated 
with [32P]DRE and analyzed by gel mobility shift assays to give a specifically-bound 
retarded band; intensity of this band was decreased by competition with excess 
unlabeled DRE but not mutant DRE oligonucleotid s. Nuclear extracts from cells 
treated with 5 mM resveratrol alone or in combination with 1 nM TCDD also formed 
retarded bands; these results were consistent with previous studies in T47D cells (267), 
but contrasted to results in HepG2 cells where resveratrol did not induce formation of a 
nuclear AhR complex and blocked formation of a TCDD- or BaP-induced nuclear AhR 
complex (266,267). The specificity of the effects of resveratrol on transformation of the 
AhR complex was further investigated using rat liver cytosol (Fig. 24C) which is readily 
transformed (dose-dependent) by TCDD to give a retarded band (lanes 9 - 11), 
whereas the solvent (DMSO) did not induce transformation (lane 12). The specificity of 
TCDD-induced transformation was confirmed by the following; competition with 
unlabeled wild-type DRE (lane 2), but not mutant DRE (lane 1), decreased intensity of 
the retarded band and the AhR antagonist 3'-methoxy-4'-nitroflavone blocked TCDD-
induced transformation (lane 3) as previously described (173,181). The effects 
observed for resveratrol show that there was a concentration-independent 
transformation of the receptor using 0.05 to 50 mM resveratrol (lanes 6 - 8) and 
coincubation of resveratrol with TCDD did not markedly affect intensities of the retarded 
bands (data not shown). In contrast, 3'-methoxy-4'-nitroflavone blocked transformation 
of the cytosolic AhR by resveratrol (lane 4). Results obtained for resveratrol suggest 
that ligand-induced transformation of the cytosolic AhR may not always predict the AhR 
agonist or antagonist activity of a compound in transcriptional assays, and this has 
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recently been demonstrated for several other compounds by Seidel and coworkers 
(411). 
 The lack of specificity associated with interactions of resveratrol with the AhR in 
cell culture and in transformation of rat hepatic cytosol (Fig. 24) suggested that the 
inhibitory effects of resveratrol on CYP1A1 mRNA and EROD activity induced by TCDD 
may be AhR-independent. Previous studies have shown that AhR antagonists such as 
3'-methoxy-4'-nitroflavone and other 3'-methoxysubstituted flavones inhibit formation of 
the nuclear AhR complex and induction of reporter gene activity by TCDD in cells 
stably- or transiently transfected with constructs containing functional DRE promoter 
inserts (173,180,181). Ciolino and Yeh (266) also showed that resveratrol inhibited CAT 
activity in HepG2 and MCF-7 cells treated with AhR agonists and transiently transfected 
with a construct containing a rat CYP1A1 gene promoter insert. In contrast, our results 
(Fig. 25) show that 1 and 10 mM resveratrol alone did not induce CAT activity in T47D or 
MCF-7 cells transfected with Ah-responsive pRNH11c; TCDD alone induced CAT 
activity and the induced response was not affected by 1 or 10 mM esveratrol, whereas 
the AhR antagonist 3'-methoxy-4'-nitroflavone blocked TCDD-induced reporter gene 
activity as previously described (173,181). Thus, in contrast to 3'-methoxy-4'-
nitroflavone, resveratrol did not exhibit AhR antagonist activity for this response. 
Effects of resveratrol on CYP1A1 mRNA and protein stability 
 The apparent conflicting results on the AhR antagonist activity of resveratrol 
obtained in this and previous studies suggested that other inhibitory mechanisms may  
also be important. A recent study showed that the steroid hormone DHEA inhibited 
basal and induced CYP1A1 gene expression in MCF-7 cells but had no effect on DRE-
dependent transcription using a construct containing the rat CYP1A1 gene promoter  
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FIG. 25. AhR agonist/antagonist activity of resveratrol in transfection studies.  
T47D (A) or MCF-7 (B) cells were transfected with pRNH11c, treated with TCDD, 
resveratrol, or their combinations, and CAT activity was determined as described in the 
Materials and Methods. 
 116
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG. 25. Continued. In a separate experiment (C), the effects of the AhR antagonist 3'-
methoxy-4'-nitroflavone (F) on TCDD-induced CAT activity were also determined. Only 
TCDD alone significantly (* p < 0.05) induced CAT activity and in combination 
treatments, only 3'-methoxy-4'-nitroflavone significantly (** p < 0.05) decreased the 
TCDD-induced response. Results are expressed as means ± SE for three separate 
experiments for each treatment group. 
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insert (145). The inhibitory effect of DHEA was associated with post-tran criptional 
destabilization of CYP1A1 mRNA and, therefore, the time-dependent effects of DHEA 
and resveratrol were determined in T47D cells pretreated with TCDD to induce CYP1A1 
mRNA levels. Actinomycin D was then added to inhibit further transcription and 
CYP1A1 mRNA levels (normalized to b-tubulin mRNA) were then determined 0, 2, 6 
and 10 hr after addition of actinomycin D. The results (Fig. 26) show that both DHEA 
and resveratrol significantly increased the rate of CYP1A1 mRNA degradation 
suggesting that, like DHEA, resveratrol also inhibits CYP1A1 by post-transcriptional 
mechanisms. Moreover, like resveratrol, DHEA also inhibited TCDD-induced EROD 
activity in T47D cells (data not shown). It is also possible that resveratrol could induce 
proteosome-dependent degradation of CYP1A1 protein, and the effects of resveratrol, 
the proteosome inhibitor MG132 and their combination on CYP1A1-dependent EROD 
activity were determined in T47D cells (Fig. 27). Eighteen hours after treatment with 1 
nM TCDD, the media was changed and cells were further incubated with resveratrol or 
resveratrol plus MG132 for a further 12 hr. None of the treatments deceased CYP1A1-
dependent activity suggesting that the effects of resveratrol on CYP1A1 expression are 
primarily directed to decreased message stability. These results coupled with the non-
specific interactions of resveratrol with the AhR (Fig. 24) indicate that resveratrol may 
inhibit CYP1A1 gene/protein expression, in part, by AhR-independent pathways. 
DRIP150 coactivation of ERa 
 DRIP150 is a member of the mediator complex of proteins, and this study 
investigates coactivation of ERa by DRIP150 in ZR-75 cells transfected with pERE3.  
E2-dependent transactivation in this cell line is minimal in cells transfected with pERE3  
alone; however, E2-reponsiveness is observed after cotransfection with minimal  
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FIG. 26. CYP1A1 mRNA stability in T47D cells treated with resveratrol and DHEA.  
T47D cells were pretreated with 1 nM TCDD for 12 hr; media was changed and cells 
were treated with 5 mM resveratrol, 1 mM DHEA, or DMSO plus 5 mg/ml actinomycin D.  
CYP1A1 mRNA levels were determined 2, 6 and 10 hr after treatment as d scribed in 
the Materials and Methods. CYP1A1 mRNA levels (relative to b-tubulin mRNA) are 
illustrated for cells treated with DMSO, DHEA or resveratrol, and both DHEA and 
reservatrol significantly (p < 0.05) decreased mRNA stability at the 10 hr time point.
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FIG. 27. Effects of resveratrol on CYP1A1-dependent EROD activity. T47D cells 
were treated with 1 nM TCDD for 18 hr; media was changed and cells were then treated 
with DMSO (control), 10 mM resveratrol, and 10 mM resveratrol plus 0.5 mM MG132 (a 
proteasome inhibitor).  EROD activity was then determined after further incubation for 1, 
3 and 12 hr as described in the Material and Methods. The concentration of MG132 
was sufficient for inhibition of TCDD-induced proteosme-dependent degradation of the
AhR in T47D cells (431). The results showed that resveratrol did not affect protein
stability as determined by CYP1A1-dependent EROD activity. Results are expressed as 
means + SEM for three separate experiments for each treatment group. 
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amounts of ERa expression plasmid. This is due, in part, to overexpression of pERE3 in 
the transfected cells which results in limiting levels of ERa. The three tandem 
consensus EREs are inserted upstream from a minimal TATA-luciferase which has 
lower intrinsic E2-responsiveness compared to constructs containing the human 
thymidine kinase or frog vitellogenin A2 gene promoters (412). E2 induced luciferase 
activity in ZR-75 cells transfected with pERE3 and enhancement of this response was 
variable and dependent on the amount of cotransfected ERa as illustrated in Figure 
28A. Maximal coactivation of ERa was observed using 2.5 - .0 ng of DRIP150 
expression plasmid and the coactivation response was decreased or squelched using 
higher amounts of DRIP150 plasmid. ZR-75 cells were also transfected with GAL4-luc 
and pM-ERa which contained full length ERa fused to the DBD of GAL4, and E2 also 
induced transactivation in this mammalian one-hybrid assay. This response was al o 
enhanced by cotransfection with DRIP150 expression plasmid (Fig. 28B). Coactivation 
required higher amounts of transfected DRIP150 in this assay, and DRIP150 did not 
affect hormone-induced transactivation in cells transfected with pM alone which 
contained the GAL4-DBD but not the ERa insert (data not shown). Figure 28C was 
similar to that described in Figure 28A and shows that DRIP150 also coactivates ERa-
mediated transactivation in ER-negative MDA-MB-231 breast cancer cells transfected 
with pERE3. 
 ERa contains two major activation domains and we therefore investigated the 
coactivation activity of DRIP150 in cells transfected with HE19 (deletion of AF1) and 
ERa-TAF1 which contains three amino acid mutations in helix 12 (D538N, E542Q and 
D545N) which inactivates AF2 (413). The results in Figure 28D demonstrate that in ZR-
75 cells transfected with pERE3 and HE19, treatment with E2 increased (> 50%)  
 121
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG. 28. Coactivation of wild-type and variant ERa by DRIP150. (A) Coactivation of 
ERa. ZR-75 cells were transfected with pERE3, different amounts of ERa expression 
plasmid (25 and 150 ng), DRIP150 expression plasmid (2.5 ng) treated with DMSO or 10 
nM E2 and luciferase activity determined as described in the Materials and Methods.  
Significant (0 < 0.05) coactivation of E2-induced activity is indicated by an asterisk and 
results are expressed as means ± SE for at least three separate determinations for each 
treatment group. Significant coactivation by DRIP150 (or mutants) in this tudy 
represents an increase in the fold induction compared to that observed for E2 alone.  
Hormone responsiveness was not observed in the absence of cotransfected ERa. (B)  
Coactivation of pM-ERa by DRIP150. ZR-75 cells were transfected with pM (empty 
vector), pM-ERa (50 ng), or DRIP150 (200 or 400 ng), treated with E2 or DMSO, and 
luciferase activity determined as described in the Materials and Methods. Significant (p < 
0.05) induction by E2 (*) and coactivation by DRIP150 (**) is indicated.   
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FIG. 28. Continued. (C) Coactivation of ERa in MDA-MB-231. Cells were treated at 
described in (A) and significant (p < 0.05) coactivation by DRIP150 is indicated (**).   
Coactivation of HE19 (D) and TAF1 (E) by DRIP150. ZR-75 cells were treated with 10 
nM E2 or DMSO, transfected with the indicated amounts of plasmids, and luciferase 
activity determined as described in the Materials and Methods. Significant (p < 0.05)
coactivation is indicated (**). SNURF coactivation of ERa (D) and DRIP150 
coactivation of ERa (E) serve as positive controls for these experiments. 
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FIG. 28. Continued. 
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luciferase activity and this response was further enhanced by cotransfection with 
DRIP150. As a positive control for this experiment, we also observed coactivation of 
HE19 by the RING finger protein SNURF as previously reported (408). A higher level of 
coactivation by SNURF was observed and this may be due, in part, to the cooperative 
coactivation of HE19 by SNURF and TATA binding protein (408). E2 induced luciferase 
activity in ZR-75 cells transfected with ERa-TAF1; however, this response was not 
enhanced by DRIP150 (Fig. 28E), whereas in the same experiment, DRIP150 
coactivated wild-type ERa (positive control). 
 These results suggest that DRIP150 primarily coactivates ERa through direct or 
indirect interactions with the AF2 domain and this was further investigated by 
competition (squelching) experiments with NR-box and AF1 proteins (AF1-p). The 
results in Figure 29A demonstrate that increasing amounts of the 2XF6 peptide (387) 
which contains 2 NR boxes fused to the yeast GAL4-DBD significantly decreased 
DRIP150 coactivation of ERa in ZR-75 cells. In contrast, transfection with the AF1 
protein which contains amino acids 1-182 from ERa did not significantly decrease (or 
squelch) DRIP150 coactivation of ERa (Fig. 29B), whereas this protein inhibited AF1-
dependent activation of GC-rich promoter constructs by ERa/Sp1 (414). These results 
suggest that coactivation of ERa by DRIP150 is primarily AF2-dependent. 
Interactions of ERa and DRIP150 
 Kang and coworkers reported that in nuclear extracts containing DRIP complex 
proteins, both wild-type and the ligand binding domain of ERa interacted with DRIP150 
in pulldown assays; however, DRIP150-ERa interactions were not observed unless 
DRIP205 was also expressed (415). Results illustrated in Figure 30A used in vitro   
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FIG. 29. Squelching of DRIP150 coactivation of ERa by NR-box (A) and ERa-AF1 
(B) peptides. ZR-75 cells were treated with DMSO or 10 nM E2, transfected with 
pERE3, DRIP150 (1 or 7.5 ng), ERa expression plasmid (50 ng), and different amounts 
of NR box or AF1-ERa expression plasmids, and luciferas ctivity determined as 
described in the Materials and Methods. Significant (p < 0.05) coactivation by DRIP150 
is indicated (*) and inhibition by ERa-AF or NR-box expression is only indicated (**).
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FIG. 30. DRIP150-ERa interactions. (A) Coimmunoprecipitation. In vitro expression of 
35S-labeled DRIP150 or ERa were immunoprecipitated by ERa antibodies as described 
in the Materials and Methods. [32P]PcDNA3 (empty vector) served as a control. (B) Gel 
mobility shift assays. [32P]ERE was incubated with ERa, in vitro expressed DRIP150 in 
the presence or absence of IgG (non-specific) or ERa antibodies, and examined in a gel 
mobility shift assay as described in the Materials and Methods. In a separate 
experiment, excess unlabeled ERE also decreased intensity of the retarded of the 
specifically bound retarded band (Bound DNA). 
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translated radiolabeled [35S]ER and [35S]DRIP150 in coimmunoprecipitation 
experiments. ERa antibodies coimmunoprecipitate ERa alone and in combination with 
DRIP150 indicating that both proteins directly interact. Interactions of the in vi ro 
translated proteins (unlabeled) were also investigated in gel mobility shift assays using 
[32P]ERE (Fig. 30B). Incubation of ERa and [32P]ERE gave a retarded band (lane 1) and 
coincubation with increasing amounts of DRIP150 increased intensity of the retarded 
band (lanes 2 - 4) but a supershifted ternary complex was not observed. DRIP150 alone 
did not form a complex with [32P]ERE (lane 5), and the DRIP150-enhanced complex 
was supershifted by ERa antibodies (lane 7) but not by non-specific IgG (lane 6). Thus, 
DRIP150 enhanced ER-ERE complex formation, and similar observations have 
previously been reported for other transcription factors (including ERa) i  gel mobility 
shift assays where two interacting proteins did not form a ternary complex with DNA; 
however, protein-DNA binding of one protein was enhanced by the other protein 
(100,416-418).   
Coactivation of ERa by mutant DRIP150 constructs 
 Wild-type DRIP150 contains 1454 amino acids (aa) with two putative NR boxes 
at 1182-1186 and 73-69. Figure 31A summarizes the effects of wild-type DRIP150 and 
mutants containing deletions of aa 1454-1145 (DRIP150m1), 1454-789 (DRIP150 m2), 
and 1454-325 (DRIP150m3) on coactivation of ERa in ZR-75 cells transfected with 
pERE3. The results show that DRIP150m1 was the only one of these deletion mutants 
that coactivated ERa, suggesting that the C-terminal NR-box was not required for 
coactivation, and the N-terminal NR-box was not sufficient for coactivation. The results 
also indicate that the aa 1144-789 are required for coactivation of ERa on an ERE 
promoter. The results in Figure 31A were obtained using 2.5 ng of wild-type/mutant  
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FIG. 31. Coactivation of ERa by wild-type and variant DRIP150 and their 
interactions in gel mobility shift assays. Coactivation of ERa by wild-type DRIP150 
and mutants 1 - 3 (A), 4 - 7 (B), and 9 - 12 (C). ZR-75 cells were transfected with 
pERE3, (50 ng) and wild-type variant DRIP150 expression plasmids, treated with DMSO 
or 10 nM E2 and luciferase activity determined as described in the Materials and 
Methods. Results are expressed as means ± SE for three separate experiments for 
each treatment group. All experiments were carried out over a range of DRIP150 (wild-
type/variant), and the maximal enhanced coactivation (fold) is reported. 
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FIG. 31. Continued. Results in Figure 31C were carried out in several separate 
experiments and combined to show the enhanced coactivation (fold), whereas results in 
Figures 4A and 4B were carried out at the same time. Significant (p < 0.05) enhancemet 
of coactivation is indicated by an asterisk.   
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FIG. 31. Continued. (D) Gel mobility shift assay. [32P]ERE and ERa were incubated with 
equal amounts of in vitro expressed wild-type or variant DRIP150 and analyzed in a gel 
mobility shift assay as described in the Materials and Methods. The specifically-bound 
retarded band (bound DNA) is indicated. (E) Expression of DRIP150 mutants.  
DRIP150m11 and DRIP150m2 (expressed tagged) were in vitro translated (lanes 1 and 
2) or transfected into COS7 cells (lanes 3 and 4), and aliquots of translated protein or 
whole cell lysates were analyzed by SDS-PAGE and immunoblot analysis as described in 
the Materials and Methods. 
 
 
 
 
 
 
 
 
 
 
 
FIG. 31. Continued. (D) Gel mobility shift assay. [32P]ERE and ERa were incubated with 
equal amounts of in vitro expressed wild-type or variant DRIP150 and analyzed in a gel 
mobility shift assay as described in the Materials and Methods. The specifically-bound 
retarded band (bound DNA) is indicated. (E) Expression of DRIP150 mutants.  
DRIP150m11 and DRIP150m2 (expressed tagged) were in vitro translated (lanes 1 and 
2) or transfected into COS7 cells (lanes 3 and 4), and aliquots of translated protein or 
whole cell lysates were analyzed by SDS-PAGE and immunoblot analysis as described 
in the Materials and Methods. 
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DRIP150 expression plasmid; however, similar results were observed for DRIP150 
mutants over a range of plasmid concentrations in separate experiments (data not 
shown). Coactivation of ERa was further investigated with a series of DRIP150 mutants 
with deletions of aa 1454-977 (DRIP150m4), 1454-886 (DRIP150m5), 1454-870 
(DRIP150m6), and 1454-865 (DRIP150m7). The results summarized in Figure 31B 
demonstrate that all of the mutants coactivated ERa in Z -75 cells transfected with 
pERE3,
 and these were also observed with different amounts of expression plasmid. A 
VXXLL motif was present in DRIP150m6 but not DRIP150m7; however, the activity of 
both mutants as coactivators of ERa suggests that the VXXLL motif was not required for 
coactivation by the DRIP150 mutant constructs. Results summarized in Figures 31A and 
31B demonstrate that the C-terminal NR box of DRIP150 is not required for coactivation 
and that amino acids 864-789 are necessary for coactivation.   
 An additional series of DRIP150 mutants containing deletions of aa 1454-850 
(DRIP150m9), 1454-827 (DRIP150m10), 1454-812 (DRIP150m11), and 1454-865/77-1 
(DRIP150m12) were also investigated as coactivators of ERa (Fig. 31C). The activities 
of these constructs were determined in separate experiments where there was some 
variability in the fold induction by E2 and the amount of mutant DRIP150 expression 
plasmid required to give maximal coactivation. Therefore, data obtained for these 
constructs are reported as fold enhancement of coactivation compared to cells treated 
with E2 alone (no coactivation). The results showed that all the DRIP150 deletion 
constructs coactivated ERa. The deletion of the N-terminal NR box (DRIP150m12) did 
not result in loss of coactivation, showing that this motif was not necessary for DRIP150 
coactivation of ERa. Thus, results of deletion analysis of DRIP150 indicates that the 23 
amino acids between aa 811-789 were required for coactivation of ERa in ZR-75 cells. 
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 We also investigated interactions of ERa and [32P]ERE in the presence or 
absence of in vitro expressed DRIP150 expression plasmids (Fig. 31D). The ERa-ERE 
retarded band (lane 1) intensity was enhanced after coincubation with wild-type
DRIP150 (lane 2) and deletion mutants m1, m2 and m3 (lanes 2 - 4). Wild-type 
DRIP150 alone did not bind [32P]ERE (lane 5), and ERa antibodies (lane 7) but not IgG 
(lane 6) supershifted the retarded band as indicated in Figure 30B. The enhanced ER-
ERE retarded band intensity was observed after coincubation not only with wild-type 
DRIP150 and mutant m1 which coactivate ERa, but also with mutants m2 and m3 that 
are inactive as coactivators. These results suggest that this response may reflect 
interactions of DRIP150 mutants with ERa in vitro but these interactions did not predict 
their activities as coactivators of ERa. DRIP150m2 and DRIP150m11 have similar 
molecular weights as illustrated in Figure 31E in which in vitro expressed DRIP150 
mutants were analyzed by SDS-PAGE and Western blot analysis (lanes 1 and 3).  
These proteins wer also observed in whole cell lysates after transfection (lanes 3 and 
4) in COS7 cells. 
Coactivation/squelching by DRIP150 coactivation peptide 
 DRIP150m8 plasmid expresses amino acids 885-755 which encompass the 
region of DRIP150 required for coactivation of ERa. Results in Figure 32A show that 
DRIP150m8 coactivates ERa at low concentrations and squelches activity at higher 
concentrations. Moreover, results summarized in Figure 32B show that DRIP150m8 
inhibits coactivation of ERa by wild-type DRIP150. DRIP150 and other deletion mutants 
also coactivate HE19 and the results in Figure 32C show that DRIP150m11 coactivates 
ERa and cotransfection with DRIP150m8 inhibits or squelches the coactivation  
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FIG. 32. Coactivation and squelching by DRIP150m8. (A) Coactivation of ERa. ZR-
75 cells were treated with DMSO or 10 nM E2 transfected with pERE3, ERa (50 ng), 
and different amounts of DRIP150m8 expression plasmid, and luciferase activity was 
determined as described in the Materials and Methods. Results of all experiments 
illustrated in this Figure are means ± SE for at least three experiments for each 
treatment group, and significant (p < 0.05) coactivation (*) and inhibition of coactivation 
(**) are indicated. (B) DRIP150m8 squelching of ERa. Z -75 cells were treated with 
DMSO or 10 nM E2 and transfected with pERE3, ERa (10 ng), DRIP150 (5 ng), and 
different amounts of DRIP150m8 expression plasmid, and luciferase activity was 
determined as described in the Materials and Methods. Significant (p < 0.05) 
coactivation by DRIP150 (*) and inhibition by cotransfection with DRIP150m8 (**) are 
indicated.  
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FIG. 32. Continued. (C) DRIP150m8 squelching of HE19. This experiment was carried 
out as described in Figure 5B, except that HE19 expression plasmid was used. 
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response. pM23 contains the minimal sequence of DRIP150 (aa 811-789, 
DIPAHLNIFSEVRVYNYRKLILC) necessary for coactivation of ERa, and this peptide is 
fused to the DBD of the yeast GAL4 protein (Fig. 33A). Transfection of ZR-75 cells with 
pERE3 and different amounts of pM23 expression plasmid showed that this chimeric 
protein coactivates ERa and then squelches this response with increasing amounts of 
transfected plasmid (Fig. 33A). This parallels a similar coactivation/squelching response 
observed for DRIP150m8 (Fig. 32A). Moreover, pM23 also inhibits DRIP150 
coactivation of ERa (Fig. 33B) demonstrating that pM23 and DRIP150m8 exhibit 
comparable coactivation of ERa at low concentrations but also squelch transactivation 
(at higher concentrations) and inhibit DRIP150 coactivation of ERa. We also examined 
the protein crystal structure database for similarities between the DRIP150 amino acid 
sequence 811-789 with other proteins. The first six residues DIPAHL fold into an a-helix 
when they occur in Lanuginosa lipase (419) and histamine N-methyltransferase (420). 
There was also homology between residues 7 - 16 (NIFSEVRVYN) of the DRIP150 23 
amino acid sequence and an -helical region in hepatocyte nuclear factor 1 (HNF1; 
NLVTEVRVYN) (421). Results in Figures 33C and 33D summarize squelching 
experiments with pM23R801P and pM23A792P which express the GAL4-23 amino acid 
fusion protein with mutations at amino acids 801 (R ® P) and 792 (A ® P). Proline 
residues were inserted to disrupt a-helical structure. The results show that pM23R801P 
did not squelch DRIP150 coactivation of ERa (Fig. 33C), whereas pM23A792P 
exhibited wild-type (pM23) activity and squelched DRIP150 coactivation of ERa (Fig. 
33D). Squelching of DRIP150 coactivation of ERa was also not observed using the 
double mutant pM23A792P/R801P (Fig. 33E). These data suggest that the sequence at 
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FIG. 33. Wild-type and variant pM23 as a coactivator and inhibitor of ERa-mediated 
transactivation. (A) pM23 coactivates/squelches ERa. ZR-75 cells were treated with 
DMSO or 10 nM E2, transfected with pERE3, ERa (10 ng), and different amounts of 
pM23 expression plasmid, and luciferase activity was determined as described in the 
Materials and Methods. Significant (p < 0.05) induction (*) and squelching (**) are 
indicated. (B) pM23 squelches coactivation of ERa by DRIP150. ZR-75 cells were 
treated as described in Figure 33A and DRIP150 (5 ng), ERa (10 ng) and pM23 (1 - 6 
ng) expression plasmids were used as indicated. Significant (p < 0.05) coactivation by 
DRIP150 (*) and squelching by pM23 (**) are indicated. 
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FIG. 33. Continued. Squelching of DRIP150 coactivation by pM23R801P (C), 
pM23A792P (D) or pM23A792P/R801P (E). ZR-75 cells were treated with DMSO or 10 
nM E2, transfected with pERE3, Ra (10 ng), DRIP150, and different amounts of pM23 
mutant expression plasmids. Significant (p < 0.05) coactivation by DRIP150 (*) and 
squelching (**) by mutant pM23 constructs are indicated. 
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FIG. 33. Continued. 
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amino acids 795-804 in DRIP150 which resembles an a-helical motif in HNF-1 is an 
important structural feature of DRIP150 required for coactivation of ERa. These data 
suggest that in addition to LXXLL motifs, other helical sequences in coactivators can 
play a role in coactivation of ERa and possible other nuclear receptors in breast cancer 
cells. 
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CHAPTER IV 
 
DISCUSSION AND CONCLUSIONS 
3’,4’-DMF as an AhR antagonist in human breast cancer cells 
 The AhR is a ligand-activated transcription factor that binds structurally diverse 
chemicals that include highly toxic halogenated aromatics (411) and chemoprotective 
phytochemicals such as I3C, DIM and bioflavonoids (132,146,234). Research in this 
laboratory identified a series of alternate-substituted (1,3,6,8- or 2,4,6,8-) alkyl PCDFs 
typified by the AhR antagonist 6-methyl-1,3,8-trichlorodibenzofuran (MCDF) that 
inhibited TCDD-induced CYP1A1, porphyria, immunotoxicity and cleft palate formation 
in mice (223,422,423). Subsequent studies showed that MCDF was an AhR agonist 
and inhibited E2-induced responses in the rodent uterus and breast cancer cells and 
mammary tumor growth in carcinogen-induced female Sprague-Dawley rats 
(221,222,227,424,425). It has also been reported that synthetic and natural flavonoids 
exhibit AhR antagonist activity and some of the most effective AhR antagonists are 
substituted 3'-methoxyflavones (173,180,181,214,215).   
 3'-Methoxy-4'-nitro- and 4'-amino-3'-methoxyflavone have been xtensively 
characterized as AhR antagonists that act by inhibiting formation of the nuclear AhR 
complex (173,180,181,214), and similar results have been observed for 2'-amino-3'-
methoxyflavone (215,216). However, many of these substituted flavones are also 
protein tyrosine kinase inhibitors and cytotoxic at doses >10 mM (193,215,216). Henry 
and coworkers (1999) recently investigated a series of 3'-methoxy-4'-substituted 
flavones and showed that the most active AhR antagonists contained 4'-substituents 
with high electron density (nitro, azido and thiocyanate). It was hypothesized that this 
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structural feature facilitated critical hydrogen-b nding with the AhR. In contrast, 3'-
methoxy-4'-aminoflavone was less active as an AhR antagonist (181) than previously 
observed in this laboratory in breast cancer cell lines (173), and this may be due, in 
part, to cell context. We also observed that although 4'-methoxyflavone did not inhibit 
induction of CYP1A1 by TCDD, this compound blocked TCDD-induced transformation 
of the rat cytosolic AhR (214), and we therefore hypothesized that 3',4'-DMF, which 
contains two vicinal methoxy groups, may be an effective AhR antagonist in breast 
cancer cell lines despite the lack of a 4'-substituent with high electron density. 
 Most previous studies have characterized the activity of AhR antagonists by 
determining their effects on CYP1A1-dependent (gene/promoter) activities and their 
interactions with the cytosolic and nuclear AhR complex. Results obtained for 3',4'-DMF 
in breast cancer cells are similar to those previously reported for other 3'-
methoxyflavones in different cell lines indicating that inhibition of TCDD-induced 
CYP1A1 or related activities is due to competitive interaction of the ligand with the 
cytosolic AhR that does not undergo transformation or nuclear translocation (Fig. 20).  
3',4'-DMF did not block inhibition of E2-induced proliferation by TCDD (data not shown) 
and this may be related to the growth inhibitory effects of 3',4'-DMF alone (Fig. 18) 
which could be due to partial ER antagonist activities or inhibition of protein kinase 
dependent pathways (193,215). However, in transcriptional activation assays using the 
E2-responsive pCKB construct, 3',4'-DMF exhibited AhR antagonist activity and 
reversed the antiestrogenic effects of TCDD in this assay (Fig. 19). Thus, 3',4'-DMF 
does not resemble MCDF which acts as an AhR agonist for this response (409) but 
resembles a-naphthoflavone which inhibits AhR-mediated CYP1A1 induction (210,212) 
and inhibition of E2-induced transactivation in breast cancer cells (208). The major 
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advantage of 3',4'-DMF over a-naphthoflavone is that the latter compound is an AhR 
antagonist at concentrations < 1 mM, whereas at higher concentrations (1 - 10 mM), a-
naphthoflavone is an AhR agonist (213). Results obtained in this study demonstrate that 
3',4'-DMF inhibits both AhR-mediated CYP1A1 induction and antiestrogenic activity in 
breast cancer cell lines by blocking transformation of the cytosolic AhR complex and 
formation of the nuclear AhR complex, and this is consistent with results of previous 
studies with other 3'-methoxy-substituted flavones (173,180,181,214-216). Previous 
studies demonstrated that 3'-methoxyflavone exhibited minimal activity as an inhibitor of 
TCDD-induced transformation of rat hepatic cytosolic receptor, whereas introduction of 
high electron density 4'-substituents gave compounds that inhibited TCDD-induced 
transformation and transcription in mouse liver cells (181). In contrast, 3'-
methoxyflavones that contain 4'-methoxy (this study) and 4'-amino groups (173) that do 
not have high electron densities are also relatively potent AhR antagonists in breast 
cancer cells suggesting that the AhR antagonist activity of these substituted flavones 
may be influenced by cell context. An important advantage in using 3',4'-DMF is the 
commercial availability of this compound. 
Involvement of a post- ranscriptional mechanism in the inhibition of CYP1A1 
expression by resveratrol in breast cancer cells 
 Resveratrol exhibits a diverse spectrum of biochemical responses that may be 
linked to health benefits associated with moderate consumption of wine (426-428). 
Several recent studies have demonstrated that resveratrol decreases CYP1A1 
mRNA/protein or related activities in cell culture and invivo and there is some evidence 
that this inhibitory response may be related to AhR antagonist properties of this 
compound (266-269). At least two major classes of AhR antagonists have been 
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identified, and these include 3'-methoxy-substituted flavones that block receptor 
transformation and formation of the nuclear AhR complex (173,180,181) and alternate 
substituted polychlorinated dibenzofurans (PCDFs). These latter compounds, typified by 
6-methyl-1,3,8-trichlorodibenzofuran, compete with TCDD for binding the AhR but form 
a nuclear AhR complex that only weakly activates DRE-dependent responses such as 
induction of CYP1A1 gene expression (222,409). Resveratrol also inhibits CYP1A1 
gene expression and related enzyme activities, and it has been suggested that 
resveratrol is also an AhR antagonist (266,267,269). 
 Our results also show that resveratrol inhibits TCDD-induced CYP1A1 mRNA 
and related enzyme activity in breast cancer cells; however, interactions of resveratrol 
with the AhR suggest that these responses may be non-specific. Treatment of T47D or 
MCF-7 cells with resveratrol resulted in formation of a nuclear AhR complex as 
determined in gel mobility shift assays, and interactions with TCDD did not markedly 
affect nuclear AhR complex formation (Fig. 24). These results were consistent with a 
previous report using breast cancer cells (267) but were in contrast to studies in HepG2 
cells (266,269) which showed that treatment with resveratrol alone did not result in 
formation of a nuclear AhR complex and, in cotreatment studies (resveratrol + TCDD), 
resveratrol inhibited TCDD-induced formation of the AhR complex. Differences 
observed in this assay may be due to cell type (breast vs. liver) and, therefore, 
interactions of resveratrol were further investigated using rat hepatic cytosol which is 
readily transformed by TCDD. Induced transformation is inhibited by pure AhR 
antagonists such as 3'-methoxy-4'-nitroflavone (Fig. 24C) (173,180,181), whereas  
resveratrol-induced transformation was concentration-i dependent and resveratrol plus 
TCDD gave minimal interactions in the assay (Fig. 24). Seidel and coworkers (2000) 
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have also reported that like resveratrol, several structurally different compounds 
induced transformation of guinea pig hepatic cytosolic AhR but did not exhibit functional 
AhR agonist activity. These data, coupled with the failure of resveratrol to exhibit AhR 
agonist activity in functional assays and AhR antagonist activity in cells transfected with 
Ah-responsive pRNH11c (Fig. 25), suggest that resveratrol-AhR interactions may be 
non-specific. 
 Nevertheless, results of this study and previous reports (266-269) clearly show 
that resveratrol decreases CYP1A1 mRNA and protein levels, and the latter response is 
not related to proteosome-d pendent degradation of CYP1A1 protein (Fig. 27). 
Therefore, we further investigated interactions between resveratrol and downregulation 
of CYP1A1 by determining post-transcriptional effects on CYP1A1 mRNA stability. A 
recent report showed a remarkable similarity between resveratrol and DHEA which both 
inhibited induction of CYP1A1 mRNA and EROD activity in breast cancer cells (429), 
and we also observed these responses for resveratrol (Fig. 22) and DHEA (data not 
shown). Moreover, like resveratrol (Fig. 25), DHEA did not inhibit induction in cells 
transfected with an Ah-responsive element (429). Our results (Fig. 26) also showed that 
both DHEA and resveratrol increased the rate of CYP1A1 mRNA degradation in T47D 
cells suggesting that resveratrol (like DHEA) also inhibits CYP1A1 expression by post-
transcriptional mechanisms. The importance and specificity of AhR-independent actions 
of resveratrol are unknown; however, a recent study reported that resveratrol also 
decreased androgen receptor mRNA levels in LNCaP prostate cancer cells (430). It is 
possible that these effects may also be linked to a post-transcriptional AhR-independent 
mechanism as reported in this study, and the role of this pathway in mediating 
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resveratrol action, particularly in hormone-responsive cancer cells, is currently being 
investigated. 
DRIP150 coactivation of ERa in ZR-75 breast cancer cells is independent of 
LXXLL motifs 
 Several nuclear coregulatory complexes that associate with transcriptio  factors 
and potentiate RNA pol II transcription have been identified and many of their individual 
subunits are identical (391,392,396,398,399,432,433). The functions of the DRIP, 
TRAP, NAT, ARC and CRISP coregulatory complexes are similar to that described for 
Mediator complexes initially purified from yeast. Interactions of these coregulatory 
complexes with NRs including ERa and ERb have been investigated, and there is 
evidence in some cell lines tha  DRIP205 anchors the protein complex to NRs 
(391,392,415,434). Several reports have investigated DRIP205 coactivation of NRs 
including both ERa and ERb. DRIP205-dependent coactivation of ER depends on both 
cell context and ER-subtype and the NR boxes of DRIP205 are required for coactivation 
(435-440). Both DRIP205 and DRIP150 also directly interact with ERa/ERb, and other 
studies confirm that DRIP150 interacts with the glucocorti oid and androgen receptors 
(393,394,415). 
 Previous studies indicate that DRIP150 coactivated glucorticoid receptor (GR)-
mediated transactivation and this response was AF1-dependent (394); however, 
coactivation of ERa by DRIP150 has not been extensively investigated. DRIP150 
coactivates ERa in MDA-MB-231 and ZR-75 cells transfected with pERE3 and 
comparable enhancement of transactivation was observed in a mammalian one-hybrid 
assay in cells transfected with pM-ERa/GAL4-luc (Fig. 28). DRIP150 also coactivated 
HE19 but not ERa-TAF1 in ZR-75 cells, suggesting that the AF1 domain of ERa was 
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not necessary for coactivation and that an intact helix 12 was required. These results 
contrast to the reported AF1-dependent coactivation of GR by DRIP150 (393) but are 
comparable to previous studies in several different cell lines showing that helix 12 is a 
critical surface of ERa which interacts with NR boxes of p160 coactivators 
(382,385,441-443). The importance of the AF2 region of ERa for coactivation by 
DRIP150 was supported by the inhibitory effects or squelching of enhanced 
transactivation in ZR-75 cells transfected with an NR box expression plasmid (Fig 29A).  
This construct contains two copies of the GRIP1 NR box and inhibits ERa-mediated 
transactivation (387). In contrast, overexpression of an AF1 peptide (aa 1-182 of ERa) 
did not affect coactivation of ERa by DRIP150 confirming the important role of AF2 of 
ERa.   
 DRIP150 contains 2 LXXLL NR box motifs in the N- (73-69) and C-terminal 
(1186-1182) regions. Their role in coactivation of ERa by DRIP150 has not been 
determined; however, previous studies show that NR boxes are critical regions fo the 
coactivation of NRs by DRIP205 (436,437,444). In contrast, deletion analysis of 
DRIP150 (Figs. 31 and 32) clearly shows that coactivation of ERa by DRIP150 deletion 
variants was NR box-independent, and a 23 amino acid sequence (aa 811-789) was 
identified as an essential region for DRIP150 coactivation of ERa (Fig. 31). Wild-type 
DRIP150 coimmunoprecipitates ERa (Fig. 30A) as previously reported (415); however, 
in gel mobility shift assays DRIP150 does not form a DRIP150/ERa/ERE ternary 
complex but enhances the ERa-ERE retarded band intensity. The failure to observe a 
supershifted ternary complex is not unprecedented since previous studies report that 
ERa enhances Sp1/Sp3 DNA binding (100,445), cyclin D1 enhances ERa DNA binding, 
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human T-cell lymphotropic virus Type I transcriptional activator (Tax) enhances CREB 
DNA binding and binding of other transcription factors in gel mobility shift assays (416-
418). Interestingly, the results also show that DRIP150 and DRIP150m1 which 
coactivate ERa also enhance the ERa-ERE retarded band; howev r, mutants that are 
inactive as coactivators (DRIP150m2 and DRIP150m3) exhibit comparable activity in 
the gel shift assay (Fig. 31D). This suggests that enhancement of ERa-ERE binding by 
DRIP 150 variants is not predictive for coactivation of ERa-mediated transactivation 
which requires the 23 amino acid 811-789 sequence. 
 We have further investigated the role of the DRIP150 "coactivation sequence" in 
hormone-induced transactivation using DRIP150m8 which contains amino acids 885-
755 and pM23 which contains DRIP150 amino acids 811-789 fused to the yeast GAL4-
DBD. Transfection of either protein gave a biphasic response typical of many 
coactivators in which low concentrations resulted in coactivation of ERa and higher 
amounts of transfected plasmids subsequently decreased or squelched transactivation 
(Fig. 32). pM23 and/or DRIP150m8 also inhibit wild-type and mutant DRIP150 
coactivation of ERa or HE19 (Fig. 32) and these results resemble responses observed 
for NR box peptides containing LXXLL sequences (387). Our results confirm that 
DRIP150 interacts with ERa as previously reported (415) and coactivates ERa in ZR-75 
(and MDA-MB-231) cells transfected with pERE3. The coactivator activity of DRIP150 
alone in ZR-75 cells contrasts to previous reports showing that ligand-dependent 
recruitment of mediator complex proteins to ERa and other nuclear receptors requires 
DRIP205 as an anchor component for complex-receptor interactions (391,392,415,434). 
However, other reports show that DRIP150 alone interacts with nuclear receptors 
(393,394) and this has been observed for ERa (Fig. 30A). A recent study also reported 
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isolation of a transcriptionally active coactivator CRSP/mediator complex that contained 
CRSP150/DRIP150 but not DRIP205/Med220 (or Med70), suggesting that DRIP205 is 
not always required for a functional mediator coactivator complex (446). This is also 
supported, in part, by chromatin immunoprecipitation sudies on the time-dependent 
recruitment of coactivators, such as SRCs and DRIPs, to the ERE of the pS2 gene 
promoter in MCF-7 cells (435). The results showed that at some time points, DRIP150 
was associated with the pS2 promoter in the absence of DRIP205, suggesting a 
DRIP205-independent role for DRIP150 as a coactivator of ERa and this is consistent 
with results of this study. 
 DRIP150 coactivation of ERa is independent of the two NR boxes and requires 
a 23 amino acid sequence DIPAHLNIFSEVRVYNYRKLILC at 789-811 (Figs. 31 and 
32). Using the protein crystal structure database, there was not a good match between 
the 23 amino acid DRIP150 sequence and other known crystalline proteins; however, 
the first six residues DIPAHL fold into an a-helix when they occur in Lanuginosa lipase 
and histamine N-methyltransferase (419,420). Amino acids 7-16 in DRIP150 are 
homologous to amino acids 69-78 in hepatocyte nuclear factor 1 which also fold into an 
a-helix (421). pM23 efficiently squelches DRIP150 coactivation of ERa (Fig. 33B), and 
we used this assay to identify the function of the two helical components within the 789-
811 amino acid region of DRIP150. Results in Figure 33 show that pM23A792P 
exhibited wild-type (pM23) squelching activity, whereas, pM23R801P and 
pM23A792P/R801P (double mutant) did not squelch coactivation of ERa by DRIP150. 
These data suggest that the a-helical structure within the NIFSEVRVYN (amino acids 
795-804) sequence is required for the activity of DRIP150 as a coactivator of ERa. 
Results of this study uniquely identify a novel sequence in DRIP150 required for 
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coactivation of ERa and demonstrate that LXXLL boxes in DRIP150 are not required for 
enhancement of ERa-dependent transactivation. Current studies are focused on the 
function of DRIP150 and the 789-811 amino acid sequence in coactivation of ERa/Sp1- 
and ERa/AP1-mediated transactivation and coactivation of other nuclear receptors. 
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